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Summary 
Tuberculosis (TB) is the leading cause of death from a single infectious 
agent worldwide and HIV-1 co-infection is the leading cause of susceptibility 
to tuberculosis. Sub-Saharan Africa has a high incidence of TB-HIV-1 co-
infection and the risk of TB in HIV-1 infected people is increased at all stages 
of the infection. Antiretroviral treatment (ART) is the most effective way to 
reduce the risk of TB in HIV-1 co-infected people. By studying the protective, 
ART induced immune reconstitution in HIV infected individuals sensitised by 
Mycobacterium tuberculosis (Mtb), we can identify correlates of protection 
against tuberculosis in the form of transcriptomic, soluble or cellular 
biomarkers. This thesis focuses on characterising Mtb-specific reconstituting 
CD4 T cells as well as soluble and transcriptomic markers in HIV infected 
persons, sensitised by Mtb, by analysing samples collected longitudinally 
during 6 months of ART.  
 
Analysis of peripheral blood mononuclear cells by 14-colour flow cytometry 
revealed the proportion and numbers of central memory CD4+ T cells 
significantly expanded in HIV infected persons on ART, while the proportion 
and numbers of effector memory and terminally differentiated effector CD4+ 
T cells decreased significantly. Additionally we noted a significant decrease 
in the proportion of activated CD4+ T cells, and IL-2 single producing CD4+ T 
cells in HIV infected persons at 6 months of ART, while polyfunctional Mtb-
specific CD4+ T cells secreting IFN-γ, IL-2 and TNF-α simultaneously, 
proportionally increased.  
 vii 
 
Analysis of soluble markers in the plasma of HIV infected persons revealed 
an overall decrease in pro-inflammatory cytokines during 6 months of ART. A 
significant decrease in IFN-γ, IL-1α, IL-1β, IL-6, IL-17A and TNF-α was 
observed, and concentrations of these cytokines fell towards those observed 
in HIV uninfected persons.  
 
Transcriptomic analyses of 30 genes normalized to 3 different housekeeping 
genes, showed an overall increase in the expression of T cell memory 
specific genes, illustrating the regeneration of the memory T cell pool in HIV-
infected adults on ART. Larger number of central memory specific genes 
showed increased expression when normalised to at least two housekeeping 
genes, as compared to effector memory specific genes. These results 
support the reconstitution of central memory CD4 T-cell specific response at 
6 months of ART.  
  
Our data provides insight into the reconstituting immune response to latent 
TB infection in the context of HIV infection and identifies potential correlates 
of decreased susceptibility to TB. We also show decreasing soluble and 
cellular factors indicative of decreasing immune activation in HIV infected 
persons receiving ART. 
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Chapter One: The Pathogenesis of 
Tuberculosis – An Overview 
1.1. Introduction 
Mycobacterium tuberculosis (Mtb) was first discovered in 1882 by Robert 
Koch [1], which was a critical moment in the history of Medicine as well as in 
our understanding of this deadly disease. Over the past century Tuberculosis 
(TB) research has facilitated our understanding of this disease, the mode of 
transmission and disease progression [2]. This was made possible through 
researchers and their findings; Devoto had recognised that healthcare 
workers were at risk of developing TB in 1920 while Riley had described the 
deposition of airborne bacteria in the lung in 1961, and the arterial 
dissemination of Mtb in the TB ward between 1960-1962 [3-6]. In 1964, 
Chapman had attributed social, amongst other factors, that were associated 
with the transmission of TB in TB-affected households [7]. Lastly, in the mid 
2000’s the phylogeographical classification of global Mtb strains and the 
advent of whole-genome sequencing for molecular tracking of TB outbreaks 
were achieved [2]. 
1.1.1. The Epidemic of Tuberculosis 
Fast forward to 2017 and TB still remains a global health problem, with it 
being the ninth leading cause of death worldwide. The burden of disease is 
an estimated 10.4 million persons contracting TB in 2016, of whom, 10% 
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were people living with HIV [8]. Additionally, there were an estimated 1.3 
million deaths among HIV uninfected persons (compared to 1.7 million in 
2000), with a further 374 000 deaths amongst HIV infected persons. 
Although there is still a high rate of mortality globally, the mortality rate has 
since fallen by an estimated 3% globally [8]. The incidence of TB is falling by 
an estimated 2% but this needs to increase by 2-3% more per annum, in 
order to reach the first milestone of the “End TB strategy” by 2020. The WHO 
European region has the fastest decline in TB incidence (from 3% in 2015 to 
4.6% in 2016) with the decline since 2010 in high TB burden countries also 
exceeding 4% per year [8].  Since 2010, the WHO in European and the 
Western regions had the fastest decline rate in TB mortality with 6% and 4% 
respectively, while other high TB burden countries have rates exceeding 6% 
per year since 2010 [8]. The proportion of people who develop TB and die 
from the disease (also known as the case fatality ratio) needs to be at 10% 
by 2020 to meet targets, but was estimated to be at 16% in 2016. TB 
treatment has prevented a predicted 44 million deaths amongst HIV 
uninfected persons, and TB treatment in conjunction with ART has prevented 
an estimated 9 million deaths in HIV infected persons between 2000 and 
2016 [8]. Finally the threat of drug resistant TB is persistent, with an 
estimated 490 000 cases of multidrug-resistant TB (MDR-TB) in 2016. An 
additional 110 000 cases were susceptible to isoniazid (INH) but resistant to 
Rifampicin (RR-TB), the most effective first line anti-TB drug, with almost 





Figure 1. 1: Estimates of the incidence of Tuberculosis in 2016. This 
map highlights the incidence of TB worldwide. Sub-Saharan Africa, has 
the highest number of TB-related deaths in HIV infected persons, with 
more than 300 persons per 100 000 population infected with TB. (Image 
sourced from WHO: Global Tuberculosis report 2016 [8]). 
1.1.2. The TB burden in South Africa and its implications 
South Africa has an estimated population of 56 million people, with an 
estimated 438 000 persons living with TB and an estimated 123 000 people 
dying as a result of TB in 2016 [8]. Of the 438 000 people that are infected 
with TB, 182 000 (~42%) are females and 256 000 (~58%) are males. 
HIV/TB co-infection accounts for a higher mortality rate than those that are 
infected with TB alone, 181 per 100 000 people compared to 41 per 100 000 
people respectively, with an estimated 100 000 people dying from HIV/TB 
co-infection in 2016 [8]. TB infection may be categorised into two clinically 
defined conditions, namely active TB and latent tuberculosis infection (LTBI). 
A diagnosis can be made for active TB when a patient presents with clinical 
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signs and symptoms of TB in addition to having evidence of Mtb infection [9]. 
Pulmonary TB may be characterised by a chronic cough (with or without the 
presence of blood), fever, sustained weight loss and wasting. Mtb is cultured 
from sputum or the microorganism is identified by nucleic acid testing, or 
acid-fast staining, for microbial confirmation and diagnosis of TB disease. 
LTBI is typically characterised by the presence of immunological 
sensitisation to mycobacterial antigens in the absence of clinical symptoms 
and can be ascertained by using a tuberculin skin test or interferon-γ release 
assay (IGRA) [9]. 
 
1.1.3. Early events in TB infection and the subsequent adaptive immune 
response to TB infection 
TB infection is most commonly acquired by the inhalation of aerosolized 
bacteria. These bacteria-containing small particles are carried via the 
airstream and are inhaled into the lungs [10]. The mycobacteria are taken up 
by alveolar macrophages and upon appropriate activation the bacteria may 
either be destroyed, or if not destroyed, may begin to replicate after a lag 
period of a few days depending on the host’s resistance [11]. Following 
bacterial replication, cell-mediated immunity and the formation of granulomas 
ensues. The presence of granuloma formation within the lung is a hallmark in 
Mtb infection and is comprised of immune cells that provide a safe 
microenvironment to establish latency, while also halting the spread of Mtb 
infection [12]. The granuloma is highly structured and is composed of 
infected alveolar macrophages (AM) and epithelial cells and is surrounded by 
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activated macrophages as well as CD4+ and CD8+ T cells that function to 
restrict the spread of the mycobacteria [13]. Continuous bacterial 
multiplication leads to the death and disruption of host cells, resulting in the 
bacilli escaping AM containment. The bacilli and resulting necrotic cellular 
debris induce an inflammatory response and in turn attract phagocytic cells 
to the site of infection. When encountered the DCs engulf the bacteria, 
migrate to the lymph nodes and present the bacteria to T cells, in order for 
antigen priming to occur and to initiate the adaptive immune response [12]. T 
cells play a critical role in the protective immunity against Mtb due to the 
intracellular lifestyle of the bacterium [14]. Pathogenesis and protection are 
mediated by cellular responses and involve the interaction of phagocytes, 
macrophage lineage, and cells in TB [14]. The production of cytokines such a 
IFN-γ and TNF-α are imperative in establishing protective immunity against 
Mtb infection as both cytokines are able to activate macrophages, that in turn 
play a significant role in the control of Mtb [14].  
 
CD4 T cells: 
The CD4 T cell subset may be divided into T helper type 1 and 2 (TH1 and 
TH2) cells; with each subset possessing the ability to produce distinctive 
cytokines [11]. T cells, B cells, neutrophils and Natural Killer (NK) cells are 
involved in the immune response to Mtb, with the CD4 TH1 cells being the 
most researched and understood, while other interleukin (IL) producing T 
cells, such as CD8 T cells, are also involved in protection against Mtb [14]. 
Upon infection Mtb stimulates CD4 and CD8 T cells, as well as other immune 
cells, to secrete IFN-γ resulting in the production of a strong type 1 immune 
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response; with the CD4 cells being the primary source of IFN-γ production 
[14]. IFN-γ is important in activating the bactericidal action in the host 
macrophages and has shown to be vital in immune protection against TB in 
both mice and humans [15]. While TH1 cells are able to control Mtb infection 
by producing IFN-γ and TNF-α, TH2 cells are characterised by their ability to 
produce IL-4 and IL-10. IL-4 plays a role in the downregulation of TH1 
responses and mouse studies have demonstrated cytokines, IL-4 and IL-10, 
to promote infection with intracellular pathogens possibly due to macrophage 
inhibition [11]. The deleterious mutations in genes encoding proteins; IL-
12p40 subunit, IL-12Rβ1 and IFN-γR1, IFN-γR2 and STAT1 are essential for 
the induction and function of TH1 cells with the presence of these mutations 
increasing susceptibility to Mtb [16]. Additionally recent evidence supports 
the activation of TH17 cells in TB with TH17 cells being able to produce IL-
17A, IL-17F, and TNF-α. The TH17 cells have pro-inflammatory functions and 
are capable of mediating anti-microbial immunity against extracellular 
bacteria and fungi [16]. Through the use of high-dose aerosol Mtb infection in 
mice, it has been shown that TH17 cells play an important role in the early 
phases of protection to Mtb  infection  [17]. CD4 T cells are pivotal in 
immunity against Mtb, however CD8 T cells also play an important role in 
immunity and protection against TB [18].  
 
CD8 T cells: 
There are multiple pathways culminating in the activation of CD8 T cells 
namely; (1) DC presentation to MHC-class I molecules, (2) active 
transmembrane transport to MHC-class I presentation pathway, (3) Mtb 
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infected cells undergoing apoptosis and forming apoptotic vesicles that are 
taken up by DCs and subsequently presented via MHC-class I molecules 
and (4) autophagy, which involves antigen presentation to and the cross 
priming of T cells in response to intracellular pathogens [19]. CD8 cells are 
able to produce cytokines with a TH1 profile and function as MHC class I 
restricted cytotoxic effector cells [11]. Mtb-infected non-phagocytic cells are 
recognised by CD8 T cells. CD8 T cells also complement CD4 T cell 
immunity by surveying a larger number and range of cell types [16]. 
Furthermore, CD8 T cells are able to produce granules containing cytotoxic 
molecules such as perforin, granzymes and granulysin that are able to lyse 
host cells, with granulysin being able to kill Mtb directly [16]. In individuals 
with HIV infection, CD8 T cells may have a greater role to play in immune 
competence [20, 21] as CD4 T cells are depleted [22] thereby highlighting 
their important role in protective immunity to Mtb. Although there is limited 
knowledge about CD8 T cells in Mtb, multifunctionality has been considered 
in protection to Mtb whereby Mtb-specific CD8 T cells produce IFN-γ and IL-
2 and were associated with protective host defence following curative TB 
treatment whereas CD4 T cell polyfunctionality may possibly be associated 
with protection, disease [23] or with antigen load [24, 25].  
 
B-cells: 
Although infiltration and activation of CD4 TH1 cells and CD8 cytolytic 
lymphocytes are a requirement in the effective control of human TB, B cells 
have been shown to play a role [26]. Naïve and memory B cells have been 
shown to be present in TB granulomas as well as in the human lungs 
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resembling germinal centre-like secondary lymphoid structures [27]. B cells 
can present antigens to T cells, are involved in the production of cytokines 
and Mtb-specific antibodies upon antigen recognition [27]. Several studies 
that demonstrate the antigen-presenting capacity of B cells and thus 
establishing an important mechanism for T cell immunity modulation [28, 29]. 
B cells, like DCs, are capable of presenting antigen that can prime T cells as 
demonstrated in studies using in vivo mouse models [30]. A study by Pape et 
al. suggested that B cells participate in the events of the early phase of the 
immune response, such as antigen presentation and T cell priming [31]. 
Various mouse models of TB have revealed a potential role for specific 
antibodies in the host defence against Mtb [32]. The induction of humoral 
immune responses in animal and human models of LTBI and active TB 
respectively have suggested that B cells play a significant role in determining 
the clinical outcome of Mtb infection [32]. As mentioned above, in infectious 
disease models, the antigen-presenting capability of B cells have been linked 
to the modulation of T cell responses and protection but the ability of B cells 
in the regulation of T cell function is not limited to antigen presentation [27]. 
Upon activation, B cells are also capable of producing cytokines and 
antibodies (immunoglobulins), both of which play an important role in the 
maturation of antigen presenting cells, and thereby influence the 
development of T cell immunity [33]. B cell development may be divided into 
3 distinct subsets, namely, B effector 1 (Be1), B effector 2 (Be2) and IL-10 
expressing cells, each of which influence the cytokine milieu and the way 
they interact with antigens and T cells [27]. Be1 cells produce IFN-γ and IL-
12. Additionally TNF-α, IL-10 and IL-6 develop once B cells are primed in a 
 9 
TH1 environment, whereas priming in a TH2 cytokine milieu will result in the 
development of the Be2 subset that is capable of producing IL-2, 
lymphotoxin, IL-4, IL-13, IL-10 and IL-6 cytokines [27]. IL-12 and IL-4 
producing B cells may prejudice the development in vitro of TH1 and TH2 
responses respectively [34, 35]. Together this demonstrates the important 
role that cytokines, produced by B cells, play in modulating immunity. 
Furthermore, our understanding of the role B cells and the cytokines 
produced by B cells play in infectious disease is still at early stages. 
1.2. Disease progression 
1.2.1. Progression from latent tuberculosis infection to active disease 
TB disease severity varies greatly and shows diverse patterns of lung 
involvement encompassing a range of infection outcomes [36-39]. Individuals 
with asymptomatic LTBI possess the ability to contain the bacteria, although 
persisting, and prevent the infection from spreading. Thus asymptomatic 
LTBI ranges from clearance of the disease to low-grade TB [36]. The 
concept of a spectrum of TB infection for LTBI allows for the stratification of 
risk of LTBI reactivation in individuals, prioritizing preventative treatment and 
emphasizing heterogeneity of host responses to Mtb [9, 40]. As expected 
individuals that are able to contain the infection well are less likely to 
reactivate infection compared to individuals with LTBI harbouring low-grade 
sub-clinical infection, with the latter at a higher risk of reactivation and 
eventually requiring treatment [9, 40]. Esmail et al. [41] demonstrated that 
patients with signs of subclinical TB disease, had a higher risk of developing 
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active TB compared to patients that had no evidence of subclinical 
pathology. In this study 4 patients developed active TB out of 10 that showed 
signs of subclinical TB; while the remaining 6 of these patients did not 
develop active disease thus demonstrating variability in disease progression. 
Additionally Berry et al. [42] conducted a study in 2010 in which they 
reported a signature unique to patients with active TB disease (in both 
intermediate and high burden settings) in comparison to patients with LTBI 
and healthy controls. Briefly this transcript signature indicated increased 
transcription of IFN-inducible genes in neutrophils, isolated from blood, 
sampled from patients with active TB. This finding also correlating with lung 
disease that was assessed by radiograph [42, 43]. Although some patients 
with LTBI did not express the transcript, approximately 10-25% of LTBI 
persons expressed a similar transcriptional profile to individuals with active 
TB. Additionally a portion of patients that received TB therapy displayed 
notable gene expression differences compared to TB treated individuals. 
This further highlights the heterogeneity that is intrinsic to the TB disease 
spectrum. The findings of these studies suggest that the site of infection, 
bacterial burden as well as the host response to infection, are linked to 
illness. Additionally a study in adolescents with LTBI demonstrated that a 
transcriptional signature in whole blood correctly identified individuals at risk 
of developing active TB up to 12 months prior to clinical diagnosis thus 
further supporting the concept of a differential risk of reactivation in 
populations [9, 44]. These findings in humans were previously observed in 
the macaque model of TB, in which a spectrum of disease was also noted 
[45, 46]. Lin and colleagues sought to characterise the histopathology, 
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pathology and immunological characteristics of macaques that were infected 
with a low dose of Mtb. Differences observed between LTBI macaques and 
macaques with active disease included bacterial burden and the degree of 
pathology [46]. Heterogeneity was noted in both groups with some monkeys 
with clinically active disease having bilateral lobe involvement and pulmonary 
cavitation compared to other monkeys with active disease that had a 
pathology in the thoracic lymph nodes and a single lung lobe [46]. Moreover 
this heterogeneity was also observed in latently infected macaques in which 
some macaques had only one lymph node involvement while others were 
classified as having an intermediate disease state. Similar findings in 
humans were observed in the study by Esmail et al. [41]. Studies in both 
macaques and humans support the concept of heterogeneity of TB and 
further suggests that patients may be segregated according to disease risk.  
 
The pro- and anti-inflammatory signals that are initiated upon Mtb infection 
are imperative in granuloma formation [47, 48]. Careful control is required  as 
these mediators possess the ability to limit and promote bacterial 
dissemination [47]. A favoured pro-inflammatory state results in the 
remodelling of the granuloma and subsequent destruction of the surrounding 
lung parenchyma [9]. Prolonged release of pro-inflammatory mediators 
culminate in active disease [49] which is in turn vital for the successful 
transmission of Mtb [50]. Conversely a shift toward the anti-inflammatory 
state favours a better host outcome, a reduced risk of activation and a better 
long-term prognosis following treatment [49, 51, 52]. Malherbe et al. found 
that in patients that appeared cured of pulmonary TB residual inflammation 
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was associated with the presence of Mtb mRNA in sputum and 
bronchoalveolar lavage (BAL) fluid samples as assessed by 
Fludeoxyglucose (FDG) Positron Emission Tomography - Computed 
Tomography (PET-CT) [52]. Patients in South Africa and South Korean 
mirrored this observation even after a year of treatment [52]. This study 
highlighted the variable host outcomes even after patients had received 
treatment as well as the heterogenous role of inflammation in TB outcome 
[9]. Another study by Marakalala et al. [53] examined the proteomes of 
granulomas from TB-infected persons and rabbits. They illustrated that 
centres of granulomas consist of pro-inflammatory eicosanoids, anti-
microbial peptides and reactive oxygen species, while the surrounding tissue 
had an anti-inflammatory signature [53]. These findings were similar to 
studies conducted with human and macaque granulomas in which the 
compartmentalization of inflammatory mediators were organised around the 
different macrophage populations [54]. Marakala et al. also proposed that the 
balance of inflammatory mediators, and the localisation, have an effect upon 
the fate of the granuloma fate and in turn the host’s outcome [53]. Together 
these studies suggest that intervention at the granuloma level could skew 
granuloma responses in way to favour host resolution as opposed to active 
disease [9].   
 
The heterogeneity of the TB immune response directly influences the local 
granuloma microenvironment. Firstly, many granulomas form due to a single 
bacterium, that in turn multiplies within the granuloma for up to 4 weeks post 
infection [55]. At this point, the adaptive immune response is initiated in 
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which case bacterial killing is observed in the majority of granulomas leading 
to approximately 10% of granulomas being sterile by 11 weeks [9]. A pilot 
study by Subbian et al. [56] illustrated variation in the extent of fibrosis in 
granulomas. Moreover, they observed variation in the density of T cells 
despite having similar numbers of macrophages in lesions. These variations 
were in accordance with bacterial load and immune activation [9] and further 
suggested that these variations may be driven by the different immune 
profiles observed from granuloma to granuloma, which are indicative of the 
maturation state of the granuloma [56]. A study by Gideon et al. found that 
the total number and phenotype of T cells varied substantially, even within 
the same animal. The range of cytokine profiles and bacterial burden within 
each granuloma also varied [57]. Of interest was the finding that less than 
10% T cells within the granuloma were able to produce cytokines in 
response to Mtb antigen stimulation, with majority of them only producing 
one cytokine, of which IFN-γ, IL-2, TNF, IL-10 and IL-17 were dominant [58]. 
They illustrated that entire granulomas were functioned as multifunctional 
cytokine environments and that various T cells contributed to the cytokine 
repertoire [9]. They concluded that both pro and anti-inflammatory cytokines, 
produced by T cells, such as IL-10 and IL-17 is necessary for a balanced 




Figure 1. 2: The spectrum of TB from early Mtb infection to active TB 
disease. The diagram depicts a model of the spectrum of responses to TB 
infection and the effect of HIV infection on TB disease susceptibility. (Image 
sourced from Barry et al. 2009 [40].) 
 
1.2.2. Susceptibility to tuberculosis and factors influencing TB/HIV co-
infection 
The probability that Mtb can be transmitted from one individual to another is 
dependent on many factors that may be exogenous or endogenous [60]. 
Individuals with a severe case of pulmonary TB may emit a higher number of 
infectious droplets by producing droplets at an elevated rate, with the rate of 
droplet production being affected by the frequency and vigour of coughing in 
addition to pathology related factors thereby allowing pathogens to escape 
into the airway [61-63]. A person that has a sputum positive result is able to 
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infect as many as 10 individuals per annum, with the possibility of each 
smear positive case in turn leading to two new cases of TB, with at least one 
being infectious [64]. Although some individuals may be a smear negative, 
they may also be able to transmit infection with the infection dose of Mtb 
being as little as one to 10 bacilli [65, 66]. The risk of infection is increased 
when a susceptible individual is within close proximity and for a prolonged 
duration of time with an infectious individual [60] with household contacts and 
care givers/healthcare workers being at a higher risk of becoming infected 
with Mtb and the development of active TB [67].  
 
Delays in diagnosing patients as well as delays in initiation of treatment of TB 
results in an increased prevalence of infectious TB, in turn resulting in the 
increased probability of onward transmission [68]. Additionally, factors that 
contribute to delays in treatment are inadequate diagnostics, the behaviour 
of individuals in seeking healthcare treatment, structural barriers to 
healthcare access and the timeous diagnosis and treatment initiation within 
the healthcare system [60].  
 
Environmental factors also play a role in increasing infection by Mtb. Closed 
indoor spaces with limited air ventilation and minimal UV light exposure 
provide the ideal environment for airborne particles containing Mtb bacilli to 
remain viable, and infectious, thereby increasing the risk of infection [61]. In 
developing countries, solid fuels are still used for cooking with the firewood 
or biomass smoke being an independent risk factor for TB disease [69].  
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Host factors play an important role in an individual’s risk of progression to 
active pulmonary disease after infection. Host related determinants of risk 
include HIV infection, diabetes, smoking, excessive alcohol use and 
malnutrition [60] with the degree of infectiousness of the inoculum influencing 
the likelihood of disease. HIV co-infection is the greatest risk factor for the 
development of active TB disease [70] and HIV also increases the chances 
of reactivation of latent TB infection [71]. Malnutrition has been shown to 
increase the risk of TB due to an impaired immune response and TB disease 
exacerbates this due to a decreased appetite and changes in metabolic 
processes [72]. Diabetes has also been shown to increase the risk of active 
TB as emerging evidence has demonstrated that the immune response to 
type II diabetes is hyperinflammatory. Smoking is also a cause of increased 
risk to TB disease, with an additional risk of death in persons with active TB 
[73]. It is believed that the nicotine in cigarettes impair clearance of mucosal 
secretions, reduce phagocytic ability of alveolar macrophages and results in 
a decreased immune response [74-76]. Alcohol has also been recognised as 
one of the strongest risk factors for TB as it alters the immune system, 
specifically altering the networks and molecules that play vital roles in 
cytokine production [77]. Although young children and infants are at a higher 
risk of rapid progression and may act as sentinel populations for ongoing 
transmission, they rarely contribute to ongoing transmission as a result of 
their lower infectiousness [78, 79]. 
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1.3. Antiretroviral therapy (ART) induced immunity  
1.3.1. ART induced immunity to intracellular pathogens 
HIV is able to enter cells via the CCR5 and CXCR4 chemokine receptors as 
well as the CD4 receptor, expressed on CD4 T cells, and inducing uptake of 
the viral particle. Upon uptake the virus undergoes replication thus leading to 
cell death, including CCR5 expressing CD4 T cells during acute HIV 
infection, when predominantly memory and effector CD4 T cells are depleted 
[80]. CCR5 antagonism prevents entry of HIV into the cell by blocking the 
CCR5 co-receptor on the surface of CD4 T cells, thus preventing viral 
replication and in turn decreases the number of infected CD4 T cells.   
 
Antiretroviral therapy (ART) is administered to HIV infected persons with the 
aim of viral load suppression leading to immune restoration. When HIV 
replication is inhibited, the previously affected CD4 T-helper cells are able to 
avoid infection by the virus thus allowing their normal functions to be carried 
out. Immune recovery is a gradual process and the time required for this to 
occur, varies from person to person and is also dependent upon the current 
stage of the infection.  
 
Following the initiation of therapy HIV infected persons experience a 
dramatic increase in numbers of CD4 T-helper cells for the first few months, 
a slower more gradual increase in subsequent months, eventually reaching a 
plateau after years of receiving ART. The initial increase in the numbers of 
CD4 T-helper cells may be attributed to the redistribution of existing cells 
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from the lymph nodes into the bloodstream. These new cells are produced 
by clonal expansion of existing cells and consist of memory cells, that have 
been primed based on previous antigen exposure, and naïve cells, that have 
the ability to encounter new pathogens and antigens.  
 
In HIV infected persons a better quality of life and improved overall health 
and survival, by reducing the incidence and severity of opportunistic infection 
and death, is expected once CD4 cell counts reach high enough numbers. 
However this can take a long time, especially in HIV infected persons with 
advanced disease and the numbers of CD4 T-helper cells rarely reach levels 
observed in HIV uninfected persons [81].  
 
Conversely, HIV infected persons initiating ART may experience Immune 
Reconstitution Inflammatory Syndrome (IRIS) in which exhibit clinical 
deterioration despite evidence of viral suppression [81]. This occurs when 
the immune system begins to recover but additionally responds to an antigen 
already present with an overwhelming inflammatory response [82, 83]. 
Interestingly, measurements of cytokines in serum point to the innate 
immune system as the source of cytokines, as IL-8 and IL-6 cytokines and C-
reactive protein (CRP) have been shown to have the highest levels 
regardless of the underlying pathogen [84-88]. 
1.3.2. ART induced immunity to Mycobacterium tuberculosis 
It has been well established that HIV infected persons are more susceptible 
to TB than HIV uninfected persons irrespective of their CD4 T cell count [89, 
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90]. Additionally HIV infected persons with decreasing CD4 T cell counts 
have an increased susceptibility to TB, and individuals having counts of less 
than 200 CD4 T cells/μL blood are more susceptible to TB than individuals 
with more than 500 CD4 T cells/μL blood [91]. HIV infected persons with 
active TB disease contain fewer CD4 T-helper cells at the site of infection 
[92] thus resulting in poor containment of Mtb bacilli. It is therefore 
anticipated that the overall decline in the number of CD4 T-helper cells, due 
to HIV infection, would further result in a decline in the number of Mtb-
specific CD4 T-helper cells [93, 94]. However HIV infection also affects other 
cells and further affects the balance of cytokines [22]. This in turn also 
prevents persons with LTBI from controlling the infection. It has also been 
shown that the initiation of ART results in a partial recovery of Mtb-specific 
CD4 T-helper cells however despite receiving reconstituting treatment, the 
numbers and proportions of cells are not comparable to those observed in 
HIV uninfected persons [95, 96]. ART is the best way to protect HIV infected 
persons developing TB, despite the fact that it lacks antimicrobial activity. In 
HIV infected persons the increase in CD4 T cells, due to ART, correlate with 
a decrease in susceptibility to develop active TB, thus suggesting that these 
T cells play an important role in protection to TB [97]. Thus the 
characterisation of Mtb-specific CD4 T cells that expand during ART, in HIV 
infected persons sensitised by Mtb, will aid in understanding ART induced 
protection to TB and aid in the identification of more reliable correlates of 
protection.  
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1.3.3. The evolution of ART leading to an increased life expectancy 
The year 1995 marked the beginning of a new era in which ART treatment 
was revolutionised. ART drug regimens were designed to incorporate the 
inhibitors of two HIV enzymes, namely reverse transcriptase (RT) and 
protease. The inclusion of two drugs that targeted both enzymes, as 
opposed to either enzyme, resulted in a significant reduction in viral load (VL) 
and a corresponding CD4 T cell count increase [98-101]. Collier and 
colleagues illustrated that the combined effect of several drugs 
simultaneously increased the effectiveness of ART by drastically reducing 
viral replication and subsequently increasing CD4 T cell counts [98]. Also 
supporting these findings were Gulick and colleagues in which the results of 
this double-blinded study indicated that at least 6 months of treatment with a 
regimen consisting of 3 drugs (indinavir, zidovudine and lamivudine) resulted 
in significantly reduced HIV RNA levels compared to HIV RNA levels 
observed in patients receiving monotherapy or bitherapy. A corresponding 
increase in CD4 T cell count was also registered, although not the highest in 
the trial, and this persisted for up to 52 weeks [101]. Lastly, in 1997 Hammer 
and colleagues conducted a study in which HIV infected persons received 
either monotherapy (indinavir) or bitherapy, consisting of zidovudine and 
lamivudine. Results of this study revealed that the proportion of persons 
receiving bitherapy had a lower chance of progressing to AIDS or death, 
compared with the proportion of persons receiving monotherapy. Additionally 
the group of persons receiving monotherapy had a higher mortality rate 
compared with those persons receiving bitherapy [99]. These studies 
prompted questions relating to immune restoration and its mechanism.  
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1.4. Correlates of protection to TB 
1.4.1. Vaccines – Past and present 
Successful vaccines have been shown to target pathogens against which 
humoral immunity is sufficient to achieve eradication and protection, however 
in order to provide sufficient protection and Mtb eradication, TB vaccines 
need to drive the cellular compartment of the immune system [16]. The only 
vaccine available against TB is Bacille Calmette-Guerin (BCG), which was 
developed by Albert Calmette and Camille Guerin in 1921, and is routinely 
administered to infants worldwide in order to provide protection against 
severe forms of TB [16]. However BCG has been shown to provide minimal 
protection to pulmonary TB, the transmissible form of TB, in adults [16]. BCG 
plays a role in protection against Mtb by inducing CD4 and CD8 T cell 
responses [102]. For ideal host protection against TB there is a need for the 
induction of both the TH1 and TH17 responses, however BCG only induces a 
TH1 response thus leading to the inferior efficacy of the BCG vaccine [103].  
 
The development of new TB vaccines ought to aim to replace BCG by 
improving recombinant BCG (rBCG) or by genetically attenuating Mtb [16],  
with rBCG being more effective than the parental BCG due to the 
introduction of genes that have been lost during in vitro attenuation [104]. 
Horwitz et al. [105] and Horwitz and Harth [106] produced the first rBCG, 
rBCG30, that overexpressed antigen Ag85b and has been shown to provide 
protection against TB in animals. rBCG30 is able to significantly increase 
Ag85b-specific T cells that inhibit intracellular mycobacteria as compared 
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with parental BCG [107]. VPM1002, the second rBCG vaccine candidate 
[108] is formed using the gene encoding Listeriolysin (Hly) inserted into the 
genome of BCG to form rBCGUre:CHly, has been shown to provide higher 
protection against Mtb challenge through aerosol infection in mice. 
rBCGUre:CHly is currently in clinical trials due to its enhanced protection 
against TB [109].  
 
DNA vaccines express the Mtb-specific antigens Ag85A, ESAT-6, Ag85B, 
PstS-3, MPT-64 and the 65kDa heat-shock protein. In infected mice, these 
proteins were found to inhibit growth of Mtb [110]. Ad5Ag85A is a viral 
vectored adenovirus serotype 5 vector vaccine expressing Ag85A and has 
been through Phase 1 clinical trials without any serious vaccine related 
adverse effects. Ad5Ag85A had immunogenicity in BCG naïve and 
previously BCG vaccinated groups but a more effectively boosted CD4 and 
CD8 T cell immunity was demonstrated in the group that had previously 
received the BCG vaccine compared to the group that did not receive BCG 
[111]. The MVA85A vaccine was the first new TB vaccine to enter clinical 
efficacy trials and was a strong contender by eliciting TH1 responses [112]. 
However MVA85A failed to induce any protection against TB infection in 
phase IIb trials in both infants and HIV-infected adults [113]. Other viral 
vector vaccines are the MVA58A combined with Crucell Ad35 vaccine 
(Phase 1 trial) and a recombinant influenza vaccine (TB/FLU-04L) that have 
completed phase 1 trials and have a phase IIa trial planned [114].  
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In 2013, MTBVAC entered phase 1 of clinical trials and is the only live-
attenuated Mtb vaccine that has entered phase I trials [115]. MTBVAC has 
been able to replicate the same safety profiles as BCG, and has also been 
shown to provide a superior form of protection [116]. Recombinant protein-
based vaccines develop less reactogenicity, and are considered more 
potent, safe and are better characterised [14] therefore, the correct 
identification of Mtb-specific antigens secreted in culture fluid is important in 
the establishment of protective immune response against TB, and for better 
vaccine design [104].  
 
Adjuvants are compounds and molecules, or macromolecular complexes, 
that are able to boost the potency and effective duration of specific 
immunological responses to antigens [117]. Subunit vaccines that contain 
adjuvants are therefore able to enhance immune responses. The adjuvants 
that are currently safe and approved for use in humans are Aluminum salts, 
AS03/04 and MF59 which promote humoral or TH2 immunity as opposed to 
TH1 immunity [118]. Hybrid 1 + IC31 is a subunit adjuvant vaccine that is a 
hybrid of ESAT6 and Ag85B antigen with IC31, and this vaccine had showed 
durable TH1 responses in patients infected with HIV [119]. Hybrid 4 + IC31 
vaccine contains the Mtb antigens Ag85B and TB10.4 in addition to IC31. In 
order to determine the immunogenicity and safety of this vaccine, a 3 arm, 
phase IIa study was announced by Aeras in 2014 [120]. The Hybrid 4 + IC31 
vaccine has been shown to enhance protection to Mtb by lengthening and 
boosting immunity induced by BCG [121]. Other adjuvant vaccines include 
Hybrid 56 + IC31 which has been shown to not only contain the latent stage 
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of TB, but has also been able to control late stage TB infection. CD4 T cell 
responses that were specific to M72/AS01 indicated immunogenicity of the 
vaccine [122, 123].  
 
Therapeutic vaccines are targeted to prevent latent infection or reduce the 
need of chemotherapy [124]. RUTI is composed of detoxified, fragmented 
Mtb cells delivered in liposomes. RUTI was able to control the latent form of 
TB infection in mice and guinea-pigs and induce a TH1/TH2 polyantigenic 
response following a short period of chemotherapy [125]. A phase I clinical 
trial of RUTI vaccine carried out in Spain in persons without a TB infection 
and prior BCG vaccination, indicated that four different doses of RUTI that 
were used were tolerable, however moderate pain was noted with higher 
doses [126]. There are approximately 16 vaccine candidates at various 
stages of clinical trials currently being carried out (Figure 1.3), however 
further research needs to be done in order to correctly identify and select 






Figure 1. 3: Current TB vaccine candidates in the vaccine pipeline. The 
vaccine candidates currently in the pipeline are viral vector based 
vaccines (purple), protein/adjuvant based vaccines (blue), 
Mycobacterial whole cell or extract based vaccines (magenta) or live 
Mycobacterial based vaccines (dark magenta). (Image sourced from 
http://www.aeras.org/pages/global-portfolio).  
 
1.4.2. Role of T-cells in protection against TB 
CD4 T cells play a vital role in protection to TB disease via the production of 
pro-inflammatory cytokines. Both human studies and animal models support 
the notion that CD4 T cells playing a central role in the control of Mtb. In 
1999 Caruso and colleagues demonstrated that mice lacking CD4 T cells 
displayed increased susceptibility to Mtb challenge compared to wild-type 
mice [127]. Additionally, mice lacking MHC class II molecules were more 
susceptible to Mtb infection than CD4 knockout mice [127]. The importance 
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of CD4 T cells in HIV infected persons was summarised by Lawn et al. 
highlighting that HIV infected persons with low CD4 counts had an increased 
susceptibility to TB disease [91]. CD4 T cells are able to further differentiate 
into T helper cell subsets depending on the cytokine stimulus received, the 
prominent transcription factor and the ability to produce certain cytokines.  
 
 
Figure 1. 4: Possible differentiation pathways for a naïve T cell, 
dependent upon the cytokine environment in which the naïve T cell is 
activated in. Naïve T cells, once primed by antigen, have the ability to 
differentiate into several different types of T helper cells. The master 
transcription factors of each subset and characteristic cytokines are also 
pictured. (Image sourced from Yu, Shui-Lian et al. 2012 [128]).  
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TH1 cells have the ability to produce IFN-γ which, in conjunction with TNF-α, 
acts synergistically to activate macrophages. This was illustrated in the early 
1990’s, by Flesch and Kaufmann [129], in a study in which it was shown that 
IFN-γ stimulates anti-mycobacterial macrophage functions in vitro. 
Additionally it was shown that blocking the function of TNF-α led to reduced 
macrophage activation and that both cytokines were required in order for 
optimal macrophage activation [129, 130] as opposed to a single cytokine. It 
was further illustrated, by Flynn and colleagues, that gene knockout mice 
lacking the TNFR1 gene [131] exhibited impaired granuloma formation thus 
leading to exacerbated tuberculosis disease. In conjunction with IFN-γ, TNF-
α is essential for the formation of granulomas during TB infection. This was 
illustrated by Algood and colleagues by neutralising TNF-α with antibodies in 
mice [132]. Mice were administered anti-TNF-α antibodies 4-6 weeks post 
infection, at which point mice were reinfected leading to their deaths. Of note 
was the loss of granuloma structure and the cell infiltrations throughout the 
lungs [132]. In humans Keane et al. found that the reported frequency of TB 
associated with anti-TNF therapy was higher compared to the frequencies of 
other opportunistic infections associated with anti-TNF therapy, thus 
indicating that anti-TNF therapy may re-activate TB in LTBI persons [133]. 
 
Sullivan and colleagues showed that mice lacking the T-bet transcription 
factor produced lower levels of IFN-γ [134]. T-bet is the master 
transcriptional regulator driving the differentiation of T cells to TH1, IFN-γ 
producing cells. Thus, lower levels of IFN-γ results in a greater bacterial 
burden and ultimately death due to Mtb infection. Additionally Green et al. 
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(2013) illustrated the importance of IFN-γ produced by CD4 T cells, by 
showing that IFN-γ produced by cells other than CD4 T cells were insufficient 
to control Mtb infection in mice. Furthermore IFN-γ deficient mice had high 
bacterial loads, following Mtb challenge, and extensive necrosis leading to 
death [135, 136]. A study by Cooper and colleagues illustrated the 
importance of IL-12 in the TH1 pathway. Since IL-12 is responsible for the 
TH1 response, IL-12p40 deficient mice exhibited lower than usual IFN-γ 
levels indicating the importance of IL-12 in this pathway [137]. Similarly in 
humans, persons with IFN-γ autoantibodies exhibited an increased 
susceptibility to Mtb infection compared to persons with functional IFN-γ 
[138]. Also, humans with genetic defects in the production TH1 of cytokines 
or transcription pathways display increased susceptibility to mycobacterial 
infections, compared to persons without TH1 genetic defects [139, 140].  
 
TH17 cells are defined by their ability to produce IL-17. Once stimulated, 
TH17 cells produce the cytokine, IL-17 that is responsible for attracting and 
activating neutrophils. TH17 cells were also thought to produce IL-22, an 
equally important cytokine in TB protection, however recent evidence has 
indicated that IL-22 is produced by a distinct subset of T cells [141]. 
Additionally, TH17 cells may be responsible for the recruitment of monocytes 
and TH1 cells to the site of granuloma formation, and thus contributing to 
protection against Mtb [142, 143]. Multiple murine studies have illustrated the 
importance of IL-17 in TB – IL-17 deficient mice have been shown to have 
poor control of Mtb as a result of defective granuloma formation [142, 144]. 
In a study conducted by Scriba and colleagues, Mtb-exposed healthy 
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persons were found to have a high proportion of TH17 CD4 Mtb-specific T 
cells in peripheral blood [141]. Sutherland and colleagues reported higher 
Mtb-specific IL-17 responses in latently infected persons compared to 
persons with active TB disease [96]. Together these data suggest an 
important role for IL-17 in TB protection. 
1.4.3. Correlates of protection  
The need to identify correlates of protection to TB disease is imperative as 
the potential use of these correlates is critical for the development and 
evaluation of an effective TB vaccine [145]. Many potential TB vaccines have 
been evaluated without a reliable correlate of protection however it is 
becoming increasingly complex to evaluate TB vaccines. The identification of 
such a correlate further has the ability to potentially determine early 
indication of efficacy, identify protective antigens and vaccine candidates, aid 
in optimising vaccine dose, provide insight regarding the schedule of 
immunisations and provide preliminary evidence of immunogenicity [145]. In 
the past Mtb-specific IFN-γ was thought to be good indicator of vaccine 
efficacy and was therefore thought to be a promising correlate of protection. 
This was supported by evidence obtained from mouse models that 
demonstrated the important role of IFN-γ in protection against Mtb infection 
in mice with IFN-γ disrupted genes [135, 136]. However, the use of Mtb-
specific IFN-γ as a correlate of protection in humans was confounded as 
Hirsch et al. observed that individuals with active and advanced TB disease 
display decreased levels of Mtb-specific IFN-γ [146, 147] and it was unclear 
whether the decreased Mtb-specific IFN-γ was the cause or the effect of the 
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TB disease. Secondly, increased Mtb-specific IFN-γ was observed in 
persons with TST conversion [148, 149]. However recent evidence points to 
the fact that Mtb-specific IFN-γ alone may not be a suitable and reliable 
correlate of protection [150]. Two studies by Kagina et al. and Mittrüker et al. 
demonstrate that Mtb-specific IFN-γ from CD4 T cells does not correlate with 
protection against TB following BCG vaccination [151, 152].  
 
Recently there has been mounting evidence suggesting that polyfunctional T 
cells have shown greater promise as correlates of protection to TB disease 
compared to Mtb-specific IFN-γ monofunctional T cells [153]. Polyfunctional 
T cells possess the ability to produce three or more cytokines, 
simultaneously. TH1 polyfunctional T cells produce IFN-γ, TNF-α and IL-2 
cytokines simultaneously. In mice, a high proportion of polyfunctional CD4 T 
cells correlate with protection against Mtb infection induced by vaccination 
[154, 155]. In humans, BCG-immunized infants generated multifunctional T 
cells however the polyfunctional profile observed did not correlate with 
protection mediated by BCG vaccination [151]. Hawkridge and colleagues 
also showed that the cytokine profile in BCG vaccinated individuals, 
administered a MVA85A booster dose, displayed a significantly increased 
frequency of polyfunctional T cells [156]. Together these findings suggest 
that polyfunctional T cells may play a pivotal role in protection against TB, 
however the function of polyfunctional T cells in TB disease still remains 
unclear [157].  
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Lastly it has been demonstrated that IFN-γ-independent mechanisms, 
mediated by CD4 T cells, may also play a role in protection against TB 
disease [153, 158]. This was partly illustrated by Gallegos and colleagues by 
adoptively transferring antigen specific CD4 effector T cells and illustrating 
the ability of these cells to confer protection to naïve hosts. This protection 
detailed an IFN-γ/TNF-α independent pathway [159]. Similarly, Wozniak and 
colleagues demonstrated that the adoptive transfer of BCG-specific TH17 
cells mediated protection to Mtb, in IFN-γ deficient mice [160]. The above 
studies indicate that perhaps IFN-γ is required for skewing CD4 T cell 
differentiation towards the TH1 effector phenotype, after which IFN-γ may be 
dispensable [153].  
1.4.4. Rationale for study 
TB is the leading bacterial cause of death in Africa [8] and while there has 
been progress in diagnosing Mtb sensitisation, applicable to low incidence 
areas, and a number of new antitubercular drugs that have recently entered 
clinical trials, there remains an urgent need to understand protective 
immunity to tuberculosis in order to define correlates of protection that will 
help better design vaccines and host directed therapies.  
 
HIV infected persons are 20-30 times more likely to develop TB than HIV 
uninfected persons who have a 10% chance of developing active TB in their 
lifetime [97]. HIV-1 co-infection is the leading cause of susceptibility to 
tuberculosis, and ART is the most effective way to reduce the risk of TB in 
HIV-1 co-infected people, reducing tuberculosis incidence by up to 67% 
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[161]. We hypothesized that longitudinal analysis of a highly susceptible 
group (HIV infected people with low CD4 counts), who undergo immune-
reconstituting ART, thus become less susceptible to TB, is a novel approach 
to understanding protective mechanisms in human TB. Therefore, in a 
previous study conducted between 2005-2007 we longitudinally followed up 
19 HIV infected adults with Mtb sensitisation over 48 weeks of ART and 
showed that the strongest correlate of increased ART mediated immunity 
was the expansion of central memory CD4 T cells [162]. Two recent studies 
addressing the mechanisms of action of promising vaccine candidates, using 
animal models have highlighted the importance of central memory T cells in 
protection against TB: the subunit vaccine containing Ag85B and ESAT-6 
boosts CD4+KLRG1- IL-2-secreting central memory T cells [163], and the 
recombinant BCG ΔureC::hly vaccine mediated protection is also based on 
the expansion of central memory CD4 T cells that are CXCR5+CCR7+ and 
express low levels of the transcription factors T-bet and Bcl-6 [164]. Thus, 
the characterisation of Mtb-specific CD4 memory T cells that expand during 
6 months of ART, in HIV infected persons that are sensitised by Mtb, will 
contribute to a better understanding of T cell mediated protection to Mtb. 
Therefore this study will contribute to the identification of correlates of 





Hypothesis 1: Central memory T cells will significantly expand during 6 
months of ART in HIV infected, Mtb sensitised individuals. 
 
Hypothesis 2: Soluble factors associated with central memory T cell function 
will be detectable in plasma and their concentrations will increase, or 
decrease, over time on ART in HIV infected Mtb sensitised individuals. 
 
Hypothesis 3: The transcriptomic signature associated with central memory T 
cells will increase over time in HIV infected persons on ART, while the 
signature associated with effector memory T cells will decrease. 
 
1.6. Aims 
The overall aim of this thesis was to define immunological markers of 
protective immune reconstitution in a cohort of HIV infected persons, 
sensitised by Mtb. 
 
Specific aim 1: To investigate by FACS analysis the expansion of central 
memory T cell subset in peripheral blood mononuclear cells. 
 
Specific aim 2: To evaluate soluble markers indicative of central memory T 
cell function in plasma from HIV infected, Mtb sensitised individuals on ART 
longitudinally using ELISA and multiplex assays. 
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Specific aim 3: To compare gene transcriptional signatures characteristic of 
central memory and effector memory T cells in 50 HIV infected persons 
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Chapter 2: Materials and Methods 
Disclaimer: 
Tissue culture procedures were performed under sterile conditions and using 
strict aseptic techniques. All experiments with unfixed cells were conducted 
in a class II bio-safety cabinet, in a bio-safety two-plus laboratory facility. 
Resultant waste generated was disposed of according to the University of 
Cape Town’s bio-hazardous waste disposal standard operating procedure. 
Reagents were used and stored per manufacturer’s instructions, unless 
otherwise stated. Lastly, laboratory equipment was serviced regularly 
according to the manufacturer’s instructions, and a daily temperature 
monitoring system was in place for all necessary equipment. 
 
2.1. Study Population and Sample Collection 
Ethical approval for the study was obtained from the Faculty of Health 
Sciences Human Research Ethics Committee, University of Cape Town, 
HREC245/2009. Fifty antiretroviral (ART) naïve, HIV infected individuals 
were recruited from the Ubuntu Clinic in Khayelitsha, Cape Town during 
2011. Individuals were sampled at baseline and after one, three and six 
months of receiving ART. These individuals had CD4 counts less than 250 
cells/µL, as per the South African National Guidelines at the time. Blood was 
drawn for the Quantiferon® Gold In-Tube assay (QFT), Enzyme-Linked 
ImmunoSpot (ELISpot) assay, RNA extraction, Peripheral Blood 
Mononuclear Cell (PBMC) separation for storage as well as CD4 count and 
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viral load tests. Sputum was also collected to determine Mtb culture 
positivity. The control group, consisting of fifty-five HIV uninfected individuals, 
was recruited from the same site throughout 2012. These individuals were 
sampled once. Blood was drawn for the QFT assay, ELISpot assay, PBMC 
separation for storage and CD4 count determination. Although 55 HIV 
infected persons and 55 HIV uninfected persons were recruited for this 
study, not all patient samples were included for each study aim. This was 
due to: 1) incomplete sample sets from timepoints being available, 2) 
availability of samples varied for each aim as some samples were previously 
used for optimisation experiments, 3) poor sample quality prevented the 
inclusion of samples in certain experiments and 4) limited sample quantity 
prevented the inclusion of samples in experiments. The number of patients, 
in each cohort, included for each experimental aim will be noted in the 
patients characteristics sub-chapter in the chapters of this thesis. 
 
2.2. Exclusion criteria 
At the time of recruitment, the following exclusion criteria applied: evidence 
or suspicion of active tuberculosis (TB), current INH or TB chemotherapy, 
grade III-IV peripheral neuropathy, pregnancy, abnormal liver function, age 
<18 years, development of active TB during longitudinal follow up as 
determined by sputum culture at 1, 3 or 6 months of receiving ART. Six 
patients cultured positive for: Mtb complex, M. fortuitum and Mycobacterium 
Other than Tuberculosis (MOTT) these patients were referred to the TB 
services for treatment and sample collection was terminated. Samples 
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leading up to the time of TB diagnosis were stored and these samples were 
analysed separately. 
 
2.3. Separation of Peripheral Blood Mononuclear Cells  
12ml of blood was collected from HIV infected individuals, and 18ml from HIV 
uninfected individuals, in Sodium Heparin tubes. PBMC were isolated using 
the Ficoll-Hypaque (Sigma Aldrich) density gradient centrifugation method. 
Ficoll-Hypaque consists of ficoll which is a carbohydrate polymer that has a 
high density. The density of ficoll is higher than that of PBMC thus resulting 
in a layer of PBMC forming above the ficoll, following centrifugation, and 
thereby facilitating the separation of PBMC from plasma, platelets, and red 
blood cells. Briefly, the blood was diluted with 1x Phosphate Buffer Saline 
(PBS) (Sigma Aldrich) in a 1 to 1 ratio. The diluted blood was then carefully 
layered over 10ml of Ficoll-Hypaque and centrifuged for 20 minutes at a 
speed of 700xg (without brake) in order to generate a gradient of cells. The 
layer of PBMC was then removed using a 3ml pasteur pipette and 
transferred to a 15ml sterilin containing 5ml of RPMI. The cells were washed 
with RPMI followed by counting. 20µL of cells were added to 20µL 0.4% 
Trypan Blue and counted using a disposable counting chamber [1]. Viable 
cells were cells that were impermeable to the dye. Cells were enumerated 
according to the following formula: 
 
𝐶𝑜𝑢𝑛𝑡 𝑝𝑒𝑟 𝑚𝑙 =
𝑡𝑜𝑡𝑎𝑙 𝑛𝑜. 𝑜𝑓 𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
𝑛𝑜. 𝑜𝑓 4𝑥4 𝑔𝑟𝑖𝑑𝑠
 𝑥 104 𝑥 𝑠𝑎𝑚𝑝𝑙𝑒 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 
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The cells were washed again and frozen. For the freezing procedure, 0.4ml 
RMPI was used to resuspend the cell pellet after which 0.5ml freezing media 
was added in a drop wise fashion while rotating the tube containing cells. 
One to ten million cells were stored in a cryovial in a chilled Mr. Frosty at -
80°C overnight, thereafter the cryovials were transferred to liquid nitrogen 
the following day.  
 
Figure 2. 1: Diagrammatic representation of blood components pre- and 




2.4. Determination of Mtb Sensitisation by Quantiferon Gold 
In-tube assay 
The Quantiferon® Gold In-Tube (Cellestis Inc., Valencia, CA) assay was 
performed, according to the manufacturer’s instructions, on all samples 
collected. One ml of whole blood was collected per tube using three tubes, 
labelled Tuberculosis (TB) Antigen, Nil and Mitogen, per individual and was 
incubated for 16-20 hours. The TB antigen labelled tube contained Mtb 
specific antigens; ESAT-6, CFP-10 and TB7.7 (peptide p38-55), while the 
mitogen contained phytohaemagglutinin-P, a polyclonal T cell activator, and 
the Nil tube served as a negative, unstimulated control. 150µL of plasma was 
removed to determine the concentration of Interferon gamma (IFN-γ) 
released from the cells, by ELISA (Cellestis Inc., Valencia CA). Prior to 
commencement of the assay, kit solutions were reconstituted according to 
the manufacturer’s instructions. Working strength conjugate was prepared by 
adding 60µL conjugate concentration to 6mL Green Diluent for each plate. 
The kit standard was reconstituted with distilled water to 8.0 International 
Units per mL (IU/mL) and mixed until complete solubilisation. Four standard 
tubes and 4 dilutions were prepared by serially diluting 150µL of the 
reconstituted kit standard to tubes S2 and S3 respectively, containing 150µL 
Green Diluent. Freeze-dried conjugate was reconstituted with 0.3mL distilled 
water and mixed gently until complete solubilisation. Lastly, the wash buffer 
was prepared by adding 1 part of 20X wash buffer to 19 parts of distilled 
water and mixed thoroughly. Following reagent preparation, 50µL of working 
strength conjugate was added to each well in a 96 well plate, followed by 
50µL of sample plasma from QFT tubes. 50µL of each standard, of known 
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concentration, was added to wells and were run in triplicate. The plate was 
sealed and allowed to mix for one minute using a plate shaker (Barnstead 
Labline). The plate was then covered in foil and incubated at room 
temperature for 2 hours. Following incubation, the wells were washed with 
400µL wash buffer 6 times with soaking for 5 seconds between each wash. 
The plate was tapped faced down on a bed of absorbent paper to remove 
residual wash buffer. 100µL of enzyme substrate solution was added to each 
well and the plate was allowed to mix on the plate shaker for 1 minute, 
followed by incubation for 30 minutes at room temperature. After exactly 30 
minutes, 50µL Enzyme Stop solution was added to all wells, thereafter the 
plate was read using the Bio-Rad iMark Microplate (Bio-Rad Laboratories) 
ELISA plate reader at 450nm with 655nm reference filter. The concentration 
of IFN-γ was measured in IU/ml and Ag-Nil readings of 0.35 IU/ml and above 
were regarded as a positive response. The remaining supernatant from the 
Quantiferon tubes was stored at -80°C and subsequently used for multiplex 
analysis.  
 
2.5. Determination of Mtb Sensitisation by an in house 
Enzyme-Linked ImmunoSpot assay 
The measurement of IFN-γ by ELISpot was performed as described 
previously [2] [3] [4] using the human Interferon-gamma ELISpotPRO kit 
(MABTECH, Nacka Strand, Sweden). Pre-coated 96 well plates (Mabtech) 
were washed 4 times with sterile PBS and blocked with R10 media (RPMI 
supplemented with 10% FCS, 0.01mg/ml of penicillin/streptomycin and 
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0.25μg/ml of fungin) for 30 minutes at room temperature. Following 
incubation, the R10 media was removed and 250 000 PBMC were added 
into wells. Antigenic stimuli consisted of a pool of ESAT6 (Rv3875, 5 μg/mL) 
and CFP10 (Rv3874, 5 μg/mL) peptides. As positive control, anti-CD3 mAb 
CD3-2 at 100ng/mL final concentration was used, while unstimulated wells 
were the negative control. Following incubation for 18 hours at 37 °C with 5% 
CO2, the plates were washed 5 times with plain PBS.  
100µL of conjugated secondary antibody was added to each well and the 
plate was allowed to incubate at room temperature for 2 hours, after which 
100µL of filtered BCIP/NBT-plus substrate solution was added to each well 
and developed until spots emerged, at which point the plate was washed 
with distilled water and allowed to dry. The number of IFN-γ producing cells 
were enumerated by an Immunospot Series 3B Analyser (Cellular 
Technology, Cleveland, OH, USA) and recorded as spot forming cells per 
million PBMC (SFC/million). ELISpot plates were retained for visual 
inspection and confirmation in the case of anomaly. Readings of 30 
SFC/million and above were regarded as a positive response. 
 
2.6. Determination of soluble markers in QFT supernatants 
by Multiplex assays 
2.6.1. Bio-Rad Pro Human Cytokine 27-plex Panel 
Frozen QFT plasma was thawed and used for multiplex analysis. 25µL of 
sample was used at a 1:3 dilution to determine the concentration of 27 
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analytes: Interleukin (IL) IL-1 beta, IL-1 Receptor Antagonist (IL-1Ra), IL-2, 
IL-4, IL-5, IL-6 IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17, EOTAXIN, 
basic Fibroblast Growth Factor (FGF), Granulocyte Colony-stimulating Factor 
(G-CSF), Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF), 
IFN-γ, Interferon gamma-induced Protein 10 (IP-10), Membrane Co-factor 
Protein-1 (MCP-1), Macrophage Inflammatory Protein-1 alpha (MIP-1α), 
Macrophage Inflammatory Protein-1 beta (MIP-1β), Regulated upon 
Activation Normal T-cell Expressed and Presumably Secreted (RANTES), 
Platelet Derived Growth Factor (PDGF), Tumor Necrosis Factor alpha (TNF-
α) and Vascular Endothelial Growth Factor (VEGF) by using a Bio-Plex Pro 
Human Cytokine 27-plex kit (Bio-Rad Laboratories, Hercules, CA).  
The lyophilized standard was reconstituted with 500μL of the standard 
diluent provided and incubated for 30 minutes at room temperature. After the 
incubation, a dilution series was prepared in order to generate an eight-point 
standard curve with a four-fold dilution between each point. 128μL of the 
reconstituted standard was added to 72μL of standard diluent in tube 1 and 
vortexed briefly. Thereafter 50μL of the standard in tube 1 was added to a 
second tube containing 150μL of standard diluent, and vortexed briefly. This 
was repeated for six tubes. A ninth tube contained 150μL of standard diluent 
only and served as a blank.  
25μL of each sample was diluted with 75μL of the included sample diluent 
and kept on ice. Beads and antibodies were vortexed briefly and re-
suspended in the kit-included assay buffer and antibody diluent respectively. 
50µL of magnetic beads pre-coated with antibodies to the above mentioned 
27 analytes were added to all wells in a 96-well plate, and washed twice with 
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wash buffer using the Bio-Rad Bio-Plex Pro wash station (Bio-Rad 
Laboratories). Fifty µL of standards were added in duplicate and 50µL of 
diluted QFT supernatant was added to the remaining wells. The plate was 
allowed to shake, at room temperature, at ± 850 rpm for 30 minutes to 
facilitate sample binding to the beads. The plate was washed 3 times with 
wash buffer, after which 25µL of conjugated antibody was added to each well 
on the plate and the plate was agitated at room temperature, at ± 850 rpm, 
for 30 minutes. After 3 washes 50µL of Streptavidin-PE was added to each 
well on the plate and shaken at room temperature, at ± 850 rpm for 10 
minutes. Following incubation, the plate was washed 3 times with wash 
buffer, the beads were re-suspended with 125µL assay buffer and shaken for 
five minutes.  
The samples were acquired on a Bio-Plex 200 system with Luminex xMap 
Technology (Bio-Rad Laboratories, Hercules, CA) using Bio-Plex Manager 
Software (version 6.1). Concentrations that were reported to be below the 
limit of detection were assigned the lowest value of the corresponding 
analyte standard.  
 
2.6.2. MERCK Milliplex MAP Human Cytokine/Chemokine Magnetic Bead 
Panel – Premixed 23 Plex 
Frozen QFT plasma was thawed and used for multiplex analysis. 25µL of 
sample was used at a 1:3 dilution to determine the concentration of 23 
analytes: IL-12p40, IL-13, IL-15, IL-17, IL-22, IL-23, IL-1Ra, IL-1α, IL-9, IL-
1β, IL-2, IL-4, IL-6, FGF-2, G-CSF, Interferon alpha 2 (IFN-α), IFN-γ, IP-10, 
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MCP-1, MIP-1α, MIP-1β, TNF-α and VEGF using a MILLIPLEX MAP Human 
Cytokine/Chemokine Magnetic Bead Panel - Immunology Multiplex Assay 
(Merck Millipore). The lyophilized standard was reconstituted with 250μL of 
distilled water. After a ten-minute incubation at room temperature, a dilution 
series was prepared in order to generate a six-point standard curve with a 
five-fold dilution between each point. 50μL of the reconstituted standard was 
added to 200μL of supplied assay buffer in tube 1 and vortexed briefly. 
Thereafter 50μL of the standard in tube 1 was added to a second tube 
containing 200μL of assay buffer, and vortexed briefly. This was repeated for 
four tubes. A seventh tube contained 200μL of assay buffer only and served 
as a blank. Kit-supplied quality controls 1 and 2 were reconstituted with 
250μL distilled water, inverted several times to mix and allowed to sit for 10 
minutes prior to use. 
25μL of each sample was diluted with 75μL of the serum matrix reagent and 
kept on ice. Beads were vortexed briefly and re-suspended in the kit-included 
bead diluent. Flat bottom plates were pre-wet by adding 200μL of wash 
buffer into each plate well, sealing the plate, and incubating on an orbital 
shaker for 10 minutes at room temperature. Following the brief incubation, 
the wash buffer was removed from the plate, and the plate was inverted and 
tapped onto absorbent tissue several times to remove residual amounts of 
wash buffer. 25μL of each standard, control and blank was added to 
respective wells, while 25μL of assay buffer was added to the remaining 
wells allocated to samples. 25μL of kit-supplied matrix solution was added to 
wells containing standards, blanks, and controls and 25μL of diluted sample 
was added to remaining wells allocated to samples. After briefly vortexing the 
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beads vigorously, 15μL was added to all wells. The plate was sealed, 
covered in foil, and incubated with agitation (at ± 850 rpm) overnight at 4°C. 
Following incubation, the plate was washed twice with wash buffer using the 
magnetic plate washer. 15μL of detection antibody was added to all wells, 
and the plate was allowed to shake at room temperature, at ± 850 rpm, for 
an hour. 15μL of Streptavidin-PE was added to each well after incubation 
and the plate was allowed to shake at room temperature, at ± 850 rpm, for 
30 minutes. After incubation the plate was washed twice, 150μL of sheath 
fluid was added to each well, and placed on the orbital shaker for five 
minutes. The samples were acquired on a Bio-Plex 200 system with Luminex 
xMap Technology (Bio-Rad Laboratories, Hercules, CA) using Bio-Plex 
Manager Software (version 6.1). Concentrations that were reported to be 
below the limit of detection were assigned the lowest value of the 
corresponding analyte standard.  
 
2.6.3. Statistical analysis 
HIV infected individuals were grouped based on their day 0 Mtb sensitisation 
status. Individuals were classified as Mtb sensitised if they had tested 
positive in the QFT assay and/or the ELISpot assay at at least one timepoint. 
Six HIV infected individuals were excluded from the analysis due to a 
positive TB culture test during follow up. We defined the response of the 
analyte as the concentration of the analyte in the nil tube plasma subtracted 
from the concentration of the analyte in the Mtb antigen (Ag) tube plasma 
(Ag-Nil). Resulting negative values were assigned a value of zero. Statistical 
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analysis was conducted using individuals that had data for all time points. 
The results from the HIV infected group were analysed longitudinally and a 
cross-sectional comparison at six months of ART was also performed with 
HIV uninfected individuals. Statistical analysis was performed using 
GraphPad Prism Version 6.0 for Mac, after consultation with a statistician. 
The Normality of data was determined using the D’ Agostino and Pearson 
normality test. Normally distributed data was analysed using Analysis of 
Variance (ANOVA) with a Dunnett’s post-test for multiple comparisons or 
paired t test. Paired data that was not normally distributed was analysed 
using the Kruskal Wallis test with a Dunnett’s post-test for multiple 
comparisons. Unpaired data that was not normally distributed was analysed 
using the Mann-Whitney U test. Correlations were investigated by the non-
parametric Spearman rank correlation. A p-value of less than 0.05 was 
considered statistically significant. 
 
2.7. RNA Isolation from TempusTM tubes 
3ml blood was collected from HIV infected individuals in TempusTM Blood 
RNA tubes and stored at -20°C until isolation. This procedure was performed 
in a Biosafety Class II Hood (BSC). Upon isolation, TempusTM tubes were left 
to thaw overnight at room temperature in a BSC. The following day, the 
thawed contents of the tube was transferred to a 50ml sterilin, 3ml of 1X PBS 
(Sigma Aldrich) was added and vortexed vigorously at maximum speed, for 
30 seconds. Tubes were centrifuged at 4°C at 3000xg for 30 minutes after 
which the supernatant was discarded into biocide. The tube, containing the 
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pellet, was inverted on absorbent paper towels for 1-2 minutes allowing the 
removal of remaining supernatant. 400μL of RNA Purification Resuspension 
Solution was added to each tube containing the RNA pellet and vortexed 
briefly to resuspend the RNA. Tubes were kept on ice while the filtration 
membrane was being prepared. Filtration membranes were labelled and 
placed in a collection eppendorf tube. 100μL of RNA Purification Wash 
Solution 1 was added to each filtration membrane to pre-wet the filter, after 
which the resuspended RNA was transferred to the filter. The following steps 
were then performed in a designated RNA-free room to avoid RNAse 
contamination. RNAseZAp (Sigma Aldrich) was periodically sprayed on 
tubes and all surfaces prior to the following steps. The resuspended RNA 
was centrifuged at 16 000xg for 30 seconds, the liquid waste discarded and 
washed again with 500μL of RNA Purification Wash Solution 1 in the same 
filtration membrane containing tube. After the second wash, the waste was 
discarded and the filtration membrane inserted into a newly labelled 
collection eppendorf tube. 500μL RNA Purification Wash Solution 2 was 
added to each tube and centrifuged at 16 000xg for 1 minute. DNAse 
treatment was performed, to remove contaminating DNA, by adding 100μL 
AbsoluteRNA wash to each filtration membrane and incubating tubes at 
room temperature for 15 minutes. Following the DNAse treatment, 500μL 
RNA Purification Wash Solution 2 was added to each filtration membrane 
and incubated for 5 minutes at room temperature, after which tubes were 
centrifuged at 16 000xg for 30 seconds. An additional wash using RNA 
Purification Wash Solution 2 was performed, followed by spinning the dry 
filtration membrane once to remove all wash solutions. The filtration 
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membrane, containing the bound RNA, was then transferred to a newly 
labelled collection eppendorf for the elution step. 100μL Nucleic Acid 
Purification Elution Solution was added to each filtration membrane and 
incubated at 70°C in a water bath for 2 minutes, followed by a spin at 
16000xg for 30 seconds. The collected RNA in the eppendorf was then 
added back into the filtration membrane and centrifuged at a maximum 
speed of 18 000xg for 2 minutes to ensure maximum elution of the bound 
RNA. After centrifuging, 90μL of the eluted RNA was transferred to a newly 
labelled eppendorf tube and subsequently stored at -80°C. An additional 2μL 
was transferred to a Polymerase Chain Reaction (PCR) tube for Nanodrop 
quantification. 
 
2.8. Determination of RNA Quality and Quantity by Nanodrop  
Isolated RNA was quantified using a Nanodrop 2000c spectrophotometer 
(Thermo Scientific). The Nanodrop 2000 makes use of spectrophotometry to 
measure the amount of light absorbed by nucleic acids and proteins. Nucleic 
acids absorb light at 260nm therefore the 260/280 ratio was used to assess 
the purity of the RNA. A ratio of between 1.8 and 2.0 was accepted as pure 
RNA. The 260/230 ratio was used to assess the protein contamination since 
contaminants absorb light at 230nm. RNA with a 260/230 ratio lower than 2.2 
was considered to be contaminated. The Nanodrop is also able to measure 
the number of RNA molecules within a single drop of RNA. 1μL of RNA was 
assessed for Nanodrop quantification. Resulting ratios and concentration of 
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RNA thereof were recorded and used as a guideline for Real Time PCR 
experiments.  
 
2.9. Determination of RNA Quality and Quantity by Agilent 
BioAnalyzer 
This is a more precise method for RNA quantification, as all nucleic acids 
absorb light at 260nm, thereby Nanodrop ratios are not specific to RNA. We 
had decided to further quantify the RNA samples using the Agilent 
BioAnalyzer (Agilent Technologies).  The BioAnalyzer makes use of 1μL of 
RNA and generates an RNA Integrity Number (RIN). The software assigns a 
value to the sample based on the integrity of the sample and this is 
determined by the electrophoretic trace of the RNA. An Agilent RNA 6000 
Nano Kit was used for sample quantification and reagents were stored at 
4°C until required. 260μL of RNA 6000 Nano gel matrix was transferred to a 
filter membrane and centrifuged at 1 500xg for 10 minutes. 4μL of RNA 6000 
Nano Dye Concentrate was added to the Nano gel matrix and centrifuged at 
13 000xg for 10 minutes. 9μL of Nano gel matrix was loaded into the gel well 
on a RNA 6000 Nano chip while on the chip priming station. The attached 
plunger was used to apply pressure as the gel was evenly dispersed 
throughout the RNA 6000 Nano chip. 9μL was also added to two designated 
wells on the chip and 5μL of RNA 6000 Nano marker was added to all 
sample wells and the ladder well. 1μL of ladder was added to the ladder well 
and 1μL of sample was added to wells allocated to samples. The prepared 
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chip was vortexed for 1 minute in the IKA vortexer (Agilent Technologies), at 




Figure 2. 2: Agilent RNA chip making use of RNA electrophoretic trace 
in order to accurately quantify the concentration of RNA in 1μL of 
sample. (image from http://www.genomics.agilent.com/en/Bioanalyzer-DNA-
RNA-Kits/Small-RNA-Analysis-Kits/?cid=AG-PT-105&tabId=AG-PR-1185). 
 
2.10. Optimization of cDNA synthesis and RT-PCR 
In order to determine which cDNA synthesis kit to use, i.e. High Capacity 
RNA-to-cDNA Kit or SuperScript® III First-Strand Synthesis System for RT-
PCR, 24 samples of varying RNA quality were selected, based on Nanodrop 
readings, to be used for a trial cDNA synthesis run. Samples were diluted to 
100ng using PCR grade water. A total volume of 9μL of diluted RNA was 
used; where RNA concentrations were too low (i.e. less than 0.00ng/μL per 
Nanodrop reading) 9μL of RNA was used for the reaction.  
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2.10.1. Reverse Transcription of RNA to cDNA using the High Capacity 
RNA-to-cDNA Kit 
After allowing the kit components to thaw on ice 10μL 2x RT buffer and 1μL 
20x enzyme mix was added together to make a mastermix per sample of 
RNA. 11μL RNA Mastermix was added to the 9μL RNA and centrifuged 
briefly to adequately mix all reagents. A total reaction volume of 20μL was 
used per sample. The reaction was incubated at 37°C for 60 minutes 
followed by a termination at 95°C for 5 minutes and a hold at 4°C in a Bio-
Rad T100 Thermal cycler. Following the 4°C hold, the cDNA was stored at -
20°C until use. 
 
2.10.2. Reverse Transcription of RNA to cDNA using the SuperScript® III 
First-Strand Synthesis System for RT-PCR 
After allowing the kit components to thaw on ice 10μL 2x RT Reaction Mix 
and 2μL RT Enzyme Mix was added together to make a mastermix per 
sample of RNA. 11μL RNA Mastermix was added to the 9μL RNA and 
centrifuged briefly to adequately mix all reagents. A total reaction volume of 
20μL was used per sample. A Bio-Rad thermocycler was used to incubate 
the reaction at 50°C for 50 minutes followed by a termination at 85°C for °5 
minutes and a hold at 4°C. 1μL RNAseH was added to each reaction and 
incubated at 37°C for 20 minutes after which the cDNA was stored at -20°C 
until use.  
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2.10.3. Real Time Polymerase Chain Reaction using SYBR Fast Green 
Master Mix 
A SYBR Fast Green mastermix was prepared for each sample by adding 
5μL SYBR, 0.2μL GNBL2 F primer (5’-CCACCACGAGGCGATTTGTG-3’), 
0.2μL GNBL2 R primer (5’-TCTGAGTGGCTCTCATCCTGG-3’) and 3.6μL 
PCR water per sample. 9μL of mastermix was aliquoted into 112 wells of a 
384 well plate. 1μL cDNA sample was added to each well and samples were 
run in duplicate. 112 wells, containing a reaction volume of 10μL, were set 
up on a 384 well plate. The plate was run on a QuantStudio 7 (Life 
Technologies) using the default PCR thermal-cycling conditions: 95°C for 20 
seconds, 95°C for 3 seconds and 60°C for 30 seconds. The reaction ran for 
40 cycles.  
 
2.10.4. Optimization conclusions 
Results of the experiment showed amplification of all samples irrespective of 
RNA concentration. It was also determined that the SuperScript® III First-
Strand Synthesis System for RT-PCR kit ought to be used as the Ct values 
generated for samples were lower than those generated using the High 
Capacity RNA-to-cDNA Kit, thereby indicating that the SuperScript® III First-
Strand Synthesis System for RT-PCR kit required a smaller number of cycles 
in order to amplify the cDNA samples. For this reason, the SuperScript® III 




Table 2. 1: Ct values generated for GNBL2 transcript using High 
Capacity RNA-to-cDNA Kit and SuperScript® III First-Strand Synthesis 
System for RT-PCR for a subset of samples 
Sample ID Mastermix Ct 
RNA concentration 
as determined by 
Nanodrop 
Recon022 High Capacity 31 -1.4 ng/μL 
 Superscript 28 -1.4 ng/μL 
Recon004 High Capacity 22 7.6 ng/μL 
 Superscript 20 7.6 ng/μL 
Recon009 High Capacity 23 18.3 ng/μL 
 Superscript 21 18.3 ng/μL 
Recon006 High Capacity 24 83.9 ng/μL 
 Superscript 22 83.9 ng/μL 
 
 
2.11. Real Time Polymerase Chain Reaction  
2.11.1. Real Time Polymerase Chain Reaction using TaqMan Fast Advance 
Mastermix and Probes 
TaqMan probes were used for RT-PCR as opposed to SYBR Green due to 
the high specificity of TaqMan probes. The following components in table 
2.2. were used to make up a PCR mastermix in a 15ml Falcon tube: 
 69 





TaqMan Fast Advance Master Mix (2x) 10.0 
TaqMan PDAR 1.0 
Nuclease-free water 7.0 





Table 2. 3: List of Taqman PDARS and amplicon sizes used in RT-PCR 
assays 
Name of Gene Assay ID Amplicon Length 
AXIN2 Hs00610344_m1 82 
CCR2 Hs00704702_s1 61 
CCR4 Hs00747615_s1 87 
CCR5 Hs99999149_s1 72 
CCR7 Hs01013469_m1 58 
CD27 Hs00386811_m1 69 
CD38 Hs01120071_m1 67 
GATA3 Hs00231122_m1 80 
GNLY Hs00246266_m1 80 
GZMA Hs00989184_m1 56 
GZMB Hs01554355_m1 134 
GZMK Hs00157878_m1 75 
ICOS Hs00359999_m1 103 
IL2RB Hs01081697_m1 74 
ITK Hs00950637_m1 88 
LEF1 Hs01547250_m1 98 
NFKB1 Hs00765730_m1 66 
PRF1 Hs00169473_m1 106 
PRKCA Hs00925193_m1 63 




Name of Gene Assay ID Amplicon Length 
SELL Hs00174151_m1 62 
TBX21 Hs00203436_m1 62 
TCF7L2 Hs00175273_m1 105 
TGFB1 Hs00998133_m1 57 
CCL5 Hs00982282_m1 70 
IGF1R Hs00609566_m1 64 
FAM129A Hs00223000_m1 94 
PRR5L Hs01029928_m1 79 
IFNG Hs00989291_m1 73 
ARHGEF18 Hs00248726_m1 106 
GAPDH Hs02758991_g1 93 
Beta Actin Hs99999903_m1 171 
18S Hs99999901_s1 187 
 
After the PCR reagents were added to a Falcon tube, the tube was vortexed 
to ensure adequate mixing, and emptied into a nuclease-free reservoir for 
dispensing with a multichannel pipette. 18μL of mastermix was added to all 
wells in a 96-well optical reaction plate, with each well containing 2μL of 
sample cDNA, after which the plate was sealed tightly with an optical plate 
sealer (Applied Biosystems) and centrifuged at 1500rpm for 1 minute to spin 
down the contents of the plate and eliminate air bubbles that may interfere 
with data acquisition. The plate was run on a QuantStudioTM 7 Flex (Applied 
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Biosystems) in fast mode, for 40 cycles, with the conditions summarized in 
Table 2.4 below: 
 
Table 2. 4: Cycling conditions for RT-PCR using Taqman Probes. 
PCR Stage Temperature (°C) Time (sec) 
Polymerase activation 95 20 
Denaturation 95 1 
Extension 60 20 
 
 
QuantstudioTM 6 and 7 Flex Real-Time PCR software (Applied Biosystems) 
was used for the instrument setup. This software measures the PCR cycle at 
which the gene of interest begins to exponentially expand above the 
threshold limit and this is referred to as the Ct value.  
 
2.11.2. Data clean up and statistical analysis 
Following acquisition of patient samples, Ct values were exported to 
Microsoft Excel 2011 for Mac in order to normalize Ct values to 
housekeeping genes (18s, β-actin and GAPDH). Transcripts that failed to 
amplify during the 40 cycles were excluded from the analysis. Normalization, 
also referred to as ΔCt values, was achieved using the formula, in which 
correction for CD4 count was also included, for each patient sample:  
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𝛥𝐶𝑡 =  
𝐶𝑡 𝑜𝑓 𝑔𝑒𝑛𝑒 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡 –  𝐶𝑡 𝑜𝑓 ℎ𝑜𝑢𝑠𝑒𝑘𝑒𝑒𝑝𝑖𝑛𝑔 𝑔𝑒𝑛𝑒
𝐿𝑜𝑔2[𝐶𝐷4]
x 1 000 
 
Following calculations of ΔCt, a decision was made to only include 
longitudinal samples with a full set of time points in the analysis to avoid 
missing values. Statistical analysis was performed using GraphPad Prism 
(version 6.0) for Mac. The Normality of data was determined using the D’ 
Agostino and Pearson normality test. Normally distributed data was analysed 
using Analysis of Variance (ANOVA) with a Dunnett’s post-test for multiple 
comparisons or paired t test. Paired data that was not normally distributed 
was analysed using the Kruskal Wallis test with a Dunnett’s post-test for 
multiple comparisons. Unpaired data that was not normally distributed was 
analysed using the Mann-Whitney U test. A p-value of less than 0.05 was 
considered statistically significant. 
 
2.12. Characterization of T cells using Flow Cytometry 
Flow cytometry is a technology that makes use of a laser and fluorescently 
labelled antibodies in order to analyze characteristics of cells. Cells are 
stained using fluorescently labelled antibodies and are allowed to pass 
through multiple lasers, each of a different colour, thus being excited and 
emitting light at various wavelengths based on the colour of the laser. The 
light emitted is then collected and filtered using mirrors and filters (i.e. optics) 
and directed to photomultiplier tubes (PMT). PMTs measure the wavelengths 
emitted and convert the optical signals into digital values that are captured by 
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the flow cytometer’s accompanying computer and thus allowing visualization. 
PMT voltages were adjusted daily, using Rainbow fluorescent particle 




Figure 2. 3: Diagrammatic representation of a flow cytometer indicating 
the (A) fluidics (B) optics (C) electronics components that makes up the 
flow cytometer (image sourced from www.semrock.com/flow-
cytometry.aspx).   
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2.12.1. Optimization of Flow Cytometry Experiments 
2.12.1.1. Marker selection for polychromatic panel  
A primary aim of the study was to characterize how Mtb specific T cells, 
change proportionally in response to ART, in cryopreserved PBMC collected 
from HIV infected persons. In order to ensure that live cells were 
characterized, and to reduce background staining, a viability marker was 
added to the panel. Since the study focused specifically on the 
characterization of T cells, antibodies against CD14 and CD19 were included 
in the panel in order to exclude monocytes and B cells respectively. A CD3 
marker was included in order to identify all T cells. CD4 was included in order 
to identify CD4 positive cells since this was a focus of the study. Due to 
limited channels on the BD Fortessa, it was decided that CD8 responses 
could be analyzed by gating on CD3 positive and CD4 negative cells, 
thereby allowing the exclusion of a CD8 marker. It was of importance to 
assess T cell memory subsets and so the markers CD27 and CD45RA were 
included in the panel. In order to assess the functionality of the T cells of 
interest, chemokine markers CXCR3, CCR4 and CCR6 were included in the 
panel. The combination of these markers allows the distinction between TH1, 
TH2, TH17 and TH1/TH17 T cells. HLA-DR and KLRG-1 were added to the panel 
in order to determine the activation and senescence profiles of the cells of 
interest, respectively. Finally the cytokines IFN-γ, TNF-α, IL-2 and IL-17A 
were of interest due to their roles in polyfunctional T cells: IL-2 plays an 
important role in the proliferation of T cells upon antigen stimulation, IFN-γ is 
known for its implications in disease control, and TNF-α is involved in the 
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recruitment of monocytes and neutrophils, IL-17A was found at the site of 
disease in TB infected individuals [5] and preliminary multiplex analysis 
indicated that measuring this cytokine and determining its source would be 
useful. It was also important to determine the source of the cytokines, as a 
follow up from the results observed in multiplex assays. 
 
2.12.1.2. Antibody titrations 
Antibody titrations were performed on all antibodies used in the panel in 
tables 2.5. and 2.6. Titrations were performed in order to obtain the optimal 
antibody titer to be used for cell staining. This further reduces background 
staining when antibodies bind to receptors on cells; and ensures the best 
separation between negatively and positively labelled cells (Lamoreaux et al. 
2006). The optimal antibody titer was determined by measuring the MFI and 
standard deviation (SD) of positive and negative populations of cells in a 
titration series. The MFI and SD were used in the formula below in order to 
determine the stain index (SI). 
 
𝑆𝐼 =




The SI and corresponding antibody concentration was plotted in order to 
generate saturation curves (Figure 2.5. A). Graphs of the positive and 
negative MFI and corresponding antibody concentration was plotted in order 
to determine the optimal titer at which the best separation occurred (Figure 
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2.5. B). Lastly, the percentage of positive cells was also plotted against the 
corresponding antibody concentration in order to determine the antibody titer 
at which the optimal yield of percentage positive cells occurs (Figure 2.5. C).  
 78 
 
Figure 2. 4: Configuration of the BD Fortessa flow cytometer used in the study, based at the South African Tuberculosis 
Vaccine Initiative (SATVI). The cytometer consists of a (A) trigon Blue laser, (B) trigon Red laser, (C) an octagon Violet laser and 
(D) an octagon Green laser; and subsequent channels for each laser.  
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Figure 2. 5: Graph depicting the (A) stain index of HLA-DR antibody 
stain index (B) the MFI of a HLA-DR negatively stained cell population 
and MFI of a HLA-DR positively stained cell population (C) percentage 




Figure 2. 6: Representative flow cytometry plots for an HLA-DR titration. The volume of HLA-DR antibody added to each tube 
is shown below each flow plot. Thawed PBMC were surface stained and the live, single cell and lymphocyte populations were 
gated on. A two-fold dilution series, using PBS, was performed in order to dilute the HLA-DR antibody. 
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2.12.1.3. Antigen stimulation 
Antigen presenting cells (APCs), such as macrophages, dendritic cells, 
Langerhans cells and to an extent B-cells, present antigen via MHC 
molecules. T cells bind to the antigen being presented via T cell receptors. A 
CD receptor also binds to the MHC molecule (i.e. CD4 binds to MHC Class II 
molecules and CD8 binds to MHC Class I molecules), and CD28 or CD27 
present on the surface of the T cell binds to B7 present on the surface of the 
antigen-presenting cell. These three bonds are required for T cell activation. 
T cells are activated upon antigen recognition, expand clonally and produce 
cytokines. In order to mimic this process in vitro, pathogen specific antigens 
are used to stimulate T cells thus resulting in activation, clonal expansion 
and cytokine production. Mycobacterium Whole Cell Lysate (Mtb WCL) from 
Mtb strain H37Rv was the antigen of choice for the polychromatic flow 
cytometry assay based on data from previous studies [6] Mtb WCL (obtained 
from BEI Resources) consists of proteins, lipids and carbohydrates present 
within the bacterial cell wall, was stored at a concentration of 20μg/mL at -20 
°C and was used at a concentration of 2μL/mL in this assay. A positive 
control was included to ensure that the assay worked optimally and that cells 
were not anergic. Staphylococcus aureus Enterotoxin B (SEB) is produced 
by the bacterium species Staphylococcus aureus and is commonly known as 
the toxin responsible for food poisoning thus making SEB a good positive 
control. SEB was stored at a concentration of 5μg/ml at -20 °C and a 
concentration of 5μL/mL was used in this assay. 
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2.12.1.3. Fluorescence Minus One Controls 
A Fluorescence Minus One (FMO) control contains all fluorochromes in a 
polychromatic panel in a single tube, except for one that is currently being 
measured. This control is set up in order to ensure that positive events of 
interest are real events and not present due to the spread of other 
fluorochromes into the channel of interest. FMO controls were conducted for 
all markers to ensure no spillover into channels, that all markers in the panel 
were compatible and that gates were drawn in the appropriate positions on 






Figure 2. 7: FMOs of a surface (A) and intracellular marker (C) included 
in the polychromatic panel. (A) CD45RA marker included in surface and 
ICS staining, (B) absence of the CD45RA marker in surface and ICS 
staining, (C) TNF-α included in the surface and ICS staining and (D) absence 
of the TNF-α marker in surface and ICS staining. FMO controls were 
conducted for all markers to ensure no spillover into channels, to ensure that 
all markers in the panel were compatible and ensure that gates were placed 
in the appropriate positions. 
2.12.1.4. Gating strategy 
In the context of flow cytometry, gating refers to the selection of a specific 
region on the flow plot that depicts the cells of interest. Cells inside the gate 
are the cells that will continue to be analyzed while those cells falling out of 
the gate will be excluded from the analysis. It is important to establish a 
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gating strategy for optimal analysis of data and that this strategy be 
applicable when analyzing all subsequent datasets.   
In this study, we used time as a parameter in order to include those cells 
acquired during consistent acquisition. Using this parameter, it was also 
possible to exclude any cell clumps or bubbles that may have been present 
within the flow cell at the time of acquisition. The FSC-A and FSC-H 
parameters were then used to gate on single cells, and SSC-A and FSC-A in 
order to gate on lymphocytes. Since the study focused on T cells, CD14 and 
CD19 markers were used to identify and exclude monocytes and B cells 
respectively, thus the CD14/CD19 negative, IFN-γ positive population was 
gated on. IFN-γ positive cells were gated on at this point in the gating 
strategy as gating on surface markers may underestimate cytokine 
responses. The IFN-γ parameter was also used to ensure that all live and 
IFN-γ producing cells were adequately selected, after which CD4 positive 
cells were gated on. Next, CD4 positive cells were characterized by the 
following markers; CCR4, CCR6, CXCR3, HLA-DR, KLRG-1. CD45RA and 
CD27 were used in order to assess the memory profiles of CD4+ T cells. 
Lastly, the ability of CD4 cells to produce the cytokines IFN-γ, TNF-α, IL-2 






Figure 2. 8: Gating strategy used for polychromatic flow panel. 
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2.12.1.5. Flow Cytometry Optimization Conclusions 
Markers of interest and fluorochromes to which they were conjugated, were 
selected based on the channels and lasers available on the SATVI BD 
Fortessa shown in Figure 2.4. Each antibody was titrated individually to 
generate SI, MFI and percentage of positive cells vs. antibody volume 
graphs to select the optimal antibody titer. The polychromatic panel was then 
tested for all surface markers to ensure that the antibodies were compatible. 
Once this was achieved the intracellular cytokine antibodies were titrated in 
order to determine optimal antibody titers, and the entire polychromatic panel 
was tested on fresh and frozen PBMC to ensure that all antibodies were 
compatible. Tables 2.5. and 2.6. contain a summary of all antibodies and 
corresponding final volumes used in this study. FMOs for every fluorochrome 
were setup to ensure that there was no spillover into adjacent channels and 
to ensure that the gates for cell populations were adequately placed on the 
flow plots. A gating strategy for optimal analysis was determined resulting in 
an optimized polychromatic flow cytometry panel for the characterization of T 
cells in HIV infected individuals sensitized by Mtb. 
 
2.12.2. Thawing of frozen PBMC and stimulation for the flow 
cytometry experiments 
Cryovials containing cryopreserved PBMC were removed from liquid nitrogen 
and placed into a 37-degree incubator to thaw for 10 minutes. Following 
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thawing cells from a single cryovial were transferred in a drop-wise fashion, 
using a Pasteur pipette, to 10ml of R10 fresh media in a 50ml sterilin. Cells 
were centrifuged for 10 minutes at 400rpm in a Heraeus Megafuge 40R 
centrifuge (Thermo Scientific), after which the cell supernatant was discarded 
and cells were resuspended by tapping the sterilin. 10ml of fresh R10 media 
was added to each sterilin and vortexed briefly to facilitate mixing. Cells were 
then counted using a counting chamber and the Bio-Rad TC20 Automated 
cell counter (Bio-Rad) for enumeration. 20μL of cells was added to 20μL 
0.4% Trypan Blue (Sigma Life Sciences) and mixed briefly, 10μL was then 
pipetted into a counting chamber and inserted into the TC20. Remaining 
cells in the sterilin were washed and resuspended with R10 media to achieve 
a final concentration of 1x106 cells/ml. Cells were then transferred to FACS 
tubes (BD Biosciences) and individual tubes were stimulated with (1) Mtb 
WCL at a concentration of 20μg per ml of cells; (2) SEB at a concentration of 
5μg per ml of cells; and (3) a single tube was left unstimulated for each 
participant. FACS tubes were incubated at 37 °C, 5% CO2 for 3 hours prior to 
the addition of Brefeldin A (BFA) at a concentration of 5μg per ml of cells. 
BFA is a protein transport inhibitor that blocks the transport of proteins 
(cytokines) from the endoplasmic reticulum to the Golgi apparatus. Cells 
were then incubated for 18 hours at 37 °C, 5% CO2 prior to staining. 
 
2.12.3. Surface and Intracellular Staining of PBMC 
Staining in this context refers to the usage of an antibody that is conjugated 
to a fluorochrome being used to bind to its receptor on a cell of interest. Light 
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of a specific wavelength, depending on the fluorochrome bound to the 
antibody, is emitted when the cells are excited by a laser in a flow cytometer. 
Intracellular staining refers to the same procedure, with the exception of the 
receptors on the cell of interest being found on the inside of the cell thereby 
requiring a further step of permeablisation to make the cell penetrable by the 
antibody. The following procedure was performed in the dark due to light 
sensitive reagents. Following overnight incubation at 37 °C, 1ml PBS was 
added to each tube of cells and tubes were centrifuged for 5 minutes at 
1500rpm. Supernatants were decanted after which cells were resuspended 
by briefly vortexing. 50μL Near InfraRed (NIR) live dead stain was added to 
each tube and vortexed lightly to mix. Tubes were covered in foil and 
incubated at room temperature for 10 minutes; during which time the surface 
stain antibody mixture was made. The volumes of antibodies in Table 2.5. 
were added together to make up the surface stain antibody cocktail. BD 
Brilliant Violet stain buffer (BD Biosciences) served as the buffer for the 
antibody cocktail and was used to bring the volume to 50μL antibody cocktail 




Table 2. 5: Anti-human antibodies used in flow cytometry surface stain 
panel 





CCR4 BV510 L291H4 BioLegend 359416 1.25 
CD45RA BV570 HI100 BioLegend 304131 0.25 
CCR6 BV605 G034E3 BioLegend 353420 1.25 
CD3 BV650 OKT3 BioLegend 317323 0.4 
CD27 BV711 O323 BioLegend 302834 0.4 
CD4 FITC RPA-T4 e-Bioscience 11-0049-42 0.4 
CD14 APC-Cy7 61D3 Invitrogen MHCD1427 0.7 
CD19 APC-Cy7 SJ25-C1 Invitrogen MHCD1927 0.7 
HLA-DR PE  BD 347401 1.2 
KLRG-1 PE.Cy5-5 13F12F2 e-Bioscience 46-9488-42 0.7 
CXCR3 PE.Cy7 IC6/CXCR3 BD 560831 1.25 
Viability APC-Cy7 N/A Invitrogen L23102 0.7 
 
Following incubation with NIR live dead dye, cells were washed using 1ml 
PBS containing 2% FCS at 1500rpm for 5 minutes; after which the cell 
supernatant was discarded and cells resuspended by briefly vortexing. 50μL 
of the surface stain antibody cocktail was added to each tube and mixed 
well. Tubes were covered in foil and left to incubate at room temperature for 
25 minutes to facilitate binding of antibodies to their respective cell surface 
receptors. Cells were washed with PBS containing 2% FCS following 
incubation and cell supernatants were discarded. 250μL BD 
CytoFix/CytoPerm buffer (BD Biosciences) was added to each tube and 
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incubated for 20 minutes at 4 °C to allow permeabilization of cells. 
Permeabilization is a reversible process that allows the antibodies to enter 
the cells and bind to markers of interest. This is achieved by the use of 
saponin, present in the buffer that binds to cholesterol molecules on the 
surface of the cell. This binding results in the formation of insoluble 
complexes between cholesterol and saponin resulting in the rearrangement 
of lipids and thus a more permeable structure. During the permeabilization 
incubation step, the intracellular marker cocktail of antibodies was made up 
according to volumes in table 2.6. BD Perm/Wash (BD Biosciences) served 
as the buffer for the intracellular cytokine antibody cocktail and was used to 
bring the volume to 50μL intracellular cytokine antibody cocktail per sample.  
 
Table 2. 6: Anti-human cytokine antibodies used in flow cytometry 
intracellular staining 





IL-17A AF647 B27 BioLegend 512310 1.0 




BioLegend 500344 1.25 





Following incubation, cells were washed with 1.5mL BD Perm/Wash (BD 
Biosciences) and 50μL of intracellular cytokine antibody cocktail was added 
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to each tube; after which the tubes were incubated at 4 °C for 30 minutes to 
allow for optimal binding of intracellular cytokine antibodies to their 
respective targets. For the final step following the incubation, cells were 
washed with 1.5mL BD Perm/Wash (BD Biosciences) and subsequently 
fixed with 200μL of 1% paraformaldehyde (Sigma Aldrich) following cell 
supernatant removal. Lastly, tubes were covered with foil and incubated at 4 
°C until acquisition on the same day. 
 
2.12.4. Compensation for Spectral Overlap 
During acquisition, fluorescence from a single fluorochrome may be detected 
in more than one detector (i.e. the intended primary detector and additional 
secondary detectors). This is referred to as spectral overlap. Correction for 
spectral overlap is achieved by mathematically subtracting the resulting 
spillover (Figure 2.9) using single stained beads. It is important to note that 
compensation control beads are as bright as, if not brighter, than the cells of 
interest, therefore the same antibody titers were used for the compensation 
controls and the polychromatic assay. For the preparation of compensation 
controls 100μL PBS containing 2% FCS was added to each tube followed by 
40μL of Anti-Mouse Ig, κ positive compensation beads (BD Biosciences). 
Antibody titers in tables 2.5 and 2.6 were then added to corresponding tubes 
and lightly vortexed to mix. Tubes were covered in foil and incubated at room 
temperature for 10 minutes to facilitate binding to compensation beads. After 
the incubation, the single stain tubes were washed with 1ml PBS containing 
2% FCS and the supernatant was discarded. The beads were then vortexed 
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lightly to ensure resuspension, and 200μL 1% paraformaldehyde was added 
to each tube to fix beads. After fixation, tubes were covered in foil and stored 
in a 4 °C fridge for up to 7 days. 
 
 
Figure 2. 9: Diagrammatic representation of expected spectral overlap 
in polychromatic panel generated by BioLegend Fluorescence Spectra 
Analyzer (www.biolegend.com/spectraanalyzer). Compensation was used 
to correct for the spectral overlap by mathematically subtracting the spillover 
in each channel. 
 
2.12.5. Data acquisition  
Samples were acquired on a BD Fortessa flow cytometer (Becton Dickinson) 
with FACSDiva software version 6.0. (Becton Dickinson) on the same day 
that antibody staining had occurred. Due to variable initial cell counts and low 
cell viability, all cells were acquired. An average of 1 000 000 events were 
acquired per tube. Compensation beads were acquired daily before the 
acquisition of samples, to allow for post-acquisition compensation. 
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2.12.6. Data clean up and statistical analysis 
Flow cytometry data analysis was conducted using Flowjo v9.9.4. (Treestar), 
Pestle version 1.7 and SPICE version 5.3 (from Mario Roederer, NIAID, NIH) 
[7]. Statistical analysis was conducted using GraphPad Prism (version 6.0). 
Mtb specific responses for each sample were valid if the antigen-stimulated 
tube contained a value greater than twice the value detected for the 
unstimulated tube, as described [8, 9]. If antigen stimulated responses were 
less than twice the value detected for the unstimulated tube, a value of 0 was 
assigned to the sample. Cytokine responses were measured by subtracting 
the unstimulated tube from the antigen-stimulated tube. All resulting negative 
values were assigned a value of 0. The absolute number of cells was 
calculated using the following formula: 
𝐴𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 =




The Normality of data was determined using the D’ Agostino and Pearson 
normality test. Normally distributed data was analysed using Analysis of 
Variance (ANOVA) with a Dunnett’s post-test for multiple comparisons or 
paired t test. Paired data that was not normally distributed was analysed 
using the Kruskal Wallis test with a Dunnett’s post-test for multiple 
comparisons. Unpaired data that was not normally distributed was analysed 
using the Mann-Whitney U test. Correlations were investigated by the non-
parametric Spearman rank correlation. A p-value less than or equal to 0.05 
was considered significant. P-values are illustrated in subsequent figures by 
asterixes and mean the following: ns refers to a p-value > 0.05, a single 
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asterisk (*) refers to a p-value ≤ 0.05, two asterix (**) refer to a p-value ≤ 
0.01, three asterix (***) refer to a p-value ≤ 0.001 and four asterix (****) refer 
to a p-value ≤ 0.0001. 
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Chapter 3:  Determination of Mycobacterium 
tuberculosis antigen-specific response in 
persons with and without HIV infection  
3.1. Introduction 
According to WHO 5-10% of individuals will develop the active form of TB 
disease in their lifetime [1, 2] In addition, the mechanism responsible for the 
progression from LTBI to active TB disease has yet to be defined. For many 
years the tuberculin skin test (TST) was used to determine exposure to the 
disease but this test is known to be confounded by vaccination with the 
Bacillus Calmette-Guerin (BCG) in addition to sensitisation by environmental 
mycobacteria [3]. These factors may render false positive TST results. 
Recently, an incremental advance has been provided by diagnostic tests that 
measure the cellular immune response to Mtb in the form of IFN-γ production 
in response to Mtb antigen stimulation. These Interferon gamma release 
assays (IGRA) make use of three proteins synthesised by Mtb, thus allowing 
these tests to be highly specific for an Mtb response [3]. The early secreted 
antigenic target 6 (ESAT-6) and culture filtrate protein 10 (CFP10) are 
encoded by the region of difference (RD1) of Mtb. This region, along with 
RD2 and RD3, were found to be deleted from the BCG vaccine strain, but 
RD1 has been established to be conserved in virulent Mtb strains [4]. The 
TST test on the other hand, is based on the tuberculin purified protein 
derivative (PPD) that is a mixture of proteins and fragments, some of which 
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is shared with other mycobacterial species and BCG vaccine strains, thus 
accounting for the poor specificity of the test [5]. The TST is also impaired by 
HIV infection [6] due to impaired cell mediated immunity in these individuals 
[7, 8].  
 
Two such IGRAs that measure the cellular immune response to TB, are the 
whole blood based QuantiFERON-TB Gold (QFT) test and the T-SPOT.TB 
test, which is based on the use of peripheral blood mononuclear cells 
(PBMC) in an enzyme-linked immunospot assay (ELISPOT) [3]. Whole blood 
is used for QFT assays and IFN-γ is released when the blood sample is 
incubated with the Mtb specific antigens [3]. An ELISA is then used to 
measure the amount of IFN-γ released by cells in the blood. In a study that 
compared the TST, QFT and T-SPOT.TB assays Rangaka et al. 
demonstrated that the T-SPOT.TB yielded a significantly higher proportion of 
interpretable results than the QFT and TST tests [3]. Results of the study 
also indicated that IGRAs, such as the QFT and T-SPOT.TB, had a higher 
sensitivity for TB infection. In addition, an advantage of using IGRAs is that 
should a patient not return to the clinic for results, the determination will 
remain valid [3]. This does not hold true for the TST test as multiple visits are 
required.  
 
IGRAs measure the amount of IFN-γ that is produced by cells in response to 
Mtb antigenic stimulation [9] and have been shown to produce accurate 
results in individuals with active TB as well as immunocompromised 
individuals [9]. However, there is still concern that these tests do not produce 
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optimal results in severely immunocompromised individuals who do not 
always mount a detectable IFN-γ response upon encounter with Mtb antigen 
[10]. This may be improved by measuring alternative biomarkers to IFN-γ. 
The quantity of such biomarkers could indicate either a normal or pathogenic 
response and therefore provide us with an individual’s health status [11]. 
Biomarkers in TB patients with active disease should predict long lasting 
treatment success, and in LTBI patients should predict treatment success 
and indicate whether reactivation is possible. In uninfected individuals, the 
quantity of a specific biomarker should indicate protection from TB when 
vaccinated [11].  
 
3.2. Characteristics of HIV infected and HIV uninfected 
persons included in this study 
Forty-four HIV infected and 50 HIV uninfected persons were included in this 
analysis. Six HIV infected persons were excluded from the study due to the 
identification of opportunistic infections during ART follow up. The 
characteristics of all patients included in the study are summarized in Tables 
3.1. and 3.2. HIV infected persons had a median age of 35 years while HIV 
uninfected persons had a median age of 27 years. Although the median age 
of HIV infected persons differed significantly from the median age of HIV 
uninfected persons, we do not believe that this difference impacted 
downstream statistics and subsequent significant differences in 
immunological markers measured. Viral suppression was achieved in HIV 
infected persons as the median viral load prior to ART was 62 933 viral 
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copies/ml, decreasing significantly (p-value < 0.0001) to levels below the 
detection limit after six months of therapy, with CD4 counts significantly 
increasing (p-value < 0.0001). The detection limit for the viral load PCR is 40 
viral copies/ml with readings <40 being regarded as below the detection limit, 
according to the National Health Laboratory Services (NHLS). 
 






HIV Infected vs. 











14/30 25/25 0.0742 
 
 
Table 3. 2: CD4 counts and Viral loads of patients. 
Median 
(IQR) 
HIV Infected Persons (n=44) 
HIV Uninfected 
Persons (n=50) 































Figure 3. 1: CD4 counts and viral loads of all persons included in the study. (A) CD4 counts of HIV infected persons (red, 
n=44) and HIV uninfected persons (blue, n=50) and (B) longitudinal viral loads, as measured by copies/ml, of HIV infected persons 































































3.3. Methods and statistical analysis 
3.3.1. Quantiferon-TB® Gold In-Tube assay 
The QFT (Cellestis Inc., Valencia, CA) assay was performed in order to 
determine Mtb sensitisation at the time of recruitment. Details are described 
in chapter 2, section 2.4. IFN-γ was measured in IU/ml and following 
subtraction of the unstimulated sample from the stimulated sample a reading 
of 0.35IU/ml, and a satisfactory mitogen response, was regarded as a 
positive response as per the manufacturer’s recommendation.  
 
3.3.2. Human Interferon-gamma ELISpot assay 
Mtb sensitisation was additionally evaluated by the ELISpot assay using the 
human Interferon-gamma ELISpotPRO kit (MABTECH, Nacka Strand, 
Sweden) as described previously [12] [13] [14] and in more detail in chapter 
2 section 2.5. ELISpot readings were recorded as numbers of Spot Forming 
Cells (SFC) per million PBMC and 30 SFC/million was regarded as cut off for 
a positive response.  
 
3.3.3. IFN-γ detection using Luminex 
Supernatants from the QFT assays were used to measure soluble IFN-γ by 
multiplex analysis using the Bio-Rad Pro Human Cytokine 27-plex kit (Bio-
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Rad Laboratories, Hercules, CA). Samples were acquired on the Bio-Plex 
200 system using Bio-Plex Manager software version 6.1. Unstimulated 
samples were subtracted from stimulated samples and concentrations that 
were below the limit of detection were assigned the lowest value of the IFN-γ 
standard. Further details are described in chapter 2, section 2.6.1. 
 
3.3.4. Surface and intracellular staining flow cytometry assay 
Cryopreserved PBMC was thawed, stimulated overnight at 37°C, 5% CO2 
with Mtb WCL (20μg/ml) and stained for assessment using flow cytometry. A 
negative control consisted of PBMC without antigen stimulation while SEB 
SAg (5μg/ml) was used as a positive control. Cells were then washed and 
stained with LIVE/DEAD Red Dead Cell stain (Invitrogen) and stained for 
surface markers using the following antibodies: anti-CD19-APC-Cy7 and 
anti-CD14-APC-Cy7 from Invitrogen; anti-CD4-FITC and KLRG-1-PE.Cy5-5 
from e-Bioscience; anti-HLA-DR-PE and anti-CXCR3-PE-Cy7 from BD; anti-
CCR4-BV510, anti-CD45RA-BV570, anti-CCR6-BV605, anti-CD3-BV650 
and anti-CD27-BV711 from BioLegend. After incubation, wash and 
permeabilization steps, the cells were stained intracellularly to detect of 
cytokines using anti-IFN-γ-Alexa Fluor 700 from BD; anti-IL-2-PE and anti-IL-
17A-Alexa Fluor 647 from BioLegend; and anti-TNF-α-eFluor450 from e-
Bioscience. The cells were then fixed and acquired on a BD Fortessa flow 
cytometer with FACSDiva software (version 6). Mtb specific responses for 
each sample were valid if the antigen-stimulated tube contained a value 
greater than twice the value detected for the unstimulated tube. If antigen 
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stimulated responses were less than twice the value detected for the 
unstimulated tube, a value of 0 was assigned to the sample. Cytokine 
responses were measured by subtracting the unstimulated from the antigen 
stimulated, and a value ≥0.05% IFN-γ was used as a cutoff to determine Mtb 
sensitisation. A detailed description of this assay can be found in chapter 2, 
section 2.12.3.  
 
3.3.5 Statistical analysis 
Statistical analysis was performed using GraphPad Prism (version 6) using 
methods for non-parametric data. The Friedman test, with correction for 
multiple comparisons, was used for paired data comparison across all 
sampling time points in HIV infected individuals, while the Kruskal Wallis test 
with correction for multiple comparisons was used for unpaired data 
comparisons across all time points in HIV infected persons. The Wilcoxon 
test is the equivalent of the non-parametric student t-test and was used to 
compare paired data in HIV infected persons at day 0 of ART and after 6 
months of ART. Additionally we also compared cross-sectional data from the 
HIV infected persons at 6 months of ART induced immune reconstitution with 
data from HIV uninfected persons using the Mann-Whitney test, used for 
unpaired data. A p-value less than or equal to 0.05 was considered 
significant. P-values are illustrated in subsequent figures by asterixes and 
mean the following: ns refers to a p-value > 0.05, a single asterisk (*) refers 
to a p-value ≤ 0.05, two asterix (**) refer to a p-value ≤ 0.01, three asterix 
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3.4.1. IFN-γ measured using the Quantiferon-TB® Gold In-Tube assay in 
HIV infected persons and HIV uninfected persons, for Mtb sensitisation 
Figure 3.2. panel A and Table 3.3. show the overall IFN-γ response, 
determined using the QFT assay, of all HIV infected persons during 6 
months of ART, and HIV uninfected persons included in this study. The cut 
off value for this assay was 0.35IU/ml and responses above this value were 
considered as a positive response. A Kruskal-Wallis test, correcting for 
multiple comparisons, in the HIV infected cohort revealed no significant 
difference in the IFN-γ response in these individuals, after 6 months of ART 
(p-value > 0.9999). However a Wilcoxon test comparing the median IFN-γ 
response at baseline with the median IFN-γ response after 6 months of ART 
revealed a significant decrease (p-value = 0.01) in HIV infected persons. 
Comparison with the HIV uninfected persons revealed that HIV uninfected 
persons had a significantly higher median IFN-γ response (p-value = 0.03). 
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3.4.2. IFN-γ detected by the human Interferon-gamma ELISpotPRO assay in 
HIV infected persons and HIV uninfected persons 
Figure 3.2. panel B and Table 3.3. show the numbers of IFN-γ positive cells 
determined using the human Interferon-gamma ELISpotPRO kit. The cut off 
value for this assay was 30 SFC/million PBMC and responses above this 
value were considered positive. When corrected for multiple comparisons, 
Kruskal-Wallis testing revealed no significant change in the number of IFN-γ 
secreting cells in HIV infected persons receiving ART over 6 months (p-value 
> 0.9999). The paired comparison between baseline and 6 months of ART 
using Wilcoxon testing also revealed no significant difference in the IFN-γ 
response in the HIV infected persons (p-value = 0.9058). Additionally when 
compared to the HIV uninfected persons, there was no significant difference 
in the number of IFN-γ secreting cells per million PBMC between the two 
cohorts (p-value = 0.354). 
 
3.4.3. IFN-γ measured using Luminex 
Soluble IFN-γ was measured using Luminex analysis in a subset of HIV 
infected and HIV uninfected persons. Figure 3.2. panel C summarises the 
measurement of IFN-γ in these persons. Since an appropriate cut off value 
for a positive response has yet to be determined for this assay, this analysis 
was used to substantiate Mtb sensitisation determined by the QFT assay. 
The Kruskal Wallis test revealed no significant difference in the concentration 
of IFN-γ measured at day 0 of ART and after 6 months (p-value = 0.4029) in 
HIV infected persons, however a non-parametric t-test revealed a significant 
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decrease in the concentration of IFN-γ produced between these two time 
points (p-value = 0.049), similar to the QFT assay. Comparison with the HIV 
uninfected persons revealed that HIV uninfected persons had a higher 
median IFN-γ concentration (p-value = 0.409) compared to HIV infected 
persons, again similar to the QFT assay results. Thus the trends observed 
for the two assays measuring soluble IFN-γ were similar.  
 
3.4.4. Mtb sensitisation determined by intracellular cytokine staining (ICS) 
assays using flow cytometry 
Figure 3.2. panel D and Table 3.3. show the overall Mtb-specific cytokine 
response determined using flow cytometry. A positive response in the 
stimulated PMBC was defined if the frequency of IFN-γ+ cells was greater 
than or equal to 0.05% of CD4 positive T cells in the background subtracted 
condition. Kruskal Wallis testing revealed no significant difference in the IFN-
γ+ response in HIV infected persons receiving ART (p-value > 0.9999). 
Additionally, a Wilcoxon test that compared the medians at baseline and 
after 6 months of ART in HIV infected persons also revealed no significant 
difference in the longitudinal IFN-γ+ response (p-value = 0.518). When the 
HIV infected persons at 6 months of ART were compared with the HIV 
uninfected persons, no significant difference between the IFN-γ+ responses 
(p-value = 0.981) was observed.  
 
We also examined at the numbers of CD4+ IFN-γ+ cells longitudinally in order 
to determine Mtb sensitisation in our cohort. This data is represented based 
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on the cut-off used above. Kruskal-Wallis testing revealed a significant 
increase in the numbers of CD4+ IFN-γ+ cells in HIV infected persons 
receiving ART (p-value = 0.028, Figure 3.2. panel E), and this was further 
supported by a Wilcoxon test comparing the numbers of CD4+ IFN-γ+ cells at 
the start of ART and after 6 months also indicating a significant increase (p-
value = 0.009). Cross sectional comparison with the HIV uninfected persons 
revealed HIV infected persons to have a significantly higher number of CD4+ 






Figure 3. 2: Graphs indicating Mtb sensitisation, determined by various 
methods, in the two groups of persons included in this study. Mtb 
sensitisation determined by (A) the QFT IGRA in HIV infected (red, n=44) 
and HIV uninfected (blue, n=50) persons, with a positive response being 
≥0.35 IU/ml, (B) the ELISpot IGRA in HIV infected (red, n=44) and HIV 
uninfected persons (blue, n=50), with a positive response being ≥30 
SFC/million, (C) Soluble IFN-γ measured by Luminex in HIV infected (red, 
n=32) and HIV uninfected (blue, n=12) persons, (D) the proportion of Mtb-
specific CD4+ IFN-γ+ T cells in HIV infected (red, n=12) and HIV uninfected 
(blue, n=6) persons determined by flow cytometry and (E) the number of 
IFN-γ+ CD4+ T cells in HIV infected (red, n=12) and HIV uninfected (blue, 






















































































































































Table 3. 3: Median and (IQR) longitudinal QFT, ELISpot, Luminex IFN-γ and cytokine+ responses determined by flow 
cytometry of all patients with corresponding p-values generated using the Kruskal Wallis test, non-parametric paired t-
test and non-parametric unpaired t-test respectively. 
Median 
(IQR) 









D0 vs. 6M 
(paired t test) 
HIV Infected at 
6M vs. 
HIV Uninfected 
(unpaired t test) 












































D0 vs. 6M 
(paired t test) 
HIV Infected at 
6M vs. 
HIV Uninfected 
(unpaired t test) 


























>0.9999 0.518 0.981 
















Table 3. 4: Summary of Mtb sensitisation in all recruited persons in the HIV infected cohort illustrated by measurement of 
IFN-γ by QFT (IU/ml), ELISpot (SFC/million) and Luminex (pg/ml). 
Patient 
ID: 
QFT IFN-γ (IU/ml) ELISpot IFN-γ (SFC/million) Luminex IFN-γ (pg/ml) 
 D0 1M 3M 6M D0 1M 3M 6M D0 1M 3M 6M 
1 0.25 0.49 0.6 0.24 16 72 80 32 223.14 0 228.29 127.14 
2 0.82 5.56 0 0 164 440       
3 13.08 2.8 3.75 3.07 292 548 236 196 533.87 731.19 0 404.02 
4 15.6 31.5 19.74 5.77 372 764 648 396 548.37 1156.93 1039.62 662.74 
5 0.05 -0.03 -0.05 0 0 44 48 4 320.68 0 251.4 0 
6 0.44 0.11 0.07 0.09 0 4 12 12 178.03 52.65 109.97 118.97 
7 0.52 2.31 0.22 0 8 32 20      
8 11.85 6.48 10.92 16.77 124 636 984 688 511.49 192.01 357.88 959.31 
9 22.2 59.5 6.9 3.6 4 296 540 172     
10 0.2 -9.76 41.2 7.67 16 136 1236 452     
11 3.57 0.88 0.73 0.31 124 12 60 44 736.05 226.41 0 115.03 
12 0.75 0.03 0.04 0.1 0 44 16 8 110.08 273.51 0 0 
13 7.31 9.45 0.3 1.2 16 400 120 72 703.77 458.73 211.02 0 
14 38.2 6.3 5.12 3.3 112 140 200 132 1620.13 560.1 438.12 394.56 
15 0.98 1.93 0.34 1.86 424 548 684 380 131.47 278.33 88.07 404.59 
16 8.37 69 32 39.1 508 1096 1580 268     
17 3.7 18.24 24.6 0 580 624 1532      
18 3.25 1.37 0.8 1.43 28 16 80 112 367.77 202.33 231.24 227.11 
19 0.01 0 57.7 26.4 -4  1040 408     
20 1.25 0.23 0.07 0.29 20 616 12 0 327.21 72.07 53.26 52.01 
21 0.51 0.71 0.21 0 4 8 12      
22 6.55 1.74 6.89 2.89 52 24 80 72 534.58 66.27 370.99 771.25 
23 0.27 0 0.35 0.4 12 28  4     
24 0.77 0.443 0.3 0.33 20 20 20 48 306.49 19.89 120.27 0 




QFT IFN-γ (IU/ml) ELISpot IFN-γ (SFC/million) Luminex IFN-γ (pg/ml) 
 D0 1M 3M 6M D0 1M 3M 6M D0 1M 3M 6M 
26 0.13 0.09 0.05 0.18 4 4 0 8 384.21 0 101.22 272.16 
27 405 478 743 42.6 3168 3200 1992 1176 10231.68 15764.73 11581.36 1317.66 
28 6.86 3.85 1.85 5.55 64 92 100 112 209.39 235.28 0 224.52 
29 0 0.06 0.54 0.13 0 4 0 72 51.28 162.05 7.41 145.95 
30 1.15 1.02 0 0 104 48             
31 0.26 0.19 0.82 0 0 16 40           
32 15.18 22.56 2.43 4.53 392 908 532 128 553.61 978.93 255.23 372.19 
33 4.96 0 0 0 124               
34 1.16 2.43 1.35 0.8 0 92 52 8 170.37 119.62 81.96 383.77 
35 0.05 0.07 0.04 0.1 4 4 34 8 324.13 15.14 0 0 
36 0.31 0.01 0.02 0.01 4 4 12 24 122.86 91.06 51.34 7.42 
37 6.9 5.8 0.73 2.35 368 592 288 204 527.63 790.4 321.81 403.86 
38 0.06 307 35.2 0 0 116 736           
39 13.98 19.29 6.19 9.18 608 824 484 140 219.91 163.36 82.63 133.84 
40 2.42 0.73 0.45 2.4 212 4 20 148 22.68 67.05 18.66 18.76 
41 0.31 215 0.18 -0.1 0 4 36 28 547.01 4597.97 562.06 0 
42 7.22 4.65 9.03 16.2 520 552 300 836         
43 0 0.08 0.01 0 0 12 16 4         
44 2.6 13.8 40 43.5 248 492 616 612 0 1522.23 2991.08 3765.32 
45 3.02 21.06 0 0 84 200             
46 0 -1.03 0.2 0 0 8 0 4 445.41 63.27 553.67 305.23 
47 0.08 0.06 0.18 0.04 28 8 44 12 17.98 25.79 83.75 0 
48 0 0.02 0.03 -0.16 0 12 0 4 362.45 73.29 251.85 294.35 
49 1.17 0.95 -0.04 2.53 40 28 4 36 435.46 269.73 228.12 1119.92 
50 0.87 0.87 0 0 72 136             
 
Shaded bars represent persons having IFN-γ measurements greater than the pre-determined cut-off values for Mtb sensitisation. 
Cut off values were 0.35 IU/ml for the QFT, 30 SFC/million for the ELISpot and 100 pg/ml for the Luminex assays.  
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Table 3. 5: Summary of Mtb sensitisation in recruited persons in the 
HIV uninfected cohort illustrated by measurement of IFN-γ by QFT 













156 48.5 48 184 997 884 
157 5.9 244 185 451 324 
158 2.9 232 186 0 12 
159 0 8 187 73.7 760 
160 92.8 672 188 250 776 
161 3.7 188 189 9.2 460 
162 1.9 280 190 0 24 
163 0.1 24 191 0.3 8 
164 2 100 192 0 0 
165 0 8 193 7.8 188 
166 0 0 194 1.8 44 
167 Not done Not done 195 0 16 
168 24.5 108 196 0.3 36 
169 1.9 180 197 0 56 
170 2.4 184 198 11.3 148 
171 24.3 1064 199 10.1 512 
172 6.1 212 200 1.9 32 
173 0.2 8 201 0.5 16 
174 20.5 256 202 0 8 
175 0 0 203 0 4 
176 0.8 60 204 14.6 256 
177 5 608 205 73 624 
178 0.4 40 206 2.4 28 
179 1.5 72 207 20 32 
180 1.5 116 208 3 76 
181 86.5 1068 209 3 28 
182 0 8 210 9.2 424 
183 2.7 44 211 4.1 60 
 
Shaded bars represent persons having IFN-γ measurements greater than 
the pre-determined cut-off values for Mtb sensitisation. Cut off values were 
0.35 IU/ml for the QFT and 30 SFC/million for the ELISpot assays.  
 
Since Mtb sensitisation was a requirement for the aims of this study, a 
subset of Mtb sensitised HIV uninfected persons was selected as the control 
cohort for each experimental aim.  
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3.4.5. Baseline correlation data of Mtb sensitised HIV infected persons 
The correlation between IFN-γ measured by Luminex and IFN-γ measured 
by ELISpot and Flow Cytometry intracellular staining at baseline, in HIV 
infected persons is summarised in Figure 3.3. and Table 3.6. The Spearman 
r correlation co-efficient determined for the QFT vs. the Luminex indicates no 
linear relationship between the variables. Additionally, a negative co-efficient 
also indicates an inverse relationship between the two variables tested. 
Similarly, the Spearman r correlation co-efficient determined for the ELISpot 
vs. Flow Cytometry also indicates no linear relationship between the 
variables, with the negative co-efficient also indicating an inverse relationship 
between the ELISpot and Flow Cytometry IFN-γ. 
 
Table 3. 6: Correlation statistics between IFN-γ determined at D0 by 
QFT and Luminex and ELISpot and Flow Cytometry intracellular 
staining in HIV infected persons. 
 
QFT vs Luminex 
IFN-γ 









Figure 3. 3: Correlation between (A) IFN-γ determined at D0 by QFT (n=44) and Luminex (n=32) in HIV infected persons 
and (B) IFN-γ determined at D0 by ELISpot (n=44) and Flow Cytometry intracellular staining (n=26) in HIV infected 
persons. 










































ELISpot vs. Flow CytometryB
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3.5. Discussion 
In order to determine Mtb sensitisation in our cohort of HIV infected persons 
receiving 6 months of ART, and our cohort of HIV uninfected persons, we 
used the QFT and ELISpot IGRAs. The cut-off values for a positive response 
to Mtb antigens were 0.35 IU/mL and 30 spot forming cells for the QFT and 
ELISpot assays respectively. Persons were regarded as Mtb sensitised if 
they registered a positive IFN-γ response (i.e. a reading higher than the 
above-mentioned cut-off values) for at least one timepoint, determined by 
either the QFT, ELISpot or Luminex assays. Discordant results between the 
QFT and ELISpot (observed in Tables 3.4 and 3.5) are expected due to 
within-subject variability and assay reproducibility [24]. The change in IFN-γ 
response is also expected and discordance between the two assays, per 
person, at one timepoint and not at another timepoint does not impact the 
sensitisation status of said person [24]. While we did not have a cut off value 
for the flow cytometry numbers of CD4+ IFN-γ+ cells analysis, Mtb 
sensitisation was also assessed by the measurement of CD4 T cell-specific 
soluble IFN-γ as well as the numbers and proportions of IFN-γ producing 
cells.  
 
Our results indicated a significant decrease in the IFN-γ production 
determined by QFT in HIV infected persons during ART. Additionally, the 
IFN-γ levels in HIV infected persons were significantly lower than that 
observed for HIV uninfected persons. At D0 34/50 HIV infected persons were 
regarded as Mtb sensitised based on QFT readings. After 1 month of ART 
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32/50 HIV infected persons were Mtb sensitised based on positive QFT 
responses, with 27/50 after 3 months of ART and 23/50 after 6 months of 
ART, based on positive QFT readings. This phenomenon may be due to 
ART-mediated immune reconstitution resulting in the redistribution of 
memory T cells back into the blood compartment. Mthiyane et al. 
demonstrated a significant increase in the proportion of persons with positive 
IFN-γ responses during the first few months of receiving ART [15]. A possible 
reason for the discordance between our results and that of Mthiyane et al. 
may be due to the release of Mtb antigen into the bloodstream thus allowing 
increased detection.  
 
Conversely there appears to be more cells secreting IFN-γ in HIV infected 
persons over time, as determined by the ELISpot assay, but this trend is not 
statistically significant. However, this was also observed in the number of 
CD4+ IFN-γ+ T cells flow cytometry data thus further supporting the ELISpot 
data. A significant expansion in the numbers of CD4+ IFN-γ+ T cells was 
observed during 6 months of ART in our cohort of HIV infected persons 
therefore also supporting the increasing trend of the number of IFN-γ+ cells 
increasing determined using the ELISpot assay.  
 
A possible reason for the discrepancy between the QFT and the ELISpot 
assays is because IFN-γ production is determined from a consistent number 
of cells (250 000 PBMC) using the ELISpot assay, while 1ml of blood is used 
for the QFT assay. Thus the total number of cells in the 1ml of blood is 
unknown at the time of sampling, and is therefore not consistent for every 
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person, and may possibly dilute the final number of cells able to respond to 
the antigenic stimuli and produce IFN-γ. Also worth mentioning is the point 
that different proportions of cells, e.g. memory T cells, may be present within 
the blood at the time of sampling and would therefore influence the IFN-γ 
production thus also accounting for differences between person to person. 
Interestingly, HIV uninfected persons at 6 months of ART had the same 
median number of IFN-γ-producing cells as HIV uninfected persons. 
Additionally, the antigens used in both assays differ with the QFT utilizing the 
TB7.7 antigen in addition to the RD-1 antigens, while the ELISpot uses only 
ESAT-6 and CFP-10 antigens [16-18].  
 
In keeping with our QFT data the levels of soluble IFN-γ, determined by 
Luminex, decreased significantly in HIV infected persons on ART. HIV 
uninfected persons had higher levels of soluble IFN-γ compared to HIV 
infected persons at 6 months of ART. This is expected as QFT supernatants 
were collected post assay and stored for Luminex experiments.  
 
Lastly the percentage of CD4+ IFN-γ+ cells determined by flow cytometry 
tended to increase in HIV infected persons after 6 months of ART, while HIV 
uninfected persons had a lower percentage of CD4+ IFN-γ cells compared to 
HIV infected persons at 6 months of ART. The results of this assay are 
further supported by the ELISpot results, as both assays measure cell-
specific IFN-γ. It is also worth noting that flow cytometry was only carried out 
for n=26 persons, while QFT and ELISpot assays were determined for n=32 
persons. This was due to the availability of samples. 
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TST was once considered the gold standard in determining LTBI but this test 
has been shown to produce confounding results in persons that have 
received BCG vaccination, due to the presence of proteins that are common 
between Mtb, BCG substrains and other Non-Tuberculosis Mycobacteria 
(NTM), thus rendering a false positive response [19-21]. Given that South 
Africa is a country endemic to TB infection, and that infants receive the BCG 
vaccine at birth, the TST is confounded and may not be able to mount a 
response as sensitive as an IFN-γ-based technique [22, 23].  For this reason, 
the measurement of IFN-γ, in response to Mtb-specific antigen, may be 
useful in determining sensitisation primarily due to Mtb-specific antigen not 
being affected by BCG vaccination. 
 
In conclusion we have demonstrated HIV infected and HIV uninfected 
persons included in our cohorts were sensitised to Mtb by at least one assay, 
namely the ELISpot, QFT, Luminex or intracellular flow cytometry (Figure 3.4 
and Tables 3.4 and 3.5). Overall, these results indicate that Mtb sensitisation 
remains relatively consistent in our cohort of HIV infected persons throughout 






Figure 3. 4: The (A) number and (B) percentage of persons sensitised 
by 1, 2, 3 or 4 assays used to determine Mtb sensitisation stratified by 
time of ART. The 4 assays included are the QFT, ELISpot, CD4+ Cytokine+ 
positive T cells determined by flow cytometry and CD4+ IFN-γ+ positive T 
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Chapter 4: Flow cytometric characterisation of 
Mycobacterium tuberculosis specific CD4+ T 
cell reconstitution in HIV Infected persons 
starting antiretroviral therapy 
4.1. Introduction 
Mtb remains a global health concern, with 10.4 million people contracting TB 
in 2016 [1]. TB infection may persist lifelong and may lay dormant in >90% of 
individuals with the remaining 10% of individuals developing active TB 
disease. Although there are many potential vaccines that are currently in 
various phases of development, the only available vaccine against Mtb is 
BCG. BCG is an attenuated version of the M. bovis strain and is able to 
provide protection against disseminated TB and TB meningitis in young 
children, however, the effects of BCG remain inconsistent against pulmonary 
TB in adolescents and adults [2, 3]. BCG induces TH1 immunity, and while 
this immunity is thought to last 10-15 years from vaccination [4] it may also 
provide immunity that exceeds several decades [5].  
 
Upon exposure to antigen, be it via vaccination or upon infection, antigen 
specific T cells are activated, begin to proliferate and are able to differentiate 
into effector T cells. The cells that have gained an effector function act to 
clear the infection with a large proportion of cells dying and the remaining 
forming memory cells [6]. Memory forms the hallmark of the acquired 
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immune system with memory T cells conferring immediate protection in 
peripheral tissue and mounting recall responses to antigens in secondary 
lymphoid organs [7]. Effector memory T cells (TEM) mediate protective 
memory while central memory T cells (TCM) mediate reactive memory that 
home to T cell areas of secondary lymphoid organs, proliferate and 
differentiate to effector cells in response to antigenic stimulation [7]. TCM 
express CD62L and CCR7 and produce the IL-2 cytokine while TEM cells 
favour the production of effector cytokines such as IFN-γ and IL-4 [8]. Both 
CD4 and CD8 T cells differentiate into TCM and TEM cells respectively, with 
both capable of producing IFNγ following antigenic stimulation [7]. The 
presence of TH1 CD4 TEM secreting IFN-γ/TNF-α have been considered 
crucial in the composition of protective memory in the infected lung [9].  
 
 
Figure 4. 1: Representation of the linear module demonstrating CD4 cell 
central memory and effector memory generation in humans. Adapted 
from Amyes et al. and Mahnke et al. [10, 11]. 
 
 125 
A previous study conducted in our lab demonstrated a significant expansion 
in the proportion of central memory CD4 T cells, characterised as CD4+ 
CD45RA−CD27+, in HIV infected persons after receiving 12 weeks of 
reconstituting cART [12]. Additionally a corresponding significant decrease 
was found in the proportion of effector memory CD4 T cells, characterized as 
CD4+ CD27− CCR7−, in the same group of individuals after 12 weeks of ART. 
Wilkinson et al. thus illustrated that the strongest correlated of immunity was 
in fact central memory CD4 T cell driven, despite the effector function being 
associated with cART reconstitution.  
 
Three studies further demonstrated the importance of protection driven by 
central memory T cells in animal models. Lindenstrøm and colleagues 
showed that BCG-primed mice boosted with the Ag85B and ESAT-6 subunit 
vaccine were able to control Mtb infection as a result of the expansion of 
CD4 central memory T cells, characterised as CD4+ KLRG1- IL-2+ [13]. 
Vogelzang et al. also used a mouse model and demonstrated that the 
recombinant BCG (rBCG) vaccine secreting the pore forming lysteriolysin 
(BCG ΔureC::hly)-mediated protection was based on the expansion of 
central memory CD4 T cells that are CXCR5+ CCR7+ and express low levels 
of the transcription factors T-bet and Bcl-6 [14]. Vogelzang and colleagues 
further validated, using adoptive transfer techniques, that it was the CD4+ 
central memory T cells rather than the CD4+ effector memory T cells that 
mediated this protection against Mtb infection [14]. Lastly a recent study in 
which MtbΔsigH-primed macaques were challenged with aerosolised Mtb 
CDC1551 revealed vaccinated macaques to elicit a strong CD4+ and CD8+ 
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central memory driven response, in which T cells were characterized as 
being CD4+ CCR5+ [15]. 
 
The phenotype of memory T cells that reconstitute during 6 months of ART, 
in HIV infected persons sensitised by Mtb, is not well characterised. This 
study therefore aimed to analyse these T cells and determine their 
functionality. For the different T cell subsets, we compared the numbers and 
proportions at baseline with the numbers and proportions after 6 months of 
ART in HIV infected persons. Additionally, the same comparison was 
performed between HIV infected persons at 6 months of ART and HIV 
uninfected controls, in order to determine how cell numbers and proportions 
compare to that observed in the HIV uninfected cohort.  
4.2. Patient Characteristics of individuals included in 
analysis 
Twenty-six HIV infected persons had cryopreserved PBMC available for all 
longitudinal follow up timepoints. Additionally, stored PBMC was available 
from 28 HIV uninfected persons, sampled cross-sectionally. All HIV infected 
persons and HIV uninfected persons included in this aim were determined to 
be Mtb sensitised based on a positive IFN-γ response determined by either 
the QFT, ELISpot or the Luminex assay at at least one timepoint. Therefore 
all persons were considered to be sensitised to Mtb. The characteristics of all 
patients included in this arm of the study are summarized in Table 4.1. 
Although the median age of HIV infected persons differed significantly from 
the median age of HIV uninfected persons, we do not believe that this 
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difference impacted downstream statistics and subsequent significant 
differences in immunological markers measured. Longitudinal analysis of 
CD4 counts and viral loads revealed that the viral loads in HIV infected 
persons were suppressed to levels below the detection limit after 6 months of 
ART (p-value <0.0001) while CD4 counts increased significantly (p-value = 
0.002) to a median of 343 cells/μL. HIV uninfected persons had a median 




Table 4. 1: Characteristics of patients included in the flow cytometry 
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Table 4. 2: Change in CD4 counts and Viral loads during ART (median 
with IQR) 
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4.3.1. Thawing cryopreserved PBMC 
Cryopreserved PBMC were removed from liquid nitrogen and allowed to 
thaw in a 37-degree, 5% CO2 incubator for 10 minutes. Thawed cells were 
transferred to fresh medium and washed, followed by counting using Trypan 
Blue (Sigma Life Sciences). 20μL of cells and 20μL 0.4% Trypan Blue 
(Sigma Life Sciences) were mixed briefly, 10μL was pipetted into a counting 
chamber and inserted into the Bio-Rad TC20 Automated cell counter (Bio-
Rad). Cells were washed again, resuspended to a final concentration of 
1x106 cells /ml and aliquoted in FACS tubes (BD Biosciences). Cells were 
stimulated with (1) Mtb WCL at 20μg /ml; (2) SEB at 5μg /ml; and (3) left 
unstimulated as negative control. The tubes were incubated at 37 °C, 5% 
CO2 for 3 hours prior to adding Brefeldin A (BFA) at 5μg /ml, followed by 
incubation overnight. 
4.3.2. Surface and intracellular staining for flow cytometry 
After overnight stimulation, cells were washed and first stained with 
LIVE/DEAD Red Dead Cell stain (Invitrogen) followed by surface markers 
using anti-CD19-APC-Cy7 and anti-CD14-APC-Cy7 (Invitrogen); anti-CD4-
FITC and KLRG-1-PE.Cy5-5 (e-Bioscience); anti-HLA-DR-PE and anti-
CXCR3-PE-Cy7 (BD Biosciences); anti-CCR4-BV510, anti-CD45RA-BV570, 
anti-CCR6-BV605, anti-CD3-BV650 and anti-CD27-BV711 (BioLegend). 
After incubation, cells were washed, permeabilized using the 
Cytofix/Cytoperm kit from BD Biosciences, and stained intracellularly for the 
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detection of cytokines using the following antibodies: anti-IFN-γ-Alexa Fluor 
700 (BD Biosciences); anti-IL-2-PE and anti-IL-17A-Alexa Fluor 647 
(BioLegend); and anti-TNF-α-eFluor450 (e-Bioscience). The cells were then 
fixed and acquired on a BD Fortessa flow cytometer with FACSDiva software 
(version 6).  
 
Definition of a positive antigen specific response: Mtb specific responses for 
each sample were valid if the proportion of cells with positive intracellular 
cytokine staining in the antigen-stimulated tube was greater than twice that 
detected in the unstimulated tube. This is to ensure at least 50% of the 
cytokines being produced are as a result of the stimulation and not as a 
result of non-specific or endogenous stimuli. If antigen stimulated responses 
were less than twice of that detected in the unstimulated tube, a value of 0 
was assigned to the sample. Cytokine responses were measured by 
subtracting the unstimulated from the antigen stimulated, and a value 
≥0.05% for any cytokine was used as a cutoff to determine Mtb sensitization. 
This value is sum of the median and twice the standard deviation of the 
unstimulated/background (i.e. 0.05%) and serves to ensure that samples 
with a high background are not falsely reported as a positive response [21, 
39]. Only positive cytokine responses were utelised for MFI and 
polyfunctional analyses. A detailed description of this assay can be found in 
chapter 2, section 2.12.3. 
 131 
4.3.3. Statistical analysis 
Statistical analysis was performed using GraphPad Prism (version 6) using 
methods for non-parametric data. The Friedman test, with correction for 
multiple comparisons, was used for paired data comparison across all 
sampling time points in HIV infected individuals. There were four sampling 
timepoints (k=4) thus the Friedman test was performed with d.f. = 3 (‘degrees 
of freedom’ = k-1 and alpha = 0.05) in order to determine p-values. The 
Kruskal Wallis test with correction for multiple comparisons was used for 
unpaired data comparisons across all time points in HIV infected persons. 
The Wilcoxon test (equivalent of the non-parametric student t-test) was used 
to compare paired data in HIV infected persons at day 0 and 6 months of 
ART. Additionally we also compared cross-sectional data from the HIV 
infected persons at 6 months of ART with HIV uninfected persons using the 
Mann-Whitney test, used for unpaired data comparisons. A p-value less than 
or equal to 0.05 was considered significant. P-values are illustrated in 
subsequent figures by asterixes and mean the following: ns refers to a p-
value > 0.05, a single asterisk (*) refers to a p-value ≤ 0.05, two asterix (**) 
refer to a p-value ≤ 0.01, three asterix (***) refer to a p-value ≤ 0.001 and 




4.4.1. Total CD4+ T cell analysis 
4.4.1.1. Memory phenotype of CD4+ T cells during 6 months of ART 
A summary of the T cell memory phenotypes is shown in Figure 4.2. and 
Table 4.3. Analysis of naïve-like T cells, characterized as 
CD4+CD27+CD45RA+, in HIV infected persons revealed no significant overall 
change in proportions and numbers over 6 months of ART after correction for 
multiple comparisons between the four timepoints (Figure 4.2. panel A and 
E, p-values 0.1445 and 0.3673 respectively). However comparing paired 
data between day 0 and 6 months of ART using non-parametric paired t-test 
revealed a significant increase in the proportions and numbers of naïve-like T 
cells in HIV infected persons (p-values = 0.0176 and 0.0067 respectively). A 
cross-sectional comparison between the HIV uninfected and HIV infected 
persons at 6 months of ART, revealed that the numbers of naïve-like T cells 
were significantly lower in the HIV infected persons (p-values <0.0001), while 
the proportions were comparable.  
 
Central memory T cells, characterized as CD4+CD27+CD45RA-, also showed 
no significant change in the proportions and numbers over 6 months of ART 
(p-values = 0.5140 and 0.0633). However, paired comparison between 
baseline and 6 months of ART revealed a significant expansion both in 
proportion and numbers of central memory T cells (Figure 4.2. panel B and 
F, p-values 0.0081 and <0.0001 respectively). When comparing to HIV 
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uninfected persons, the numbers of central memory T cells were significantly 
lower in HIV infected persons at 6 months of ART (p-value <0.0001), while 
the proportions were comparable (p-value = 0.5220). 
 
Contrary to the early differentiated cells described above, the proportion of 
effector memory T cells, characterized as CD4+CD27-CD45RA-, significantly 
decreased (Figure 4.2. panel C, p-value = 0.001) after correction for multiple 
comparisons, in HIV infected persons during 6 months of ART. No significant 
change was observed for the numbers however (Figure 4.2. panel G, p-value 
>0.9999), after correction for multiple comparisons. Similar results were 
found when comparing proportions and numbers of effector memory T cells 
at baseline and 6 months of ART using non-parametric t-tests (p-values 
0.0002 and 0.1730). Cross-sectional comparison between the HIV infected 
persons at 6 months of ART and the HIV uninfected persons revealed no 
significant difference in the proportion of effector memory T cells (p-value = 
0.4365), however HIV uninfected persons had significantly higher numbers of 
effector memory T cells compared to HIV infected persons (p-value 
<0.0001).  
 
Lastly terminal effector memory T cells, characterised as CD4+CD27-
CD45RA+, showed no significant difference in proportion and numbers in HIV 
infected persons over 6 months of ART using multiple comparison testing 
(Figure 4.2. panel D and H respectively, p-values 0.3608 and >0.9999 
respectively). However non-parametric t-tests between baseline and 6 
months of ART, revealed a significant decline in the proportion (p-value 
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=0.0407) but not numbers (p-value = 0.1014) of terminal effector memory T 
cells. Comparison with the HIV uninfected persons revealed no significant 
proportional difference between the two cohorts (p-value = 0.0891) but HIV 
uninfected persons had significantly higher numbers of terminal effector 
memory T cells (p-value = 0.0061) compared to HIV infected persons at 6 




Figure 4. 2: Memory phenotype of CD4+ T cells based on CD27 and CD45RA surface expression determined by flow 
cytometry. A – D: Proportion of CD4+ T cells expressing, or not expressing, CD27 and CD45RA in HIV infected persons (red, 
n=26) during 6 months of ART, and HIV uninfected persons (blue, n=28). E – H: Number of CD4+ T cells expressing CD27 and 
CD45RA per 106 cells in HIV infected persons (red, n=26) during 6 months of ART, and HIV uninfected persons (blue, n=28). 
Graphs represent medians and IQR data for each cell subset and p-values were determined using the paired t-test.  
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4.4.1.2. Activation and Senescence markers on CD4+ T cells during 6 
months of ART 
The expression of HLA-DR was used to determine activation in CD4+ T cells, 
while KLRG-1 expression was used to determine senescence in CD4+ T 
cells. A summary of the results is shown in Figure 4.3. and Table 4.4. After 
correction for multiple comparisons, the proportion (p-value < 0.0001) but not 
numbers (p-value >0.9999) of activated T cells, characterized as CD4+HLA-
DR+, significantly decreased in HIV infected persons during 6 months of ART 
(Figure 4.3. panels A and C respectively). Non-parametric t-test similarly 
revealed a significant decrease in the proportion (p-value <0.0001) but not 
numbers (p-value = 0.5424) of activated T cells in HIV infected persons 
between day 0 and 6 months of ART. We next compared the proportions and 
numbers of activated T cells in HIV infected persons to that of HIV uninfected 
persons and found that HIV infected persons had a significantly higher 
proportion (p-value = 0.0005), but lower numbers (p-value = 0.0073), of 
activated T cells at 6 months of ART.  
 
Correction for multiple comparisons revealed no significant change in the 
proportion and numbers of senescent T cells in HIV infected persons over 6 
months of ART (Figure 4.3. panels B and D, p-values 0.3190 and <0.9999 
respectively). However non-parametric t-test between baseline and 6 months 
of ART revealed a significant decrease in the proportion of KLRG-1+ T cells 
(p-value =0.0493). The numbers of KLRG-1+ T cells similarly tended to 
decline in HIV infected persons during ART (p-value = 0.0516). Comparing to 
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HIV uninfected persons, there was no significant difference in the proportion 
of KLRG-1+ T cells in HIV infected persons at 6 months of ART (p-
value=0.3686), but the numbers were significantly higher compared to HIV 
infected persons at 6 months of ART (p-value = 0.0001). 
 
 
Figure 4. 3: Activation and Senescence of CD4+ T cells based on HLA-
DR and KLRG-1 expression determined by flow cytometry. 
Proportion of CD4+ T cells expressing HLA-DR (A) and KLRG-1 (B) in HIV 
infected persons (red, n=26) over 6 months of ART, and HIV uninfected 
persons (blue, n=28). Numbers of CD4+ T cells expressing HLA-DR (C) and 
KLRG-1 (D) in HIV infected persons (red, n=26) after 6 months of ART, and 
HIV uninfected persons (blue, n=28). Graphs represent medians and IQR 
data. 
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4.4.1.3. Chemokine receptor expression on CD4+ T cells during 6 months of 
ART 
A summary of the expression of the chemokine receptors, CXCR3, CCR4 
and CCR6, on CD4+ T cells is shown in Figure 4.4. and Table 4.5. Non-
parametric tests correcting for multiple comparisons revealed no significant 
change in the proportion of T cells expressing CXCR3 (p-value = 0.9755), 
CCR4 (p-value = 0.7957) or CCR6 (p-value = 0.1901) in HIV infected 
persons during 6 months of ART (Figure 4.4. panels A, B and C 
respectively). With the exception of CCR4, non-parametric t-testing mirrored 
the above mentioned trends with p-values = 0.4227 and 0.0993 for CXCR3 
and CCR6 respectively. Additionally, non-parametric testing revealed a small 
but significant increase (p-value = 0.0414) in the proportion of T cells 
expressing the CCR4 chemokine receptor.  Interestingly while the proportion 
of T cells expressing CXCR3 and CCR6 chemokine receptors was 
significantly higher in HIV uninfected persons compared to HIV infected 
persons at 6 months (p-values = 0.0019 and 0.0233), there was no 
significant difference in the proportion of T cells expressing CCR4 receptors 
between the groups (p-value = 0.3460).  
 
Similarly, no significant change was observed in the numbers of T cells 
expressing CXCR3 (p-value > 0.999) or CCR6 (p-value = 0.9117) in HIV 
infected persons over 6 months of ART, after correction for multiple 
comparisons. However the numbers of T cells expressing CCR4 chemokine 
receptors significantly expanded (p-value = 0.0085). Non-parametric testing 
 142 
in HIV infected persons between day 0 and 6 months of ART revealed a 
significant increase in T cell numbers expressing CXCR3 (p-value = 0.0096), 
CCR4 (p-value = 0.0001) or CCR6 (p-value = 0.0451) (Figure 4.4. panels D, 
E and F respectively). Lastly, cross-sectional comparisons revealed that HIV 
uninfected persons had significantly higher numbers of T cells expressing 
CXCR3 (p-value < 0.0001), CCR4 (p-value < 0.0001) or CCR6 (p-value < 
0.0001) compared to HIV infected persons at 6 months of ART. 
 
 
Figure 4. 4: Chemokine receptor expression on CD4+ T cells defined by 
flow cytometry analysis. 
A – C: Proportion of CD4+ T cells expressing CXCR3, CCR4 or CCR6 in HIV 
infected persons (red, n=26) after 6 months of ART, and HIV uninfected 
persons (blue, n=28). D – F: numbers of CD4+ T cells expressing CXCR3, 
CCR4 or CCR6 per 106 cells in HIV infected persons (red, n=26) after 6 
months of ART, and HIV uninfected persons (blue, n=28). Graphs represent 
medians and IQR data. 
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4.4.1.4. Cytokine production by CD4+ T cells during 6 months of ART 
A summary of the cytokines, IFN-γ, TNF-α, IL-2 and IL-17A, produced by 
Mtb WCL stimulated CD4+ T cells, is shown in Figure 4.5 and Table 4.6. 
Figure 4.6. indicating the baseline levels of cytokines is also included, in 
which unstimulated PBMC is used to determine basal cytokine production. 
 
Using non-parametric tests correcting for multiple comparisons, we noted 
that the proportion and numbers of T cells producing IFN-γ, defined as CD4+ 
IFN-γ+, remained unchanged in HIV infected persons during 6 months of 
ART (Figure 4.5. panels A and E, p-values >0.9999 and 0.7453 
respectively). Comparing paired data between day 0 and 6 months of ART 
also showed no significant change in the proportion of CD4+ IFN-γ+ cells (p-
value = 0.7660), however the numbers of CD4+ IFN-γ+ cells showed a 
significant increase (p-value = 0.0127) in these persons. Cross-sectional 
comparison with HIV uninfected persons revealed no significant difference in 
the frequency or numbers of CD4+ IFN-γ+ cells at 6 months of ART (p-values 
= 0.4264 and 0.3222 respectively).  
 
The proportion of cells producing TNF-α in response to Mtb WCL stimulation, 
defined as CD4+TNF-α+, significantly decreased in HIV infected persons over 
6 months of ART (Figure 4.5. panel B, p-value = 0.003) after correction for 
multiple comparisons. A similar observation was made when comparing day 
0 with 6 months of ART (p-value = 0.0130), however the numbers of 
CD4+TNF-α+ cells remains unchanged in those with a measurable response 
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(Figure 4.5. panel F, p-value = 0.1909). HIV uninfected persons had a 
significantly lower proportion (p-value <0.0001) and numbers (p-value = 
0.0053) of CD4+TNF-α+ cells, compared to HIV infected persons at 6 months 
of ART. 
 
Similar to TNF-α, the proportion of IL-2 producing T cells in response to Mtb 
WCL stimulation, defined as CD4+IL-2+ T cells, significantly decreased in HIV 
infected persons over 6 months of ART (Figure 4.5. panel C, p-value = 
0.0005) following correction for multiple comparisons. Paired comparison 
between day 0 and 6 months data also showed a significant decrease 
(p=0.002). Interestingly however, the numbers CD4+IL-2+ T cells in HIV 
infected persons during 6 months of ART tended to increase, although not 
reaching significance (Figure 4.5. panel G, p-value = 0.0826). Cross-
sectional comparison showed HIV infected persons at 6 months of ART to 
have significantly higher proportion (p-value < 0.0001), but not numbers (p-
value = 0.1932) of CD4+IL-2+ T cells compared to the HIV uninfected 
persons. 
 
The proportion of IL-17A producing T cells, defined as CD4+IL-17A+, 
significantly decreased in HIV infected persons during 6 months of ART 
(Figure 4.5. panel D), p= 0.0005 using non-parametric t-tests and p= 0.0035 
with correction for multiple comparisons. The numbers of CD4+IL-17A+ T 
showed no change in HIV infected persons during 6 months of ART (p-value 
= 0.1909 with a p-value > 0.999 after correction for multiple comparisons). 
HIV uninfected persons had significantly higher proportions (p-value < 
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0.0001) but not numbers (p-value = 0.5832) of CD4+IL-17A+ T cells, 
compared to HIV infected persons at 6 months of ART. However this was 




Figure 4. 5: Cytokine production of CD4+ T cells determined by flow cytometry. 
A – D: Proportion of CD4+ T cells producing IFN-γ, TNF-α, IL-2 or IL-17A in HIV infected persons (red, n=26) during 6 months of 
ART, and HIV uninfected persons (blue, n=28). E – H: Numbers of CD4+ T cells producing IFN-γ, TNF-α, IL-2 or IL-17A in HIV 
infected persons (red, n=26) during 6 months of ART, and HIV uninfected persons (blue, n=28). Graphs represent medians and 
IQR of data.  
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Figure 4. 6: Measurement of cytokines from unstimulated PBMC 
determined by flow cytometry.  
Unstimulated PBMCs were isolated from HIV infected persons receiving 6 
months of ART (n=26, red), and HIV uninfected persons (n=28, blue) and 
were intracellularly stained for (A) TNF-α, (B) IFN-γ, (C) IL-2 and (d) IL-17A.    
 
4.4.1.5. Assessment of Mtb-specific CD4+ T cell functionality based on 
cytokine production 
This section focuses on the qualitative cytokine data from Mtb-specific CD4+ 
T cells. Boolean gating was used in order to determine the functionality of 
Mtb-specific CD4+ T cells and this analysis was conducted in order to assess 






























































































the functional capacity of Mtb-specific CD4+ T cells from HIV infected 
persons regained following 6 months of ART. 
 
Our findings identified eight distinct cytokine-producing antigen-specific CD4+ 
T cell populations in HIV infected and uninfected persons, summarised in 
Figure 4.7. and Table 4.7. These populations were further grouped based on 
the number of cytokines each population was able to produce (i.e. 1, 2 or 3 
cytokines), summarised in Figures 4.7. and 4.8. and Table 4.7.  
 
Our Mtb-specific qualitative cytokine data showed that HIV infected persons 
at day 0 of ART had a single cytokine positive (IFN-γ+ or TNF-α+ or IL-2+) cell 
dominant response (64%), followed by the double positive cytokine 
producing cells (26%) and lastly the triple positive cytokine producing cells 
(10%). The proportion of triple positive cytokine producing cells significantly 
increased in HIV infected persons after 6 months of ART (p-value = 0.0121) 
and was significantly higher than proportions observed in the HIV uninfected 
persons (Figure 4.8. panel A, p-value = 0.0008). 
 
Interestingly, the cytokine response at 6 months of ART in HIV infected 
persons was dominated by the Mtb-specific double positive cytokine 
producing cells (55%) followed by the Mtb-specific single positive cytokine 
producing cells (25%) and the Mtb-specific triple positive cytokine producing 
cells (20%). When compared with the HIV uninfected persons, higher 
proportions of the double positive cytokine producing cells were observed in 
the HIV infected persons at 6 months of ART. Further analysis revealed that 
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the IL-2+TNF-α+ and the TNF-α+IL-17A+ Mtb-specific cytokine subsets 
(Figure 4.8. panels D and E respectively) may have contributed to the 
increased proportion of double positive cytokine producing cells as the 
proportion of these cells appear to increase, although not significantly (p-
values = 0.3905 and 0.1421 respectively), in HIV infected persons 
throughout 6 months of ART. Proportions of Mtb-specific IL-2+TNF-α+ and the 
TNF-α+IL-17A+ double positive cytokine secreting cells were higher in HIV 
infected persons at 6 months of ART (p-values  <0.0001 and 0.2040 
respectively) than proportions observed in HIV uninfected persons.  
 
The single positive (IFN-γ+ or TNF-α+ or IL-2+) cytokine producing cells 
dominated the response (78%) in HIV uninfected persons (Figure 4.7. panel 
C), followed by the double positive cytokine producing cells (19%) and lastly 
the triple cytokine producing cells (3%). When we assessed the Mtb-specific 
CD4+ single positive cytokine producing T cells individually, we noted that 
HIV uninfected persons had significantly higher proportions of Mtb-specific 
IFN-γ+ single positive cells, and Mtb-specific IL-17A+ single positive cells 
compared to HIV infected persons during 6 months of ART (Figure 4.8. panel 
F and H, p-values < 0.0001 respectively). The higher proportions of these 
single cytokine producing cells thus contribute to the dominance observed in 
HIV uninfected persons. Although not significant, HIV uninfected persons 
also had higher proportions of Mtb-specific IL-2+ single positive cells 
compared to HIV infected persons after 6 months of ART (Figure 4.8. panel 
G, p-value = 0.4066). 
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Longitudinal analysis revealed that the proportions of Mtb-specific IL-17 
single positive cells did not differ in HIV infected persons during 6 months of 
ART (p-value = 0.2643) however compared to HIV uninfected persons, 
significantly higher proportions of Mtb-specific IL-17 single positive cells were 
observed in HIV uninfected persons (Figure 4.8. panel H, p-value <0.0001). 
The proportions of Mtb-specific IL-2 single positive cells showed a significant 
decrease in the proportion of cells in HIV infected persons during ART 
(Figure 4.8. panel C, p-value <0.0001), while Mtb-specific single positive 
IFN-γ secreting cells remained unchanged in HIV infected persons during 
ART (Figure 4.8. panel F, p-value 0.2437). 
 
Additionally, the longitudinal analysis of Mtb-specific IFN-γ+TNF-α+ double 
positive cells increased in HIV infected persons during 6 months of ART 
(Figure 4.8. panel B, p-value = 0.2437) although not significantly, and 
proportions of Mtb-specific IFN-γ+TNF-α+ double positive cells were similar in 
HIV infected persons (p-value = 0.0520). Lastly, the proportion of Mtb-
specific IL-2+IL-17A+ double positive cells significantly decreased in HIV 
infected persons during ART (Figure 4.8. panel C, p-value = 0.0494) and 
significantly higher proportions of this cell subset were observed in HIV 
uninfected persons (p-value = 0.0219). 
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 Figure 4. 7: Pie charts showing co-production of cytokines from Mtb-specific CD4+ T cells determined by flow cytometry 
analysis. Pie chart representing the polyfunctional capacity of Mtb-specific CD4+ T cells in (A) HIV infected persons at day 0 of 
ART, (B) HIV infected persons at 6 months of ART and (C) HIV uninfected persons. Blue slices represent the proportion of cells 
producing three of the cytokines measured, in this case IFN-γ+TNF-α+IL-2+ producing cells, while the red slices represent the 
proportion of cells producing a combination of any two cytokines and the green slices represent cells producing only one cytokine. 




Figure 4. 8: Frequency of Mtb specific CD4+ T cells expressing IFN-γ, TNF-α, IL-2 and IL-17A cytokines as measured by 
flow cytometry. 
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4.4.2. Analysis of Mtb specific CD4+ T cells  
Mtb specific cells were defined as at least 0.05% of CD4+ T cells positive for 
either IFN-γ, TNF-α or IL-2 cytokine following subtraction of the unstimulated 
sample (i.e. Mtb specific cells= Mtb WCL - Nil ≥ 0.05%).  
4.4.2.1 Memory phenotype of Mtb specific T cells in response to 6 months of 
ART 
A summary of the Mtb-specific T cell memory phenotypes are shown in 
Figure 4.9. and Table 4.8. The proportion of naïve-like 
(CD4+Cytokine+CD27+CD45RA+), central memory (CD4+ 
Cytokine+CD27+CD45RA-) and effector memory T cells 
(CD4+Cytokine+CD27-CD45RA-), remained unchanged in HIV infected 
persons during 6 months of ART (Figure 4.9. panels A – C respectively, p-
values = 0.9893, 0.7796 and > 0.9999 respectively), the numbers of these 
cells tended to increase, although not significantly with the exception of the 
effector memory T cells (Figure 4.9. panels E - G, p-values = 0.2025, 0.0520 
and 0.0297 respectively). Cross-sectional comparison with the HIV 
uninfected persons revealed the HIV infected persons at 6 months of ART to 
have a lower proportion and numbers of Mtb-specific naïve-like T cells (p-
values = 0.4888 and 0.0077), while no difference in proportion of central 
memory and effector memory T cells was observed between the two groups 
(p-value = 0.9859 and > 0.9999). However, HIV uninfected persons had 
significantly higher numbers of Mtb-specific central memory and effector 
memory T cells (p-value = 0.0001 and 0.006) compared to HIV infected 
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persons at 6 months of ART. The proportion of terminal effector memory T 
cells (CD4+Cytokine+CD27-CD45RA+) tended to decrease in HIV infected 
persons during 6 months of ART (p-value = 0.1088), while their numbers 
tended to increase, although not significantly (p-value = 0.6385). Lastly, 
cross-sectional comparison with the HIV uninfected persons revealed no 
difference in proportion and numbers of Mtb-specific terminal effector 






Figure 4. 9: Memory phenotype of Mtb specific CD4+ T cells as assessed by flow cytometry.  
A – D: Proportion of CD4+ T cells expressing CD27 and CD45RA in HIV infected persons (red, n=12) after 6 months of ART, and 
HIV uninfected persons (blue, n=8). E – H: Number of CD4+ T cells expressing CD27 and CD45RA per 106 cells in HIV infected 
persons (red, n=12) after 6 months of ART, and HIV uninfected persons (blue, n=8). Graphs represent medians and IQR data. 
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4.4.2.2. Activation and Senescence of Mtb specific CD4+ T cells during the 
first 6 months of ART 
A summary of the activation and senescence of CD4+Cytokine+ T cell 
phenotypes is shown in Figure 4.10. and Table 4.9. The proportion of 
activated T cells, characterized as CD4+Cytokine+HLA-DR+, in HIV infected 
persons during 6 months of ART (Figure 4.10. panel A, p-value = 0.414) 
tended to decrease, (p-value = 0.4140) while their numbers (Figure 4.10. 
panel C) tended to increase, although not significantly (p-value = 0.2904). 
Cross-sectional comparison with the HIV uninfected persons revealed HIV 
infected persons at 6 months of ART still have significantly higher 
proportions (p-value = 0.0200) but not numbers (p-value = 0.3347) of HLA-
DR expressing cells compared to HIV uninfected persons.  
 
The proportion of senescent T cells, characterized as, CD4+Cytokine+KLRG-
1+, remained unchanged in HIV infected persons during 6 months of ART 
(Figure 4.10. panel B, p-value = 0.923 and > 0.9999 after correction for 
multiple comparisons), while their frequency tended to increase (Figure 4.10. 
panel D), although not significantly (p-value = 0.1502 and 0.7466 after 
correction for multiple comparisons). When compared with the HIV 
uninfected persons the proportion of senescent T cells did not differ between 
the groups (p-value = 0.8863) although HIV uninfected persons had 
significantly higher numbers of senescent T cells compared to HIV 





Figure 4. 10: Activation and Senescence of Mtb specific CD4+ T cells as 
measured by flow cytometry. 
Proportion of CD4+Cytokine+ T cells expressing HLA-DR (A) and KLRG-1 (B) 
in HIV infected persons (red, n=12) after 6 months of ART, and HIV 
uninfected persons (blue, n=8). Number of CD4+ T cells expressing HLA-DR 
(C) and KLRG-1 (D) per 106 cells in HIV infected persons (red, n=12) after 6 
months of ART, and HIV uninfected persons (blue, n=8). Graphs represent 
medians and IQR data for each cell subset.  
 





















































































































































Table 4. 9: Median and (IQR) frequency and number of Mtb specific CD4+ T cells expressing HLA-DR and KLRG-1 with 
corresponding p-values.  
Median (IQR) HIV Infected persons (n=12) 
HIV Uninfected 
persons (n=8) 




HIV Infected D0 
vs. 6M 
(paired t test) 
HIV Infected at 
6M vs. HIV 
Uninfected 
(unpaired t test) 
 
Day 0 of 
ART 




















































0.7466 0.1502 0.0302 
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4.4.2.3. Chemokine receptor expression on Mtb specific CD4+ T cells during 
the first 6 months of ART 
A summary of the expression of chemokine receptors, CXCR3, CCR4 and 
CCR6, on CD4+ T cells is shown in Figure 4.11. and Table 4.10. The 
proportion of cells expressing CXCR3 (CD4+Cytokine+CXCR3+), CCR4 
(CD4+Cytokine+CCR4+) and CCR6 (CD4+Cytokine+CCR6+) remained 
unchanged during 6 months of ART (Figure 4.9. panels A – C with p-values 
= 0.5667, 0.2904 and 0.3168 respectively) however the numbers of these 
cells expanded, significantly for CCR4+ and CCR6+ T cells (Figure 4.11. 
panels D – F with p-values = 0.4951, 0.0006 and 0.0187 respectively). 
Cross-sectional comparison with the HIV uninfected persons revealed HIV 
uninfected persons to have a significantly higher proportions and numbers of 
CXCR3+ T cells compared with HIV infected persons at 6 months of ART (p-
values = 0.0013 and 0.0001 respectively). While the proportion of CCR4+ 
and CCR6+ T cells did not differ between the two groups (p-values = 0.5346 
and 0.0558 respectively), the numbers of these cells were significantly higher 
in HIV uninfected persons (p-values = 0.0034 and < 0.0001 respectively) 





Figure 4. 11: Chemokine receptor expression on Mtb specific CD4+ T 
cells as measured by flow cytometry. 
A – C: Proportion of CD4+Cytokine+ T cells expressing CXCR3, CCR4 or 
CCR6 in HIV infected persons (red, n=12) after 6 months of ART, and HIV 
uninfected persons (blue, n=8). D – F: Number of CD4+ T cells expressing 
CXCR3, CCR4 or CCR6 per 106 cells in HIV infected persons (red, n=12) 
after 6 months of ART, and HIV uninfected persons (blue, n=8). Median and 
IQR data are represented on graphs, for each cell subset.  
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HIV Uninfected 
persons (n=8) 
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0.1399 0.0187 <0.0001 
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4.4.2.4. Assessment of Mtb-specific CD4+ T cell functionality based on 
cytokine production 
This section focuses on the qualitative cytokine data from Mtb-specific CD4+ 
T cells. Boolean gating was used in order to determine the functionality of 
Mtb-specific CD4+ T cells and this analysis was conducted in order to assess 
the functional capacity of Mtb-specific CD4+ T cells from HIV infected 
persons regained following 6 months of ART. 
 
Our findings identified eight distinct cytokine-producing antigen-specific CD4+ 
T cell populations in HIV infected and uninfected persons, summarised in 
Figure 4.13. and Table 4.11. These populations were further grouped based 
on the number of cytokines each population was able to produce (i.e. 1, 2 or 
3 cytokines), summarised in Figures 4.12. and 4.13. and Table 4.11.  
 
Our Mtb-specific qualitative cytokine data showed that HIV infected persons 
at day 0 of ART had a single cytokine positive (IFN-γ+ or TNF-α+ or IL-2+) cell 
dominant response (44%), followed by the double positive cytokine 
producing cells (34%) and lastly the triple positive cytokine producing cells 
(22%). The proportion of triple positive cytokine producing cells significantly 
increased in HIV infected persons after 6 months of ART (p-value = 0.0273) 
and was significantly lower than proportions observed in the HIV infected 
persons (Figure 4.13. panel A, p-value = 0.0158). 
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Interestingly, the cytokine response at 6 months of ART in HIV infected 
persons was dominated, almost equally, by the Mtb-specific triple positive 
cytokine producing cells (45%) and the Mtb-specific double positive cytokine 
producing cells (42%). Both proportions of cells expanded throughout the 6 
Months duration of ART in HIV infected persons. When compared with the 
HIV uninfected persons, higher proportions of the double positive cytokine 
producing cells were observed in the HIV infected persons at 6 months of 
ART. Further analysis revealed that the IL-2+TNF-α+ and the TNF-α+IL-17A+ 
Mtb-specific cytokine subsets (Figure 4.13. panels D and E respectively) may 
have contributed to the increased proportion of double positive cytokine 
producing cells as the proportion of these cells appear to increase, although 
not significantly (p-values = 0.4961 and 0.5781 respectively), in HIV infected 
persons throughout 6 months of ART. Proportions of Mtb-specific IL-2+TNF-
α+ and the TNF-α+IL-17A+ double positive cytokine secreting cells were 
higher in HIV infected persons at 6 months of ART (p-values = 0.0018 and 
0.9137 respectively) than proportions observed in HIV uninfected persons.  
 
The single positive (IFN-γ+ or TNF-α+ or IL-2+) cytokine producing cells 
dominated the response (81%) in HIV uninfected persons (Figure 4.13. panel 
C), followed by the double positive cytokine producing cells (17%) and lastly 
the single cytokine producing cells (2%). When we assessed the Mtb-specific 
CD4+ single positive cytokine producing T cells individually, we noted that 
HIV uninfected persons had significantly higher proportions of Mtb-specific 
IFN-γ+ single positive cells, and Mtb-specific IL-17A+ single positive cells 
compared to HIV infected persons during 6 months of ART (Figure 4.13. 
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panel F and H, p-value = 0.0001 and p-value < 0.0001 respectively). The 
higher proportions of these single cytokine producing cells thus contribute to 
the dominance observed in HIV uninfected persons. The proportions of Mtb-
specific IL-2+ single positive cells did not differ  in HIV infected persons 
during 6 months of ART compared to HIV uninfected persons (Figure 4.13. 
panel G p-value = 0.8316).  
 
Longitudinal analysis of the Mtb-specific single positive cytokine producing 
cells, revealed that the proportions of Mtb-specific IL-2 single positive, and 
IL-17A single positive cells showed no change in HIV infected persons during 
ART (Figure 4.13. panels G and H, p-values = 0.0078 and 0.9453 
respectively). Mtb-specific single positive IFN-γ secreting cells also remained 
unchanged in HIV infected persons during ART (Figure 4.13. panel F, p-
value = 0.8438). 
 
Additionally, the longitudinal analysis of Mtb-specific IFN-γ+TNF-α+ double 
positive cells remained unchanged in HIV infected persons during 6 months 
of ART (Figure 4.13. panel B, p-value = 0.5703), and proportions of Mtb-
specific IFN-γ+TNF-α+ double positive cells were similar in HIV infected 
persons (p-value = 0.2374). Lastly, the proportion of Mtb-specific IL-2+IL-
17A+ double positive cells significantly decreased in HIV infected persons 
during ART (Figure 4.13. panel C, p-value = 0.0078) however proportions of 
this cell subset did not differ significantly from that observed in HIV 
uninfected persons (p-value = 0.1522).  
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Figure 4. 12: Pie charts showing co-production of cytokines from Mtb-specific CD4+ T cells determined by flow cytometry 
analysis. Pie chart representing the polyfunctional capacity of Mtb-specific CD4+ T cells in (A) HIV infected persons at day 0 of 
ART, (B) HIV infected persons at 6 months of ART and (C) HIV uninfected persons. Blue slices represent the proportion of cells 
producing three of the cytokines measured, in this case IFN-γ+TNF-α+IL-2+ producing cells, while the red slices represent the 
proportion of cells producing a combination of any two cytokines and the green slices represent cells producing only one cytokine.
A B C 
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Figure 4. 13: Frequency of Mtb specific CD4+ T cells expressing IFN-γ, TNF-α, IL-2 and IL-17A cytokines as measured by 
flow cytometry. 
  
















IFNg+ IL-2+ IL-17A- TNFa+
* *
A







































IFNg+ IL-2- IL-17A- TNFa+B















IFNg- IL-2+ IL-17A- TNFa-
**
G




















IFNg+ IL-2- IL-17A- TNFa-
***
F














IFNg- IL-2- IL-17A+ TNFa+E















IFNg- IL-2+ IL-17A+ TNFa-
**
C





































D0 vs. 6M 
(paired t test) 
HIV Infected at 





Day 0 of 
ART 
1M 3M 6M     
%CD4+Cytokine+IFN-γ+ IL-











0.4484 0.0273 0.0158 
%CD4+Cytokine+IFN-γ+ IL-











>0.9999 0.5703 0.2374 
%CD4+Cytokine+IFN-γ+ IL-











>0.9999 0.8438 0.0001 
%CD4+Cytokine+IFN-γ- IL-
























D0 vs. 6M 
(paired t test) 
HIV Infected at 





Day 0 of 
ART 
1M 3M 6M     
%CD4+Cytokine+IFN-γ- 











>0.9999 0.4961 0.0018 
%CD4+Cytokine+IFN-γ- 











0.0070 0.0078 0.8316 
%CD4+Cytokine+FN-γ- IL-











0.6296 0.5781 0.9137 
%CD4+Cytokine+IFN-γ- 











>0.9999 0.9453 <0.0001 
 178 
4.5. Discussion 
Using flow cytometry, we determined the memory profile of reconstituting 
CD4+ T cells in HIV infected persons sensitised by Mtb, and compared this to 
the memory profile of CD4+ T cells in the HIV uninfected control group. We 
also determined the expression of certain chemokine receptors, the 
activation and senescence profile and the overall cytokine secreting capacity 
of CD4+ T cells in both cohorts.  
 
The proportions and numbers of naïve and central memory CD4+ T cells 
significantly expanded in HIV infected persons on ART, while the proportions 
and numbers of effector memory and terminally differentiated effector CD4+ 
T cells decreased significantly. Additionally, these trends were reflected in 
the case of the Mtb specific CD4+ T cells, with the exception of effector 
memory CD4+ T cells; the frequencies of this cell population significantly 
expanded in HIV infected persons during ART. Wilkinson et al. first 
demonstrated the significant expansion in the proportion of CD4 central 
memory T cells in HIV infected persons with LTBI, receiving ART [12]. 
Additionally they reported a significant decrease in the proportion of effector 
memory CD4 T cells. These phenomena were noted at 12 weeks of ART. 
Furthermore Riou et al. demonstrated that pathogen-specific early 
differentiated, such as Mtb-specific, CD4 T cells have a higher capacity to 
replenish in HIV infected persons receiving ART, compared to pathogen-
specific late differentiated CD4 T cells [16]. Two studies in addition to those 
described in section 4.1. above, Kipnis et al. and Anderson et al., have also 
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demonstrated, by use of the murine model, the importance of memory T cells 
in TB protection [4, 17]. Both made use of adoptive transfer techniques to 
transfer CD4+CD44loCD62Lhi central memory T cells from BCG-vaccinated 
mice [4] or TB infected mice [17] to naïve mice and illustrated a significant 
decline in the bacterial burden in the lungs of mice  post Mtb challenge, 
suggesting that these cells mediate protection.  
 
The significant decrease in the proportion, but not the numbers, of activated 
and senescent CD4+ T cells was observed in HIV infected persons on ART 
but the numbers of activated T cells observed in the HIV infected persons 
remained unchanged during ART. This was also observed in the Mtb specific 
CD4+ T cells. The significant decrease in the proportion of senescent CD4+ T 
cells indicates that cells display a less differentiated phenotype thereby 
indicating that the cells may possibly be exhausted. Similarly Riou et al. 
demonstrated a significant decrease in CD4 T cells co-expressing CD38 and 
HLA-DR markers, and cells expressing HLA-DR only, LTBI HIV infected 
persons [16]. A study conducted in HIV uninfected, BCG vaccinated infants, 
without any chronic disease and household exposure to an adult with active 
TB, revealed that HLA-DR+ CD4+ T cells associate with increased TB risk 
[18]. This further substantiates our findings that the decrease in CD4+ HLA-
DR+ T-cells in HIV infected persons, undergoing immune reconstitution 
through ART, may be identified as a correlate of protective immunity to TB. 
In keeping with our results, a recent study by Wilkinson et al. further 
demonstrated that LTBI HIV infected persons exhibited a higher expression 
of HLA-DR on Mtb-specific cells, compared to HIV uninfected persons, 
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similar to the expression of HLA-DR in the CD4 T cell compartment [19]. We 
observed an expansion in the CD4 T cell compartment, of the proportion of 
activated CD4 T cells significantly declined while the actual numbers of 
activated CD4 T cells remained unchanged. This may be attributed to a 
decreased need for activated CD4 T cells and thus a decline in the 
proportion of activated cells, and corresponding proportional increase in the 
proportion of cells that may be needed. 
 
The numbers of CD4+ T cells expressing CXCR3, CCR4 and CCR6 
chemokine receptors remained significantly lower than that observed in HIV 
uninfected persons, indicating that the homing potential of these CD4+ T cells 
may not be completely restored by 6 months of ART thus inhibiting their 
trafficking from the bloodstream into peripheral organs. However, the 
proportions of CCR4 positive cells significantly expanded during 6 months of 
ART to the levels seen in the HIV uninfected persons. The observations 
made regarding the frequencies of these cells were mirrored in the Mtb 
specific CD4+ T cells. Cecchinato et al. illustrated that the long term use of 
ART (greater than 3 years) in HIV infected persons, and the corresponding 
significant decrease in viral load to levels below the detection limit, is not 
sufficient to restore the ability of cells to respond to stimuli and in turn not 
being able to traffic from the bloodstream to peripheral organs [20]. Riou et 
al. also noted unchanged expression of CXCR3, CCR4 and CCR5 
chemokines in Mtb-specific CD4 T cells in LTBI and HIV co-infected persons 
[21] thus further substantiating our findings.  
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The overall cytokine secreting capacity of CD4+ T cells was determined for 
all HIV infected persons and indicated that following 6 months of ART, HIV 
infected persons showed a significant decrease in proportion of CD4+ T cells 
producing TNF-α, CD4+ T cells producing IL-2 and CD4+ T cells producing 
IL-17A, however the numbers of CD4+ T cells producing IL-2 and CD4+ T 
cells producing IL-17A increased in this group of persons. The proportion of 
CD4+ IFN-γ producing T cells remained unchanged, however the numbers of 
CD4+ IFN-γ producing T cells significantly expanded.  
 
Lastly we assessed the qualitative polyfunctional cytokine secreting capacity 
of CD4+ T cells and Mtb-specific CD4+ T cells  and observed that the 
proportion of CD4+ T cells with the ability to secrete three cytokines (IFN-
γ+TNF-α+IL-2+) simultaneously, significantly expanded in HIV infected 
persons following 6 months of ART. Additionally, HIV uninfected persons had 
a significantly lower proportion of IFN-γ+TNF-α+IL-2+ polyfunctional CD4 T 
cells compared to HIV infected persons after 6 months of ART. While the role 
of polyfunctional cells has yet to be clearly defined in TB [22] Day et al. 
illustrated that PPD-specific polyfunctional T cells are associated with active 
TB disease and bacterial load [23]. However, our results are similar to those 
demonstrated by Bunjun et al. in which they found LTBI and HIV co-infected 
persons to have a higher proportion of IFN-γ+TNF-α+IL-2+ polyfunctional T 
cells compared to HIV uninfected persons [24]. Conversely, Kalsdorf et al. 
and Jambo et al. found lower proportions of IFN-γ+TNF-α+IL-2+ polyfunctional 
T cells in HIV infected persons compared to HIV uninfected persons [25, 26]. 
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Sutherland and colleagues also demonstrated an expansion in Mtb-specific 
polyfunctional CD4 T cells, in HIV infected persons, after ART [27]. 
 
Additionally the single cytokine secreting cells dominated the cytokine 
response in HIV infected persons at day 0 of ART, in Mtb-specific CD4+ T 
cells. Interestingly at 6 months of ART, the cytokine response was dominated 
by single positive and cells secreting two cytokines in Mtb-specific CD4+ T 
cells. These results were similarly reported by Bunjun et al., Jambo et al. and 
Kalsdorf et al. in which HIV infected persons displayed an Mtb-specific profile 
consisting of monofunctional and bifunctional cytokine expression [24-26]. 
Both IFN-γ and TNF-α play pivotal roles in macrophage activation, and in 
turn preventing the growth of Mtb [28]. Murine and human studies have 
additionally demonstrated the requirement of IFN-γ for resistance to Mtb 
infection [29-33]. IL-2 is known for its proliferative role [34, 35] and is 
required by antigen-specific cells to undergo clonal expansion [36]. However 
a definitive role of IL-2 in LTBI and TB disease has yet to be established. 
 
Overall, a lower Mtb-specific response was detected in our cohort of HIV 
infected persons receiving ART. A possible reason for the reduced detection 
is the absence of Mtb-specific cells to begin with, due to early depletion of 
this cell subset as a result of HIV infection [24, 37-40]. A limitation in this 
study is the reliance on antigenic stimulation in order to measure a Mtb-
specific response, thus limiting the analysis solely to persons that are able to 
mount a detectable Mtb-specific response. We opted for the use of Mtb 
WCL, a pool of lipids, proteins and carbohydrates present within the Mtb 
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H37Rv strain, in order to maximise our ability to detect a response and at the 
same time without compromising the specificity of the response. Overcoming 
the reliance of antigenic stimulation may be possible through the use of a 
novel technology, or analysis program, that will facilitate the detection of 
antigen specific responses that are below current levels of detection based 
on available technologies. Additionally, it is important to note that these 
individuals are immune compromised and therefore pre-determined 
sensitisation cut-off values may not be applicable to this cohort. This was 
further observed by Esmail et al [41]. We defined the memory response 
based on the use of CD45RA and CD27 markers, which unfortunately cannot 
identify stem cell memory T cells (CD45RA+CD45RO-CCR7+CD27+) [42] that 
are the intermediate subpopulation between naïve-like and central memory T 
cells. Inclusion of the CCR7 and CD62L markers would have been beneficial 
and would further allow the identification of this subpopulation. Also, although 
we were powered to conduct the above assays the loss of persons due to 
incomplete timepoints resulted in a lower overall number of samples 
available for analysis. Furthermore the cryopreservation of samples may 
have affected cell viabilities and cell numbers also affecting the ability to 
detect a Mtb-specific response in immune-compromised persons. 
 
This study focused on the characterisation of Mtb-specific CD4 central 
memory T cells as potential correlate of protection to TB. Effector molecules 
are also sourced from CD8 T cells and may therefore play a vital role in TB 
immunity and thus it may be worthwhile looking at the CD8 compartment in 
LTBI HIV infected persons receiving ART. Further experiments are needed 
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to confirm the findings in a larger cohort, including a control cohort of 
individuals with active TB disease. A longitudinal study looking at Mtb-
specific responses in individuals that progress to active disease may provide 
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Chapter 5: Analysis of soluble markers from 
QFT supernatants of HIV Infected persons 
sensitised by Mycobacterium tuberculosis, 
receiving antiretroviral therapy 
 
5.1. Introduction 
Tuberculosis remains one of the highest causes of mortality with an 
estimated 10.4 million people developing active TB in 2016 [1]. The BCG 
vaccine is currently the only available vaccine against TB, but it lacks 
effectiveness for lifelong protection against TB infection. The Quantiferon TB 
Gold assay is used in research and as a diagnostic test for Mtb that 
measures IFN-γ responses against Mtb specific antigens [2]. This test 
however, is unable to differentiate between the active form of TB and latent 
TB infection. 
 
Upon entry into the pulmonary alveolus, Mtb interacts with the airway 
epithelial cells, macrophages, dendritic cells and neutrophils [3]. This 
interaction triggers a host immune defence comprised of cytokines, 
chemokines and other inflammatory molecules to kill and contain the bacteria 
[4]. Infected dendritic cells (DC) migrate to the lymph nodes where they 
initiate an adaptive immune response to control the growth of Mtb [5]. T and 
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B cells also play a role in the control and elimination of Mtb by antigen 
presentation and antibody production [6]. Many of these events are initiated 
by cytokines that have an influence on surrounding cells. The type of 
cytokines that are produced is dependent on the type of immune cell and 
their interaction with the bacteria [7]. T cells, DCs, macrophages and other 
immune cell signals are mediated by cytokines, such as IFNγ, TNFα, IL-2 
and IL-10, and these interactions have an impact on disease severity and 
outcome [8]. Cytokines play a key role at sites in which Mtb is present and 
cytokine signalling is representative of a checkpoint of the immune response 
against Mtb [7]. Several studies using gene knockout murine models have 
illustrated that cytokines such as IFN-γ, TNF-α and IL-12 play and important 
role in Mtb control [9-14]. IL-1 has also been shown to be required for host 
resistance to Mtb infection and studies in mice have found that a deficiency 
of IL-1 leads to susceptibility to infection [15]. 
 
IFN-γ production by CD4 TH1 cells is important for a protective immune 
response against Mtb [13]. DCs, activated by Mtb, produce IL-12 which plays 
an important role in the induction of protective IFN-γ T cell responses against 
primary infection [13, 16]. Apart from the induction of IFN-γ, IL-12p40 plays 
an important role in the continuous production of IL-12p70 to sustain TH1 
responses in the lung to control chronic infection [17]. A study in IFN-γ 
deficient mice showed IFN-γ and IL-17 producing T cells were induced 
following infection with Mtb and furthermore, IFN-γ limited the IL-17 
producing T cell population thereby suggesting that the IFN-γ pathway is 
potentially an important factor in limiting mycobacterial associated immune-
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mediated pathology [18]. Although IL-23 is essential for a IL-17 response 
during Mtb infection, it is not required for IFN-γ responses in the presence of 
IL-12p70 [19]. It has been shown that the central role of these cytokines is to 
initiate a TH1 phenotype whereby downstream effector functions ensure the 
death of Mtb bacilli [20]. 
 
IL-10 plays a role in immune suppression and is produced by many cell types 
such as macrophages, DCs, neutrophils, T and B cells. IL-10  has an 
essential role in regulating the immune response and limiting 
immunopathology [21]. It inhibits the production of IL-12, thereby inhibiting 
TH1 responses [22]. IL-10 also plays a role in inhibiting macrophage killing of 
intracellular pathogens and production of TNF-α [23], therefore IL-10 plays a 
role in regulating the immune response to Mtb and ultimately disease 
outcome [24] .  
 
TNF-α is produced by many immune cells and plays a role in the activation 
of macrophages, induction of chemokines as well as the upkeep of the 
granuloma [13, 25]. The role of TNF-α in the control of Mtb infection in 
humans was highlighted in a study whereby patients, who were latently 
infected with Mtb, receiving anti-TNF therapy had an increased rate of 
reactivation of active TB [26]. TNF-α is important in providing resistance to 
Mtb infection and may also have a role in the promotion of phagocytosis and 
intracellular killing of Mtb [27]. Although IFN-γ, TNF-α and IL-1 have been 
shown to have protective roles for the host, if left unregulated, they can be 
detrimental to the host.  
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Type 1 IFN is well known for its role in antiviral immunity but the 
overexpression of type 1 IFN following Mtb infection has a detrimental effect 
on the host [28, 29]. Type 1 IFN has also been shown to express the 
production of IL-1 and IL-12 after Mtb infection and therefore, type 1 IFN may 
increase susceptibility of an individual to Mtb infection [30]. More importantly 
Berry et al. revealed a 393 transcript whole-blood signature for active TB that 
was dominated by a IFN-inducible gene profile, consisting of type 1 IFN-αβ 
and IFN-γ genes [29] and furthermore revealed that this signature was 
resolved in persons during TB therapy. This suggests that this signature may 
be used to measure efficacy of treatment, and may also provide insight into 
the host response to Mtb infection [29]. The uncontrolled production of TNF-
α may cause an increased pathology at higher levels [27]. 
 
Following determination of Mtb sensitisation, QFT supernatants were used to 
measure Mtb-specific soluble markers using multiplex Luminex analysis.  
 
5.2. Patient characteristics 
Thirty-two HIV infected persons and 12 HIV uninfected persons were 
included in this arm of the study based on availability of stored QFT 
supernatants for all longitudinal follow up timepoints. All HIV infected persons 
and HIV uninfected persons included in this aim were determined to be Mtb 
sensitised based on a positive IFN-γ response determined by either the QFT, 
ELISpot or the Luminex assay at at least one timepoint. Therefore all 
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persons were considered to be sensitised to Mtb. The characteristics of all 
patients included are summarized in Table 5.1. Although the median age of 
HIV infected persons differed significantly from the median age of HIV 
uninfected persons, we do not believe that this difference impacted 
downstream statistics and subsequent significant differences in 




Table 5. 1: Characteristics of patients included in the analysis of 
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5.3. Methods and statistical analysis 
Frozen QFT plasma from 32 HIV infected and 12 HIV uninfected persons 
was thawed and used for multiplex analysis. 25µL of sample was used at a 
1:3 dilution ratio to determine the concentrations of the analytes IL-1β, IL-
1Rα, IL-2, IL-4, IL-5, IL-6 IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17, 
EOTAXIN, basic FGF, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-
1β, RANTES, PDGF, TNF-α and VEGF using the Bio-Plex Pro Human 
Cytokine 27-plex kit (Bio-Rad Laboratories, Hercules, CA). The analytes IL-
12p40, IL-22, IL-23, IL-1α, FGF-2 and IFN-α were measured using the 
MILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead Panel - 
Immunology Multiplex Assay (Merck Millipore). Multiplex assays were carried 
out according to the manufacturer’s instructions detailed in chapter 2, section 
2.6. Acquisition was performed on the Bio-Plex 200 system with Luminex 
xMap Technology (Bio-Rad Laboratories, Hercules, CA) using the Bio-Plex 
Manager Software (version 6.1). The response of the analyte was defined as 
the concentration of the analyte in the nil tube plasma subtracted from the 
concentration of the analyte in the Mtb antigen (Ag) tube plasma (Ag-Nil), 
with resulting negative values being assigned a value of 0. Ag-Nil values 
were assessed using statistics, described below, and plotted on subsequent 
graphs. 
 
Statistical analysis was performed using GraphPad Prism (version 6) using 
methods for non-parametric data. The Friedman test, with correction for 
multiple comparisons, was used for paired data comparison across all 
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sampling time points in HIV infected individuals. There were four sampling 
timepoints (k=4) thus the Friedman test was performed with d.f. = 3 (‘degrees 
of freedom’ = k-1 and alpha = 0.05) in order to determine p-values. The 
Kruskal Wallis test with correction for multiple comparisons was used for 
unpaired data comparisons across all time points in HIV infected persons. 
The Wilcoxon test (equivalent of the non-parametric student t-test) was used 
to compare paired data in HIV infected persons at day 0 and 6 months of 
ART. Additionally we also compared cross-sectional data from the HIV 
infected persons at 6 months of ART with HIV uninfected persons using the 
Mann-Whitney test, used for unpaired data comparisons. A p-value of less 
than or equal to 0.05 was considered statistically significant. P-values are 
illustrated in subsequent figures by asterixes and mean the following: ns 
refers to a p-value > 0.05, a single asterisk (*) refers to a p-value ≤ 0.05, two 
asterix (**) refer to a p-value ≤ 0.01, three asterix (***) refer to a p-value ≤ 
0.001 and four asterix (****) refer to a p-value ≤ 0.0001. 
  
5.4. Results 
The analytes measured were broadly grouped based on their functions into 5 
groups namely; pro-inflammatory, T cell growth factors, chemoattractants, 
growth factors and anti-inflammatory. First we explored each analyte 
individually in order to determine how the concentrations changed over time 
on 6 months of ART. 
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5.4.1. Pro-inflammatory analytes 
A summary of the pro-inflammatory cytokines measured is shown in Figure 
5.1. and Table 5.3. The Friedman test of differences among repeated 
measures was conducted in order to determine the difference in 
concentration of analytes across all timepoints of sampling, for HIV infected 
persons. This test also corrects for multiple comparisons. A Friedman test 
statistic of 14 (d.f. = 3) which was statistically significant (p-value = 0.002) for 
the decreasing concentration of IFN-γ produced by HIV infected individuals 
after 6 months of ART, was calculated. We also assessed the concentration 
of IFN-γ at day 0 and after 6 months of ART and found that the concentration 
of IFN-γ decreased significantly in HIV infected persons, during 6 months of 
ART (Figure 5.1. panel A, p-value = 0.0498). Lastly, a cross sectional 
comparison between HIV infected persons at 6 months of ART with HIV 
uninfected persons, revealed no significant difference in the concentration of 
IFN-γ produced by either group of individuals (p-value = 0.409).  
Friedman tests, with d.f. = 3, were conducted for the longitudinal analysis for 
the remaining analytes, and generated statistically significant test statistics 
for IL-1α (27), IL-1β (25), IL-6 (16), IL-17A (17) and TNF-α (17) with p-values 
< 0.0001, < 0.0001, 0.0014, 0.0009 and 0.0008 respectively. The Friedman 
test statistic generated for IL-12p70 was 2.3, and was not statistically 
significant (p-value = 0.522). 
When we compared the concentrations of analytes IL-1α (Figure 5.1. panel 
B), IL-1β (Figure 5.1. panel C), IL-6 (Figure 5.1. panel D), IL-17A (Figure 5.1. 
panel F) and TNF- α (Figure 5.1. panel G) at day 0 and after 6 months of 
ART, we found a significant decrease in the abovementioned analytes in HIV 
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infected persons during ART (p-values < 0.0001, 0.0009, 0.006, 0.006 and 
0.0007 respectively). However the concentration of IL-12p70 remained 
unchanged in HIV infected persons for the duration of therapy (Figure 5.1. 
panel E, p-value = 0.784). 
Lastly, comparison with the HIV uninfected persons revealed a number of 
differences: HIV infected persons produced significantly higher 
concentrations of IL-1α (p-value = 0.017) and IL-6 (p-value = 0.0005) 
compared to HIV uninfected persons, even after 6 months of ART. Although 
not significant, HIV infected persons also produced higher concentrations of 
IL-1β (p-value = 0.104) compared to HIV uninfected persons. IL-17A, TNF-α 
and IL-12p70 concentrations measured in both cohorts were 
indistinguishable between them (p-values = 0.173, 0.439 and 0.484 
respectively).  
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Table 5. 3: Median and IQR of pro-inflammatory cytokines measured in HIV infected and HIV uninfected cohorts and 
corresponding p-values. 
 HIV Infected Persons (n=32) 
HIV Uninfected 
Persons (n=12) 




HIV Infected D0 
vs. 6M 
(paired t test) 













































< 0.0001 0.0009 0.104 
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HIV Uninfected 
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Figure 5. 1: Pro-inflammatory cytokines, (A) IFN-γ, (B) IL-1α, (C) IL-1β, (D) IL-4, (E) IL-12p70, (F) IL-17A and (G) TNF-α, 
measured in QFT supernatants of HIV infected persons during 6 months of ART, and HIV uninfected persons using 
Luminex. Data points on graphs represent log transformed detectable concentrations of analytes for patients.  


























































































































































































































5.4.2. TH2 cytokines 
A summary of the TH2-associated soluble markers measured are shown in 
Figure 5.2. and Table 5.4. A Friedman test statistic of 2.5 (d.f. = 3) was not 
statistically significant (p-value = 0.48) for the change in concentration of 
IFN-α2 produced by HIV infected individuals after 6 months of ART. An 
increase was seen in the concentration of IFN-α2, although not significant, in 
HIV infected persons during 6 months of ART (Figure 5.2. panel A, p-value = 
0.86). A cross sectional comparison between HIV infected persons at 6 
months of ART with HIV uninfected persons, revealed that HIV infected 
persons produce significantly higher concentrations of IFN- α2 compared to 
that of HIV uninfected persons (p-value = 0.039). A Friedman test (d.f. = 3) 
rendered a test statistic of 8.7, which was statistically significant (p-value = 
0.034) only for IL-4 concentrations in HIV infected persons receiving ART. 
Friedman test statistics for IL-5 (2.9), IL-13 (4.4), IL-10 (6.2), IL-1RA (6.5) 
and IL-9 (6.8) were not statistically significant (p-values = 0.4, 0.218, 0.103, 
0.089 and 0.077 respectively) in HIV infected persons during ART. Although 
not significantly, concentrations of IL-4 (Figure 5.4. panel B, p-value = 
0.072), IL-5 (Figure 5.2. panel C, p-value = 0.226), IL-10 (Figure 5.2. panel 
E, p-value = 0.366), IL-13 (Figure 5.2. panel F, p-value = 0.529) and IL-1RA 
(Figure 5.2. panel G, p-value = 0.814) tended to decrease in HIV infected 
persons during 6 months of ART, while concentrations of IL-9 (Figure 5.2. 
panel D, p-value = 0.02) declined significantly in the same cohort of 
individuals. 
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Comparison with the HIV uninfected persons indicated that HIV infected 
persons produced significantly higher IL-4 (p-value = 0.041) concentrations, 
and higher, but not significant, concentrations of IL-10 (p-value = 0.603) and 
IL-1RA (p-value = 0.738) than HIV uninfected persons. Interestingly, HIV 
uninfected persons produced significantly higher concentrations of IL-5 (p-
value = 0.021) and IL-13 (p-value = 0.032) compared to HIV infected 
persons. Lastly, HIV infected and uninfected persons produced similar 
amounts of IL-9 (p-value = 0.434). 
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Table 5. 4: Median and IQR of TH2 cytokines measured in HIV infected and HIV uninfected cohorts and corresponding p-
values. 
 HIV Infected Persons (n=32) 
HIV Uninfected 
Persons (n=12) 




HIV Infected D0 
vs. 6M 
(paired t test) 
HIV Infected at 
6M vs. 
HIV Uninfected 
(unpaired t test) 
















































0.077 0.02 0.434 
 205 
 
 HIV Infected Persons (n=32) 
HIV Uninfected 
Persons (n=12) 




HIV Infected D0 
vs. 6M 
(paired t test) 













































 Figure 5. 2: TH2 cytokines, (A) IFN-α2, (B) IL-4, (C) IL-5, (D) IL-9, (E) IL-10, (F) IL-13 and (G) IL-1RA, measured in QFT 
supernatants of HIV infected persons during 6 months of ART, and HIV uninfected persons using Luminex. Data points on 
graphs represent log transformed detectable concentrations of analytes for patients.  























































































































































































































5.4.3. T cell growth factors 
A summary of the soluble T cell growth factors measured are shown in 
Figure 5.3. and Table 5.5. Friedman test statistics (d.f. = 3) of 9.5 for IL-2 
and 5.4 for IL-15 were calculated indicating a statistically significant increase 
for IL-2 concentrations (p-value = 0.023) but not for IL-15 (p-value = 0.145) 
concentrations in HIV infected persons during ART (p-value = 0.145). The 
concentrations of IL-2 (Figure 5.3. panel A) and IL-15 (Figure 5.3. panel C) 
tended to increase in HIV infected persons sensitised by Mtb, during 6 
months of ART (p-values = 0.253 and 0.197) although not significantly as 
determined by paired t-test.  
A cross sectional comparison between HIV infected persons at 6 months of 
ART with HIV uninfected persons, revealed no difference in IL-2 
concentrations between HIV uninfected persons and HIV infected persons 
(p-value = 0.079), while the opposite was observed for IL-15. HIV infected 
persons produced significantly higher concentrations of IL-15 compared to 
HIV uninfected persons (p-value = 0.021). IL-7 concentrations measured in 
HIV infected persons during 6 months of ART did not differ significantly 
(Figure 5.3. panel B, p-value = 0.978). Comparison with the HIV uninfected 
persons revealed no difference in IL-7 concentrations compared to HIV 
infected persons (p-value = 0.275) and the Friedman test statistic of 3.6 (d.f. 




Table 5. 5: Median and IQR of T cell growth factors measured in HIV infected and HIV uninfected cohorts and 
corresponding p-values. 
 HIV Infected Persons (n=32) 
HIV Uninfected 
Persons (n=12) 




HIV Infected D0 
vs. 6M 
(paired t test) 














































Figure 5. 3: T cell growth factors, (A) IL-2, (B) IL-7 and (C) IL-15, measured in QFT supernatants of HIV infected persons 
during 6 months of ART, and HIV uninfected persons using Luminex. Data points on graphs represent detectable log 
transformed concentrations of analytes for patients. 
 




























































































5.4.4. Chemoattractant analytes 
A summary of soluble chemoattractant markers measured are shown in 
Figure 5.4. and Table 5.6. A Friedman test statistic of 6.3 (d.f. = 3), which 
was not statistically significant (p-value = 0.098), was calculated for Eotaxin 
concentrations produced by HIV infected individuals after 6 months of ART. 
Concentrations of Eotaxin in HIV infected persons declined during ART 
(Figure 5.4. panel A, p-value = 0.781) although not significantly while the 
comparison between HIV infected and HIV uninfected persons revealed that 
HIV infected persons produced higher concentrations of Eotaxin, although 
not significant, (p-value = 0.164).  
Friedman test statistics, with d.f. = 3, for IL-8 (5.6), MIP-1α (5.9), MIP-1β 
(6.6) and Rantes (6.3) concentrations were not statistically significant (p-
values = 0.135, 0.117, 0.085 and 0.099 respectively) in HIV infected persons 
after 6 months of ART. Meanwhile, IL-8 (Figure 5.4. panel B), MIP-1α (Figure 
5.4. panel E), MIP-1β (Figure 5.4. panel F) and RANTES (Figure 5.4. panel 
G) concentrations decreased in HIV infected persons during ART (p-values = 
0.386, 0.069, 0.36 and 0.725 respectively). Comparison with the HIV 
uninfected persons revealed that HIV infected persons produced significantly 
higher MIP-1α and MIP-1β concentrations than HIV uninfected persons (p-
values = 0.006 and 0.0002), while IL-8 concentrations were also higher in 
HIV infected persons (p-value = 0.293) although not significant. RANTES 
concentrations in HIV infected persons did not differ significantly from that 
produced by HIV uninfected persons (p-value = 0.376). 
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Friedman test statistics (d.f. = 3) of 9.9 and 4.5 were generated for IP-10 and 
MCP-1, with the test statistic being statistically significant for IP-10 (p-value = 
0.019) but not for MCP-1 (p-value = 0.208). The concentrations of IP-10 
increased significantly in HIV infected persons (Figure 5.4. panel C, p-value 
= 0.005) and MCP-1 concentrations in HIV infected persons followed the 
same increasing trend, although not significant (Figure 5.4. panel D, p-value 
= 0.467). Lastly IP-10 concentrations in HIV uninfected persons were 
significantly higher than concentrations observed for HIV infected persons (p-
value = 0.003), while the opposite was observed for MCP-1 concentrations 
(p-value = 0.078).  
  
 212 
Table 5. 6: Median and IQR of chemoattractant analytes measured in HIV infected and HIV uninfected cohorts and 
corresponding p-values. 








D0 vs. 6M 
(paired t 
test) 
HIV Infected at 
6M vs. 
HIV Uninfected 
(unpaired t test) 
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6M vs. 
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Figure 5. 4: Chemoattractant analytes, (A) Eotaxin, (B) IL-8, (C) IP-10, (D) MCP-1, (E) MIP-1α, (F) MIP-1β and (G) Rantes, 
measured in QFT supernatants of HIV infected persons during 6 months of ART, and HIV uninfected persons using 
Luminex. Data points on graphs represent log transformed detectable concentrations of analytes for patients.  
























































































































































































































5.4.5. Growth factors  
A summary of soluble growth factors measured are shown in Figure 5.5. and 
Table 5.7. A Friedman test statistic of 9.8 (d.f. = 3) which was statistically 
significant (p-value = 0.02) was calculated for the concentration of basic FGF 
produced by HIV infected individuals after 6 months of ART. Concentrations 
of basic FGF in HIV infected persons following 6 months of ART declined 
although not significantly (Figure 5.5. panel A, p-value = 0.154). Comparison 
with the HIV uninfected persons revealed that HIV infected persons 
produced similar concentrations, after 6 months of ART, of basic FGF (p-
value = 0.247).  
Friedman test statistics (d.f. = 3) determined for FGF-2 (7.8) and G-CSF (19) 
were statistically significant (p-values = 0.05 and 0.0002), while Friedman 
statistics for VEGF (4.8) and PDGF (3.8) were not statistically significant (p-
values = 0.183 and 0.279). Similar to basic FGF, FGF-2 (Figure 5.5. panel B) 
and PDGF (Figure 5.5. panel E) concentrations declined in HIV infected 
persons (p-values = 0.132 and 0.765), while G-CSF (Figure 5.5. panel C), 
and VEGF (Figure 5.5. panel F) concentrations significantly decreased in 
HIV infected persons (p-values = 0.0006 and 0.039). Comparisons with the 
HIV uninfected persons revealed that FGF-2 concentrations produced by HIV 
infected and uninfected persons were indistinguishable (p-value = 0.9749), 
while HIV infected persons produced significantly higher concentrations of G-
CSF (p-value = 0.002) and VEGF (p-value = 0.279) although not significant. 
Conversely, HIV uninfected persons produced higher concentrations of 
PDGF (p-value = 0.339) than HIV infected persons. 
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The median concentration of GM-CSF (Figure 5.5. panel D) was 
undetectable in both HIV infected persons following 6 months of ART, and 




Table 5. 7: Median and IQR of growth factors measured in HIV infected and HIV uninfected cohorts and corresponding p-
values. 
 HIV Infected Persons (n=32) 
HIV Uninfected 
Persons (n=12) 




HIV Infected D0 
vs. 6M 
(paired t test) 









































0.0002 0.0006 0.002 
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 HIV Infected Persons (n=32) 
HIV Uninfected 
Persons (n=12) 




HIV Infected D0 
vs. 6M 
(paired t test) 















































Figure 5. 5: Growth factors, (A) FGF basic, (B) FGF-2, (C) G-CSF, (D) GM-CSF, (E) PDGF and (F) VEGF measured in QFT 
supernatants of HIV infected persons during 6 months of ART, and HIV uninfected persons using Luminex. Data points on 
graphs represent detectable log transformed concentrations of analytes for patients.  























































































































































































Following this analysis method, we decided to determine whether the pro-
inflammatory analyte concentrations correlated with each other and whether 
this changed during 6 months of ART.  
 
5.4.6. Correlations of analyte concentrations measured in HIV infected 
persons during 6 months of ART 
 A correlation matrix was generated for all pro-inflammatory analytes 
measured at day 0 and after 6 months of ART. The Spearman correlation 
values and corresponding p-values are summarised in Figure 5.7. Spearman 
correlations revealed that IL-1β correlated positively with IL-6, IL-17A and 
TNF-α (p-values < 0.0001, 0.011 and 0.001 respectively). IL-1α also 
positively correlated with TNF-α (p-value = 0.027) and IL-12p70 positively 
correlated with IL-17A and TNF-α (p-values = 0.001 and 0.034 respectively) 
in HIV infected persons at day 0.  
 
During 6 months of ART, Spearman correlations revealed that IL-1β 
remained positively correlated with IL-17A, TNF-α and IL-6 (p-values = 
0.0022, 0.005 and < 0.0001 respectively) and IL-17A remained positively 
correlated with TNF-α (p-value = 0.024). Additionally it was determined that 
IL-6 now positively correlated with IL-17A (p-value = 0.004), whereas IL-
12p70 no longer correlated with IL-17A and TNF-α; and IL-1α no longer 
correlated with TNF-α as previously noted. 
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For an unbiased analysis, we conducted paired t-tests and ANOVA statistical 
analysis, for each timepoint comparison, followed by correction for multiple 
comparison using the Benjamini-Hochberg procedure. The p-values 
generated from these tests were used to calculate and plot the 
corresponding 1 minus p-value numerical figures, as coloured dots on a set 
of axes, that are displayed in Figure 5.7. A vertical line was placed at 0.95 on 
the x-axis representing the cut-off value for statistical significance, and thus 
all coloured dots to the right of the line represent comparisons for which 
there was a significant difference between any two timepoints. This analysis 
was performed with the help of the statistician, Dr. Maia Lesosky.  
 
Following correction for multiple comparisons it was evident that the pro-
inflammatory group of analytes, specifically IFN-γ, TNF-α, IL-6, IL-17A and 
IL-1β (Figure 5.6.), had changed significantly at various timepoints during 
ART, in line with the correlation analysis above. Additionally this unbiased 
analysis had also indicated that there were significant differences in the 
concentrations of IL-4, G-CSF, basic FGF and IP-10 at, at least one 




Figure 5. 6: Figure representing 1-p-values conducted for comparisons of each timepoint, after correction for multiple 
comparisons, in HIV infected persons during 6 months of ART. 
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Figure 5. 7: Correlation matrix of pro-inflammatory analytes measured in HIV infected persons. Spearman r values at (A) 




33 markers were analysed using the Luminex assay in HIV infected persons 
undergoing immune reconstitution through antiretroviral treatment, to identify 
potential soluble markers of protective immunity to TB, in HIV infected 
persons sensitised by Mtb. 
  
Our results revealed a significant decrease in the pro-inflammatory cytokines 
IFN-γ, IL-1α, IL-1β, IL-6, IL-17A and TNF-α in HIV infected persons after 6 
months of ART. Although not significant, IL-12p70 mirrored this trend. 
Additionally our results indicated that after 6 months of ART, concentrations 
of pro-inflammatory cytokines fell to concentrations similar to, or lower than 
that observed in HIV uninfected persons. Xiong and colleagues found 
significantly higher concentrations of pro-inflammatory cytokines, TNF-α, IL-6 
and IP-10, in patients with pulmonary TB compared to patients with no TB 
[31].  
 
The release of IFN-γ is mediated by innately-derived TNF-α, IL-2 and the 
autocrine binding of itself [32]. IFN-γ in turn plays a pivotal role in immune 
activation as it mediates the transcription of at least 200 genes via the Janus 
kinase/signal transducers and activators of JAK/STAT transcription pathway 
[33]. Moreover IFN-γ is required for the attraction of immune cells to the sites 
of inflammation and is also vital in order for lymphocyte-endothelial 
interactions to occur. This is achieved by the upregulation of adhesion 
molecules and the secretion of the chemoattractants RANTES, IP-10, MIP-
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1α, MIP-1β and MCP-1 [33]. IFN-γ produced by TH1 cells leads to 
macrophage activation thus resulting in the death of Mtb bacilli and 
increased MHC class II molecule expression, in turn promoting antigen 
recognition. IL-6 serves a double role in mediating inflammation and the host 
response. It therefore plays an essential role in the immune response after 
Mtb infection [34, 35].  
 
IL-17 is characterised as a pro-inflammatory cytokine and has a role in 
inflammation initiation and in the induction of chemokine gradients [7, 36, 
37]. IL-17 has also been shown to play a role in macrophage accumulation 
[38] thus Khader and Cooper have suggested that IL-17 may play a role in 
the accumulation of polymorphonuclear cells [39]. Based on this evidence, it 
has been suggested that IL-17 has an impact on the inflammatory response 
to mycobacteria [40, 41].  
 
Once activated, by the ingestion of neutrophils containing dead bacilli, 
macrophages release TNF-α [42] while IL-1β is released upon ingestion of 
live bacilli [7]. TNF-α is required for granuloma formation and in the lymph 
node, TNF-α acts with an array of cytokines (including IL-1β and IL-6) to 
promote TH17 cell differentiation [7]. TNF-α is known to promote 
phagocytosis in macrophages resulting in the death of Mtb bacilli, however 
increased levels of TNF-α have been associated with increased pathology 
[43]. IL-1β contributes towards the resistance to Mtb infection, during the 
early stages of infection [44], although increased concentrations may be 
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detrimental to the host [45] and IL-1β has been associated with acute chronic 
inflammation [46].  
 
Interestingly we noted IP-10 concentrations significantly increased in HIV 
infected persons during 6 months of ART. Xiong and colleagues found 
significantly higher levels of IP-10 in patients with TB compared to healthy 
patients [31]. IP-10 is currently the leading alternative biomarker for the 
detection of Mtb antigen specific responses for diagnostic purposes [33]  
having been shown to have a greater sensitivity than IGRAs in HIV infected 
adults and children [33, 47, 48]. IP-10 is a chemoattractant that is secreted 
by antigen-presenting cells (APCs) and is also induced via cell surface 
receptor interactions between APCs and T cells [49-51]. It binds to the 
CXCR3 receptor that is involved in regulating innate and adaptive immune 
responses by chemotaxis [52, 53]. Chemokines, such as IP-10, induce 
inflammation thereby mediating a protective anti-TB immune response, 
however excessive chemokine-induced lung inflammation can drive lung 
pathology [54]. Additionally increased chemokine levels may promote Mtb 
proliferation and therefore increased bacterial burdens [55]. 
 
The concentrations of the TH2-associated cytokines; IL-4, IL-5, IL-10, IL-13, 
IL-1RA and IL-9, chemoattractant soluble markers; EOTAXIN, IL-8, MIP-1α, 
MIP-1β and RANTES, growth factor analytes; basic FGF, FGF-2, PDGF, G-
CSF and VEGF tended to decline in HIV infected persons during 6 months of 
ART. G-CSF and VEGF significantly declined after ART, with VEGF 
concentrations falling to undetectable levels. GM-CSF was undetectable in 
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both cohorts. Conversely the concentrations of IFN-α2, T cell growth factors 
IL-2, lL-7 and IL-15, chemoattractant MCP-1 tended to increase in the same 
cohort of individuals. 
 
While overall, we show a decline in concentrations in the majority of analytes 
measured in our HIV infected persons receiving ART cohort, our study has 
several limitations, including a relatively small sample size and a 
heterogeneous cohort. While we recruited a sufficient number of HIV infected 
(n=50) and HIV uninfected persons (n=55) in order to be powered for this 
study, we were unable to include all recruited persons for these analyses due 
to missing time points during follow up of ART, and the costs associated with 
these assays. Currently there is no gold standard for the detection of latent 
TB infection thus some discordant results, between the QFT and ELISpot, 
from the same person is expected due to assay limitations [56, 57]. Moreover 
while our results reflect an Mtb-specific response, we are unable to 
determine the cellular source of each analyte due to limitations of this assay. 
Therefore our results are representative of the innate and adaptive immune 
response to LTBI. We were also unable to assess every potential soluble 
marker, in order to perform an unbiased assessment, due to a limited 
number of markers being incorporated into a single kit panel.  
 
In conclusion our results point to a decrease in immune activation as 
demonstrated by the decline in the majority of soluble analytes detected. 
Importantly we observed a significant decrease in the pro-inflammatory 
analytes that are predominantly responsible for chemokine induction, 
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downstream activation of immune cells and the orchestration of immune cells 
to the site of infection.   
 229 
References 
1. (WHO) WHO: Global Tuberculosis report 2016. 2016. 
2. Diel R et al: Interferon-gamma release assays for the diagnosis of 
latent Mycobacterium tuberculosis infection: a systematic review 
and meta-analysis. Eur Respir Journal 2011, 37(1):88-99. 
3. O'Garra A et al: The immune response in tuberculosis. Annu Rev 
Immunol 2013, 31:475-527. 
4. Sharma M et al: Pulmonary epithelial cells are a source of 
interferon ‐ γ in response to Mycobacterium tuberculosis 
infection. Immunology & Cell Biology 2007, 85(3):229-237. 
5. Ernst JD: The immunological life cycle of tuberculosis. Nature 
Reviews Immunology 2012, 12(8):581-591. 
6. Achkar JM, Casadevall A: Antibody-mediated immunity against 
tuberculosis: implications for vaccine development. Cell host & 
Microbe 2013, 13(3):250-262. 
7. Etna MP et al: Pro- and anti-inflammatory cytokines in 
tuberculosis: a two-edged sword in TB pathogenesis. Semin 
Immunol 2014, 26(6):543-551. 
8. Munk M, Emoto M: Functions of T-cell subsets and cytokines in 
mycobacterial infections. The European Respiratory Journal 
Supplement 1995, 20:668s-675s. 
9. Flynn JL et al: An essential role for interferon gamma in 
resistance to Mycobacterium tuberculosis infection. Journal of 
Experimental Medicine 1993, 178(6):2249-2254. 
10. Flynn JL et al: Tumor necrosis factor-α is required in the 
protective immune response against Mycobacterium 
tuberculosis in mice. Immunity 1995, 2(6):561-572. 
11. Cooper AM et al: Disseminated tuberculosis in interferon gamma 
gene-disrupted mice. Journal of Experimental Medicine 1993, 
178(6):2243-2247. 
12. Cooper AM et al: Interleukin 12 (IL-12) is crucial to the 
development of protective immunity in mice intravenously 
infected with Mycobacterium tuberculosis. Journal of Experimental 
Medicine 1997, 186(1):39-45. 
13. Flynn JL, Chan J: Immunology of tuberculosis. Annu Rev Immunol 
2001, 19(1):93-129. 
 230 
14. Keane J et al: Tuberculosis associated with infliximab, a tumor 
necrosis factor α–neutralizing agent. New England Journal of 
Medicine 2001, 345(15):1098-1104. 
15. Mayer-Barber KD et al: Innate and adaptive interferons suppress 
IL-1alpha and IL-1beta production by distinct pulmonary myeloid 
subsets during Mycobacterium tuberculosis infection. Immunity 
2011, 35(6):1023-1034. 
16. Cooper AM: Cell-mediated immune responses in tuberculosis. 
Annu Rev Immunol 2009, 27:393-422. 
17. Feng CG et al: Maintenance of pulmonary Th1 effector function in 
chronic tuberculosis requires persistent IL-12 production. The 
Journal of Immunology 2005, 174(7):4185-4192. 
18. Cruz A et al: Cutting edge: IFN-γ regulates the induction and 
expansion of IL-17-producing CD4 T cells during mycobacterial 
infection. The Journal of Immunology 2006, 177(3):1416-1420. 
19. Khader SA et al: IL-23 compensates for the absence of IL-12p70 
and is essential for the IL-17 response during tuberculosis but is 
dispensable for protection and antigen-specific IFN-γ responses 
if IL-12p70 is available. The Journal of Immunology 2005, 
175(2):788-795. 
20. Gallegos AM et al: A gamma interferon independent mechanism of 
CD4 T cell mediated control of M. tuberculosis infection in vivo. 
PLoS pathogens 2011, 7(5):e1002052. 
21. Saraiva M, O'garra A: The regulation of IL-10 production by 
immune cells. Nature Reviews Immunology 2010, 10(3):170. 
22. Fiorentino DF et al: IL-10 acts on the antigen-presenting cell to 
inhibit cytokine production by Th1 cells. The Journal of 
Immunology 1991, 146(10):3444-3451. 
23. Bogdan C et al: Macrophage deactivation by interleukin 10. 
Journal of Experimental Medicine 1991, 174(6):1549-1555. 
24. Redford P et al: The role of IL-10 in immune regulation during M. 
tuberculosis infection. Mucosal Immunology 2011, 4(3):261. 
25. Clay H et al: Tumor necrosis factor signaling mediates resistance 
to mycobacteria by inhibiting bacterial growth and macrophage 
death. Immunity 2008, 29(2):283-294. 
26. Harris J, Keane J: How tumour necrosis factor blockers interfere 
with tuberculosis immunity. Clinical & Experimental Immunology 
2010, 161(1):1-9. 
 231 
27. Nolan A et al: Elevated IP-10 and IL-6 from bronchoalveolar lavage 
cells are biomarkers of non-cavitary tuberculosis. The 
International Journal of Tuberculosis and Lung Disease 2013, 
17(7):922-927. 
28. Manca C et al: Virulence of a Mycobacterium tuberculosis clinical 
isolate in mice is determined by failure to induce Th1 type 
immunity and is associated with induction of IFN-α/β. 
Proceedings of the National Academy of Sciences 2001, 98(10):5752-
5757. 
29. Berry MP et al: An interferon-inducible neutrophil-driven blood 
transcriptional signature in human tuberculosis. Nature 2010, 
466(7309):973-977. 
30. Novikov A et al: Mycobacterium tuberculosis triggers host type I 
IFN signaling to regulate IL-1β production in human 
macrophages. The Journal of Immunology 2011, 187(5):2540-2547. 
31. Xiong F et al: Analysis of cytokine release assay data using 
machine learning approaches. Int Immunopharmacol 2014, 
22(2):465-479. 
32. Boehm U et al: Cellular responses to interferon-γ. Annu Rev 
Immunol 1997, 15(1):749-795. 
33. Chegou NN et al: Beyond the IFN-gamma horizon: biomarkers for 
immunodiagnosis of infection with Mycobacterium tuberculosis. 
Eur Respir J 2014, 43(5):1472-1486. 
34. Tanaka T et al: IL-6 in inflammation, immunity, and disease. Cold 
Spring Harbor Perspectives in Biology 2014, 6(10):a016295. 
35. Singh PP, Goyal A: Interleukin-6: a potent biomarker of 
mycobacterial infection. Springerplus 2013, 2(1):686. 
36. Miyamoto M et al: Endogenous IL-17 as a mediator of neutrophil 
recruitment caused by endotoxin exposure in mouse airways. 
The Journal of Immunology 2003, 170(9):4665-4672. 
37. Kolls JK, Lindén A: Interleukin-17 family members and 
inflammation. Immunity 2004, 21(4):467-476. 
38. Sergejeva S et al: Interleukin-17 as a recruitment and survival 
factor for airway macrophages in allergic airway inflammation. 
American Journal of Respiratory Cell and Molecular Biology 2005, 
33(3):248-253. 
39. Khader SA, Cooper AM: IL-23 and IL-17 in tuberculosis. Cytokine 
2008, 41(2):79-83. 
 232 
40. Khader SA et al: IL-23 Compensates for the Absence of IL-12p70 
and Is Essential for the IL-17 Response during Tuberculosis but 
Is Dispensable for Protection and Antigen-Specific IFN-
  Responses if IL-12p70 Is Available. The Journal of Immunology 
2005, 175(2):788-795. 
41. Umemura M et al: IL-17-mediated regulation of innate and 
acquired immune response against pulmonary Mycobacterium 
bovis bacille Calmette-Guerin infection. The Journal of 
Immunology 2007, 178(6):3786-3796. 
42. Persson YAZ et al: Mycobacterium tuberculosis-induced apoptotic 
neutrophils trigger a pro-inflammatory response in macrophages 
through release of heat shock protein 72, acting in synergy with 
the bacteria. Microbes and Infection 2008, 10(3):233-240. 
43. Ray JCJ et al: Synergy between individual TNF-dependent 
functions determines granuloma performance for controlling 
Mycobacterium tuberculosis infection. The Journal of Immunology 
2009, 182(6):3706-3717. 
44. Yamada H et al: Protective role of interleukin-1 in mycobacterial 
infection in IL-1 α/β double-knockout mice. Laboratory 
Investigation 2000, 80(5):759-767. 
45. Etna MP et al: Pro-and anti-inflammatory cytokines in 
tuberculosis: a two-edged sword in TB pathogenesis. In: 
Seminars in Immunology: 2014: Elsevier; 2014: 543-551. 
46. Tsao TC et al: Imbalances between tumor necrosis factor-α and 
its soluble receptor forms, and interleukin-1β and interleukin-1 
receptor antagonist in BAL fluid of cavitary pulmonary 
tuberculosis. CHEST Journal 2000, 117(1):103-109. 
47. Yassin MA et al: Use of tuberculin skin test, IFN-γ release assays 
and IFN-γ-induced protein-10 to identify children with TB 
infection. European Respiratory Journal 2013, 41(3):644-648. 
48. Kabeer BS et al: Comparison of interferon gamma and interferon 
gamma-inducible protein-10 secretion in HIV–tuberculosis 
patients. AIDS 2010, 24(2):323-325. 
49. Xia Y et al: Distinct effect of CD40 and TNF-signaling on the 
chemokine/chemokine receptor expression and function of the 
human monocyte-derived dendritic cells. Cellular & Molecular 
Immunology 2008, 5(2):121-131. 
50. Ruhwald M et al: IP-10 release assays in the diagnosis of 
tuberculosis infection: current status and future directions. 
Expert Rev Mol Diagn 2012, 12(2):175-187. 
 233 
51. Ohmori Y et al: Tumor necrosis factor-alpha induces cell type and 
tissue-specific expression of chemoattractant cytokines in vivo. 
The American Journal of Pathology 1993, 142(3):861. 
52. Groom JR, Luster AD: CXCR3 in T cell function. Experimental cell 
research 2011, 317(5):620-631. 
53. Liu M et al: CXCL10/IP-10 in infectious diseases pathogenesis and 
potential therapeutic implications. Cytokine & Growth Factor 
Reviews 2011, 22(3):121-130. 
54. Monin L, Khader SA: Chemokines in tuberculosis: the good, the 
bad and the ugly. Semin Immunol 2014, 26(6):552-558. 
55. Algood HMS et al: Chemokines and tuberculosis. Cytokine & 
Growth Factor Reviews 2003, 14(6):467-477. 
56. Mandalakas A et al: High level of discordant IGRA results in HIV-
infected adults and children. The International Journal of 
Tuberculosis and Lung Disease 2008, 12(4):417-423. 
57. Hesseling AC et al: Highly discordant T cell responses in 
individuals with recent exposure to household tuberculosis. 




Chapter 6:  Transcriptomic Analysis of Central 
Memory Cell-specific and Effector Memory Cell-
specific genes in Whole Blood from HIV 
Infected persons, sensitised by Mycobacterium 
tuberculosis 
6.1. Introduction 
Following antigen exposure, memory T cells are classified into either central 
memory T cells or effector memory T cells based on the expression of 
certain markers that are indicative of their functions. These functions include 
proliferative capacity, differentiation capacity, cytokine secretion, senescence 
profile and the ability to home or migrate. Central memory T cells are early 
differentiated CD27+ memory T cells, that have been shown to home to the 
secondary lymphoid organs [1]. Conversely effector memory T cells are late 
differentiated CD27− memory T cells that exhibit effector functions, such as 
the ability to produce high levels of IFN-γ, and have been shown to migrate 
into peripheral sites of inflammation [1].  
 
A study conducted by our collaborators, Dintwe PhD, 2014, [2] aimed to 
characterize naïve-like Mtb-specific T cells at the transcriptional level by 
measuring the expression of genes that are differentially expressed between 
naïve, effector, central memory and stem cell like memory T cells. They 
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therefore selected genes, based on literature available, that were 
differentially expressed between the aforementioned memory T cell subsets. 
Genes translated into products such as cytokines and cytokine receptors, 
chemokine receptors, inhibitory molecules, co-stimulatory molecules, 
kinases, transcription factors, molecules that play a role in homing and 
migration and effector molecules were selected. They subsequently 
determined genes that were differentially expressed in the memory T cell 
sub-populations. Thus, ICOS, SELL, PRKCA, TCF7L, LEF1, NFκβ, CD38, 
ITK, IGF1R, ARHGEF18, AXIN2, CCR7 and CD27 had a higher expression 
in central memory T cells compared to effector memory T cells while the 
genes; GNLY, RORC, TGF-β, PRF1, CCL5, IFN-γ, CCR2, GATA, GZMA, 
GZMB, GZMK, PRR5L, TXB21, IL-2Rβ, CCR4, CCR5 and FAM129A had a 
higher expression in effector memory T cells compared to central memory T 
cells. We determined the expression of these T cell memory genes during 
ART in collaboration, with the hypothesis that the transcriptomic signature 
associated with central memory T cells will increase over time in HIV infected 
persons on ART, while the signature associated with effector memory T cells 
will decrease. We therefore compared gene transcriptional signatures 
characteristic of central memory and effector memory T cells in HIV infected 
persons starting ART and sampled at day 0, 1 month, 3 months and 6 
months of ART. 
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6.2. Patient characteristics of individuals included in analysis 
Forty-five HIV infected persons were included in this arm of the study based 
on availability of blood stored in Tempus® tubes for RNA extraction at all 
follow up timepoints. An additional 23 patients recruited from the same site, 
and using the same inclusion criteria, were also included in this arm of the 
study thus bringing the total number of HIV infected persons to 68, with 
median age 33 (29-37) years, 49 males/ 19 females. All HIV infected persons 
and HIV uninfected persons included in this aim were determined to be Mtb 
sensitised based on a positive IFN-γ response determined by either the QFT, 
ELISpot or the Luminex assay at at least one timepoint. Therefore all 
persons were considered to be sensitised to Mtb. Blood for RNA isolation 
was not collected from the HIV uninfected persons. The characteristics of all 





Table 6. 1: Characteristics of patients included in the transcriptomic 
analysis of CM- and EM- T cell specific genes in whole blood 
 HIV Infected Persons (n=68) 
Median Age (years) 33 (29-37) 
Gender Male/Female 49/19 
 
 




HIV Infected Persons (n=68) 






















6.3. Methods and statistical analysis 
RNA from blood stored in TempusTM Blood RNA tubes was isolated using 
the Tempus™ Spin RNA Isolation Kit, according to the manufacturer’s 
instruction, after tubes were allowed to thaw overnight at room temperature. 
Following isolation the RNA quantity and quality was determined using 
Nanodrop spectrophotometry and the Agilent Bioanalyzer. Briefly the 
260/280 ratio, determined by the Nanodrop, was used to assess the purity of 
the RNA with a ratio of between 1.8 and 2.0 being accepted as pure RNA. 
The 260/230 ratio was used to assess the possibility of contamination and 
RNA with a 260/230 ratio lower than 2.2 was considered to be contaminated. 
Using the electrophoretic trace of the RNA, the Bioanalyzer assigned RIN 
values to all RNA patient samples based on the integrity. RIN values >8 
indicate high quality RNA.  
 
RNA was reverse transcribed to generate cDNA using the SuperScript® III 
First-Strand Synthesis System for RT-PCR kit, according to the 
manufacturer’s instructions. Taqman probes were used to detect the Ct 
values of exponentially amplified cDNA using RT-PCR. The data generated 
for each gene of interest was normalised to 3 housekeeping genes, 18S, β-
actin and GAPDH, and corrected for CD4 counts by further normalising to 
Log2[CD4] for each patient, in Microsoft Excel 2011 and subsequent data 
analysis was performed using GraphPad Prism (version 6.0).  
 
Statistical analysis was performed using GraphPad Prism (version 6) using 
methods for non-parametric data. The Friedman test, with correction for 
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multiple comparisons, was used for paired data comparison across all 
sampling time points in HIV infected individuals. There were four sampling 
time points (k=4) thus the Friedman test was performed with d.f. = 3 
(‘degrees of freedom’ = k-1 and alpha = 0.05) in order to determine p-values. 
The Kruskal Wallis test with correction for multiple comparisons was used for 
unpaired data comparisons across all time points in HIV infected persons. 
The Wilcoxon test (equivalent of the non-parametric test) was used to 
compare paired data in HIV infected persons at day 0 and 6 months of ART. 
A p-value of less than or equal to 0.05 was considered statistically 
significant. P-values are illustrated in subsequent figures by asterixes and 
mean the following: ns refers to a p-value > 0.05, a single asterisk (*) refers 
to a p-value ≤ 0.05, two asterix (**) refer to a p-value ≤ 0.01, three asterix 




The results of the RT-PCR experiments were analysed longitudinally, after 
being normalized to the three housekeeping genes 18S, β-actin and GAPDH 
in order to generate ΔCt values. The genes we selected were T cell-specific 
genes and since RT-PCR was conducted on RNA isolated from whole blood, 
as opposed to RNA of specific memory T cells, we corrected for CD4 counts 
in order to represent the data with respect to the number of CD4 T cells. This 
was achieved by dividing the ΔCT value at each timepoint by the Log2[CD4] 
count of the patient at the corresponding timepoint. We then represented the 
 240 
data using bar graphs and compared the resulting medians at day 0 to 
medians after 6 months of ART, for each gene normalised to each 
housekeeping gene. A summary of all comparisons is shown in Table 6.5. 
We then grouped the genes based on whether there was a significant 
difference in gene expression levels during ART when normalised to each of 
the three housekeeping genes. It is important to note that a decrease in the 
ΔCT/CD4 indicates an increase in expression of the particular gene, and vice 
versa. 
 
Following analysis the genes GNLY, PRF1, RORC and TCF7L2 showed no 
significant change in expression, in HIV infected persons during 6 months of 
ART, when normalised to 18S, β-actin and GAPDH (Figure 6.1. Panels A-D). 
The genes ICOS, ITK, NFκβ1, PRKCA, ARHGEF18, AXIN2, CCR7, CD27, 
IGF1R, LEF1, CD38, SELL and TCF7L2 were shown to be more highly 
expressed in central memory CD4 T cell subsets as opposed to effector 
memory CD4 T cell subsets (Mpanda et al. unpublished). Similarly, we 
observed a significant increase in the expression of ICOS, ITK, NFκβ1 and 
PRKCA (p-values = 0.029, 0.0001, 0.0011 and 0.0017 respectively) when 
normalised to the 18S housekeeping gene (Figure 6.2. Panels A-D). The 
expression of ARHGEF18, AXIN2, CCR7, CD27, IGF1R and LEF1 
significantly increased after 6 months of ART (Figure 6.3. Panels A-H) when 
normalised to 18S and β-actin housekeeping genes (p-values summarised in 
Table 6.3.), while CD38 and SELL expression significantly increased when 
normalised to 18S and GAPDH (p-values summarised in Table 6.3.).   
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Conversely the genes CCL5, CCR2, CCR4, CCR5, FAM129A, GATA3, 
GZMA, GZMB, GZMK, IFN-γ, IL-2RB, PRF1, PRR5L, RORC, TBX21 and 
TGFβ1 were shown to be more highly expressed in effector memory CD4 T 
cell subsets (Mpanda et al. unpublished). With the exception of TBX21, the 
expression of aforementioned genes significantly increased, in HIV infected 
persons during 6 months of ART, when normalised to the 18S housekeeping 
gene (p-values = 0.003, 0.0012, 0.0001, 0.009, 0.0189, 0.0073 and 0.0022 
respectively, Figure 6.4. Panels A-H). TBX21 exhibited a decrease in gene 
expression when normalised to the housekeeping gene GAPDH (p-value = 
0.0176, Figure 6.3. Panel I) while expression remained relatively consistent 
when normalised to the other housekeeping genes. 
 
Table 6. 3: P-values for comparing changes of central memory CD4 T 
cell specific gene expression between day 0 and 6 months of ART in 








ARHGEF18 <0.0001 0.0399 0.7218 
AXIN2 <0.0001 0.0165 0.0754 
CCR7 <0.0001 0.0051 0.0608 
CD27 <0.0001 0.0012 0.073 
IGF1R <0.0001 0.0005 0.0084 
LEF1 0.0005 0.0058 0.1568 
CD38 0.0094 0.8935 0.0395 
SELL 0.0264 0.3725 0.0001 
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Lastly the expression of the effector memory CD4 T cell specific genes 
CCR2, FAM129A, GZMB, GZMK and IL-2RB, in HIV infected persons after 6 
months of ART, significantly increased when normalised to the 18S and β-
actin housekeeping genes but not to GAPDH (Figure 6.5. Panels A-E, p-
values summarised in Table 6.5.).  
 
Table 6. 4: P-values for comparing changes of effector memory CD4 T 
cell specific gene expression between day 0 and 6 months of ART in 








CCR2 0.0001 0.0028 0.6296 
FAM129A <0.0001 0.0036 0.068 
GZMB <0.0001 0.0424 0.6715 
GZMK 0.0003 0.0033 0.0586 




Figure 6. 1: Gene expression of (A) GNLY, (B) PRF1, (C) RORC and (D) TCF7L2 showing no significant change after 6 
months of ART compared to day 0 of ART, when normalised to 3 housekeeping genes using RT-PCR. Graphs are a 






























































































































































































































































































































Figure 6. 2: Gene expression of central memory CD4 T cell-specific genes (A) ICOS, (B) ITK, (C) NFΚβ1 and (D) PRKCA 
showing a significant change after 6 months of ART compared to day 0 of ART, when normalised to 18S housekeeping 
gene using RT-PCR. Graphs are a measure of ΔCt normalised to CD4 counts, a decrease in the ΔCT/CD4 indicates an increase 

































































































































































































































































































































Figure 6. 3: Gene expression of central memory CD4 T cell-specific genes (A) ARHGEF18, (B) AXIN2, (C) CCR7, (D) CD27, 
(E) CD38, (F) IGF1R, (G) LEF1 and (H) SELL showing a significant change after 6 months of ART compared to day 0, when 
normalised to two housekeeping genes using RT-PCR. Graphs are a measure of ΔCt normalised to CD4 counts, a decrease in 























































































































































































































































































































































































































































































































































































































































Figure 6. 4: Gene expression of effector memory CD4 T cell-specific genes (A) CCL5, (B) CCR4, (C) CCR5, (D) GATA3, (E) 
GZMA, (F) IFN-γ, (G) PRR5L, (H) TBX21 and (I) TGFβ1, showing a significant change after 6 months of ART compared to 
day 0, when normalised to one housekeeping gene using RT-PCR. Graphs are a measure of ΔCt normalised to CD4 counts, a 































































































































































































































































































































































































































































































































































































































































































































































Figure 6. 5: Gene expression of effector memory CD4 T cell-specific genes (A) CCR2, (B) FAM129A, (C) GZMB, (D) GZMK 
and (E) IL-2RB showing a significant change after 6 months of ART compared to day 0, when normalised to two 
housekeeping genes using RT-PCR. Graphs are a measure of ΔCt normalised to CD4 counts, a decrease in the ΔCT/CD4 




























































































































































































































































































































































































































Table 6. 5: Median and p-values for comparing the expression level of 
genes at day 0 and 6 months of ART, normalised to 18S  
Gene/Median 
Day 0 of 
ART 
1M 3M 6M 
D0 of ART 
vs. 6M 
p-value 
ARHGEF18 1923 1807 1790 1699 <0.0001 
AXIN2 2554 2510 2377 2293 <0.0001 
CCL5 1367 1277 1282 1215 0.0003 
CCR2 1664 1522 1545 1452 0.0001 
CCR4 2162 1997 1964 1960 0.0012 
CCR5 2115 1984 1926 1894 0.0001 
CCR7 2096 1951 1941 1772 <0.0001 
CD27 2148 2026 2017 1880 <0.0001 
CD38 2210 2130 2197 2021 0.0094 
FAM129A 1935 1773 1742 1709 <0.0001 
GATA3 2275 2151 2066 2059 0.0001 
GNLY 1499 1364 1354 1354 0.0524 
GZMA 1771 1697 1669 1623 0.0009 
GZMB 1935 1827 1809 1654 <0.0001 
GZMK 2013 1867 1862 1782 0.0003 
ICOS 2384 2289 2288 2160 0.0292 
IFN-γ 2221 2089 2148 2028 0.0189 
IGF1R 2124 1949 1933 1887 <0.0001 
IL-2RB 2187 1977 1963 1873 <0.0001 
ITK 2077 1950 1915 1856 0.0001 
LEF1 1811 1849 1876 1657 0.0005 
NFΚβ-1 2048 1919 1910 1833 0.0011 
PRF1 1968 1795 1848 1838 0.2939 
PRKCA 2330 2216 2147 2015 0.0017 
PRR5L 2045 1983 1898 1860 0.0073 
RORC 2690 2646 2666 2532 0.0897 
SELL 1365 1334 1286 1264 0.0264 
TBX21 2257 2143 2153 2185 0.1696 
TCF7L2 2193 2211 2195 2048 0.1664 
TGFβ-1 1529 1435 1466 1344 0.0022 
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Table 6. 6: Median and p-values for comparing the expression of genes 
at day 0 and 6 months of ART, normalised to β-actin. 
Gene/Median 
Day 0 of 
ART 
1M 3M 6M 
Day 0 of ART 
vs. 6M 
p-value 
ARHGEF18 775 757 698 708 0.0399 
AXIN2 1425 1399 1321 1208 0.0165 
CCL5 206 192 218 183 0.127 
CCR2 524 427 481 413 0.0028 
CCR4 976 943 925 959 0.1905 
CCR5 929 909 842 855 0.083 
CCR7 929 936 804 754 0.0051 
CD27 990 940 911 862 0.0012 
CD38 1076 1060 1112 1081 0.8935 
FAM129A 771 726 664 670 0.0036 
GATA3 1103 1022 985 1007 0.1229 
GNLY 304 272 276 263 0.1989 
GZMA 617 596 574 549 0.1647 
GZMB 763 736 714 691 0.0424 
GZMK 813 780 766 724 0.0033 
ICOS 1147 1147 1193 1202 0.6801 
IFN-γ 1032 976 1014 1019 0.5229 
IGF1R 938 897 850 732 0.0005 
IL-2RB 926 901 861 869 0.0092 
ITK 877 865 815 808 0.0514 
LEF1 692 695 743 555 0.0058 
NFΚβ-1 884 864 834 834 0.0848 
PRF1 738 717 712 787 0.7193 
PRKCA 1068 1089 1071 1013 0.7469 
PRR5L 858 964 820 880 0.7887 
RORC 1496 1511 1529 1519 0.7859 
SELL 191 213 191 234 0.3725 
TBX21 1015 1078 1043 1067 0.6002 
TCF7L2 1054 1103 1081 999 0.6906 
TGFβ-1 345 338 365 313 0.5013 
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Table 6. 7: Median and p-values for comparing the expression of genes 
at day 0 and 6 months of ART, normalised to GAPDH  
Gene/Median 
Day 0 of 
ART 
1M 3M 6M 
Day 0 of 
ART vs. 6M 
p-value 
ARHGEF18 440 448 410 420 0.7218 
AXIN2 1063 1109 1071 1032 0.0754 
CCL5 -158 -123 -121 -130 0.1091 
CCR2 134 105 123 114 0.6296 
CCR4 639 625 622 668 0.8857 
CCR5 581 592 572 599 0.8752 
CCR7 584 601 528 538 0.0608 
CD27 613 623 596 569 0.073 
CD38 702 738 771 743 0.0395 
FAM129A 440 436 403 399 0.068 
GATA3 775 721 713 704 0.3107 
GNLY -183 -136 -114 -119 0.1437 
GZMA 271 289 288 288 0.4721 
GZMB 397 400 409 398 0.6715 
GZMK 487 451 460 430 0.0586 
ICOS 850 854 879 844 0.68 
IFN-γ 694 653 690 691 0.6806 
IGF1R 592 547 538 510 0.0084 
IL-2RB 593 604 568 520 0.1571 
ITK 545 547 535 508 0.8693 
LEF1 369 369 387 316 0.1568 
NFΚβ-1 528 537 511 567 0.4757 
PRF1 364 389 421 468 0.4757 
PRKCA 789 777 758 769 0.8135 
PRR5L 552 611 505 625 0.0793 
RORC 1145 1246 1269 1227 0.523 
SELL -127 -80 -94 -56 0.0001 
TBX21 658 722 681 742 0.0176 
TCF7L2 706 757 754 756 0.155 
TGFβ-1 5.0 51 36 45 0.117 
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6.4. Discussion 
In order to identify a transcriptomic signature that may provide insights to 
protective immunity to TB, we used RT-PCR to determine the expression of 
selected genes in HIV infected Mtb sensitised persons during ART. The 
selection of genes was based on results from a previous study, Dintwe PhD 
2014, in which the genes were shown to be differentially expressed between 
central memory and effector memory T cells. Genes selected included 
cytokines and cytokine receptors, chemokine receptors, inhibitory molecules, 
co-stimulatory molecules, kinases, transcription factors, molecules that play 
a role in homing and migration and effector molecules, in which the genes; 
ICOS, SELL, PRKCA, TCF7L, LEF1, NFκβ, CD38, ITK, IGF1R, ARHGEF18, 
AXIN2, CCR7 and CD27 were shown to have a higher expression in central 
memory T cells while the genes; GNLY, RORC, TGF-β, PRF1, CCL5, IFN-γ, 
CCR2, GATA, GZMA, GZMB, GZMK, PRR5L, TXB21, IL-2Rβ, CCR4, CCR5 
and FAM129A had a higher expression in effector memory T cells.  
 
Our results indicated a significant increase in expression of the central 
memory-specific genes: ARHGEF18, AXIN2, CCR7, CD27, CD38, IGF1R, 
LEF1 and SELL when normalised to two housekeeping genes. In the case of 
the gene IGF1R, a significant increase in gene expression was noted 
irrespective of the housekeeping gene used for normalisation.  
 
While the expression and role of these genes in LTBI infection has yet to be 
determined, a number of the aforementioned genes play a role in cell 
trafficking and the ability of cells to home, or the modulation of intercellular 
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proteins leading to the transcription of genes. The product of ARHGEF18, 
Rho guanine nucleotide exchange factor 18, is responsible for proteins 
involved in the regulation of cellular processes such as cytoskeletal 
rearrangements, gene transcription, cell growth and motility [3]. AXIN2 (axis 
inhibition protein 2) has been shown to play an important role in the 
regulation of the stability of β-catenin in the Wnt signalling pathway [4]. The 
activation of the Wnt signalling pathway has also been shown to elevate 
AXIN2 expression. CCR7 (chemokine receptor type 7) is the receptor for 
CCL19 and CCL21 chemokines, and plays a role in the migration of memory 
T cells to secondary lymphoid organs [5]. Additionally CCR7 knockout mice 
were found to have activated, naïve Ag85B-specific CD4 T cells that were 
able to proliferate in the lung. These mice also displayed compromised 
resistance to Mtb infection compared to wildtype mice [6]. CD27 is present 
on the surface of CD4 T cells and is a receptor involved in co-stimulation. 
CD27 downregulates as naïve T cells differentiate into central memory T 
cells and subsequently effector memory T cells, thus central memory T cells 
express CD27 while effector memory T cells lack the CD27 receptor [7]. 
Additionally, Petruccioli et al. observed a significantly higher proportion of 
CD45RA- CD27+ T cells in LTBI and persons cured of TB compared to 
persons with active disease [8]. They therefore concluded that increased 
CD27+ is a marker of TB containment as they found a higher frequency of 
CD4+ IFN-γ+ CD27+ T-cells in LTBI while a higher frequency of CD4+ IFN-γ+ 
CD27- T-cells was associated with active TB [8].  
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CD38 is found on the surface of many immune cells and plays a role in the 
regulation of intracellular calcium, that in turn controls numerous processes 
such as cell activation and proliferation, hormone secretion and immune 
responses to name a few [9]. IGF1R, insulin-like growth factor, has tyrosine 
kinase activity and plays a critical role in transformation events. IGF1R 
knockout mice displayed signs of growth deficiency with some mice dying 
shortly after birth [10]. LEF1 (Lymphoid enhancer-binding factor 1) is a 
transcription factor that mediates the Wnt signalling pathway, leading to the 
expression of Wnt target genes [11, 12]. SELL is the gene responsible for the 
transcription of L-selectin, also known as, CD62L. The protein product of 
SELL is a homing receptor required by lymphocytes to enter secondary 
lymphoid tissues. CD62L is expressed on the surfaces of T cells with central 
memory T cells expressing L-selectin to localize in secondary lymphoid 
organs, and effector memory T cells not expressing CD62L [1]. 
 
The functions of 2 out of the 8 central memory-specific genes, AXIN2 and 
LEF1, that were found to change significantly during 6 months of ART in our 
cohort, indicate that they play an important role in the canonical Wnt 
signalling pathway. The Wnt signalling pathway has been associated with 
motility, cellular proliferation, apoptosis, differentiation and polarization of 
cells, in invertebrates and mammals [13], and involves the LEF1/TCF family 
of transcription factors and β-catenin. In the absence of Wnt ligands the 
phosphorylation of β-catenin leads to ubiquitylation and proteosomal 
breakdown thus preventing nuclear translocation of β-catenin and in turn 
preventing enhanced transcription of Wnt-dependent genes [14]. The 
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presence of Wnt ligands leads to the inactivation of the destruction of β-
catenin through the action of AXIN, among other proteins, thus β-catenin 
levels accumulate leading to nuclear translocation. Once in the nucleus β-
catenin drives the expression of TCF/LEF-dependent genes, that play a role 
in survival, cell differentiation and proliferation [15] (Figure 6.6). 
 
 
Figure 6. 6: The canonical Wnt signalling pathway.  (Image sourced from 
Villaseñor et al. [15]). Left: the absence of Wnt ligands the phosphorylation of 
β-catenin results in reduced Wnt-dependent gene expression. Right: Wnt 
ligands inactivate the β-catenin destruction complex leading to nuclear 
translocation of β-catenin and the expression of LEF-dependent genes. 
 
The roles of Wnt family proteins in Mtb infection remains controversial. It has 
been demonstrated in vitro that Wnt3 reduced the secretion of TNF-α 
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cytokine, but did not influence expression of the TNF-α gene in Mtb infected 
macrophages. This was mediated via the canonical pathway as Wnt3 was 
shown to induce β-catenin stabilisation and AXIN2 expression in this system 
[16]. Conversely Neumann et al. demonstrated using a murine model that 
Wnt3 promoted the expression of ARGINASE 1 in Mtb infected macrophages 
[17]. ARGINASE 1 has been shown to promote anti-inflammatory effects. 
Furthermore, Wnt3 has also been shown to inhibit IL-6 production in murine 
macrophages, during Mtb infection, therefore further supporting the anti-
inflammatory phenotype [17]. Baba et al. illustrated that the Wnt signalling 
pathway has a role in maintaining an undifferentiated cell state by showing 
that expression of β-catenin in lymphoid or myeloid cells generated 
uncommitted cells with the potential to differentiate into multilineages [18]. 
This further supports the expression of these genes that showed a 
significantly increased expression in central memory T cells, which are early 
differentiated cells. Overall, we observed an increase in T cell memory 
specific gene expression in HIV infected persons receiving ART and our 
results illustrate that 8 out of the 13 central memory CD4 T cell-specific 
genes showed a significantly increased expression when normalised to at 
least 2 reference genes. After applying the most stringent analysis (i.e. 
normalisation to at least two reference genes), the genes that exhibited 
significant increase were specific to central memory T cells, thereby 
supporting our hypothesis that the expression of central memory T cell 
specific genes increase over 6 months of ART. Our findings support the 
expansion of early differentiated T cells during ART induced protective 
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immune reconstitution and may offer insight into the mechanisms of ART-
mediated prevention of TB in HIV-1 infected persons. 
 
There were several limitations to our study: firstly the genes included for 
analysis were based on studies in HIV uninfected persons while our results 
depict expression in HIV infected persons during ART, therefore it is 
important to acknowledge the effect of HIV infection during analysis. 
Secondly while blood samples were collected from HIV uninfected persons 
for soluble and cell marker analysis, we did not collect blood for 
transcriptomic analysis thus we lacked a control group for analysis of this 
arm of the study. We therefore were unable to determine the expression of 
our set of genes in HIV uninfected persons and use this cohort for 
comparison purposes. Additionally we initially planned to conduct either 
microarray or RNA-seq experiments, as opposed to RT-PCR, in order to 
identify a transcriptomic signature indicative of protective immunity in our 
cohort. However due to insufficient RNA quality, we opted to measure the 
expression of selected genes instead. Our RNA was extracted from whole 
blood as opposed to selected cell populations. The RT-PCR results may thus 
have been more unambiguous and specific to each cell subset if we were 
able to conduct experiments using RNA from separated T cell subsets.  
Despite this, we observed an overall increase in gene expression in HIV 
infected persons receiving ART and our results illustrate that out of the 13 
central memory CD4 T cell-specific genes, 8 showed a significantly 
increased expression when normalised to at least 2 housekeeping genes. 
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After applying the most stringent analysis (i.e. normalisation to at least two 
housekeeping genes), we observed that the genes that exhibited significant 
increase were central memory specific genes (Figure 6.7), thereby 
supporting our hypothesis that the expression of central memory T cell 
specific genes increases over 6 months of ART.  
 
 
Figure 6. 7: The number of central memory- (CM) or effector memory 
(EM) CD4 T cell -specific genes that significantly increased in HIV 
infected persons during 6 months of ART after normalisation to either 
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Chapter 7: Overall Discussion and Conclusion 
The objectives of this thesis are summarised below: 
i. We firstly characterised Mtb-specific CD4 T cells in HIV infected 
persons, sensitised by Mtb, during the first 6 months of antiretroviral 
treatment induced immune reconstitution. This was achieved using a 
15 colour flow cytometry panel assessing T cell memory phenotype, 
senescence profile, homing marker expression and cytokine 
secretion to assess their functional capacity. We hypothesised that 
central memory CD4 T cells with high proliferative capacity and the 
ability to home to the site of infection upon re-exposure to antigen will 
expand significantly, based on previous findings, and therefore may 
play a protective role against TB in HIV infected persons. 
ii. Secondly, using ELISA and multiplex assays, we aimed to evaluate 
soluble markers in plasma from HIV infected, Mtb sensitised 
individuals starting ART and followed up for 6 months. Analytes 
assessed included pro-inflammatory, anti-inflammatory, chemo-
attractant, growth factors and T cell growth factors. We hypothesised 
that soluble factors associated with central memory T cell function will 
be detectable in plasma and that their concentrations will change 
over time on ART in HIV infected Mtb sensitised individuals. 
iii. Lastly, we aimed to compare gene transcriptional signatures 
characteristic of central memory and effector memory T cells using 
quantitative RT-PCR in HIV infected persons starting ART and 
sampled at day 0, 1 month, 3 months and 6 months of ART.  
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Using flow cytometry we characterised Mtb-specific CD4 T cells in HIV 
infected persons and observed an expansion in the number and proportion 
of central memory CD4 T cells, and a corresponding decrease in the 
proportion of effector memory CD4 T cells. We were thus able to confirm the 
findings of a previous study in our group, in a larger cohort of individuals [1]. 
Riou et al. also identified pathogen-specific early differentiated CD4 T cells to 
have a higher capacity to replenish in HIV infected persons receiving ART, 
compared to pathogen-specific late differentiated CD4 T cells [2]. This further 
supports the concept of different T cell subpopulations possessing diverse 
potentials to be replenished during ART.  
 
Additionally we observed a significant decrease in the proportion of activated 
CD4 T cells, and senescent CD4 T cells in our cohort. Similarly Riou et al. 
demonstrated a significant decrease in CD4 T cells co-expressing CD38 and 
HLA-DR, and cells expressing HLA-DR only, in HIV infected LTBI individuals 
[2].  
 
We also assessed the numbers and proportions of CD4 T cells expressing 
single cytokines and observed that the proportions of cells producing either 
IL-2, IL-17A or TNF-α decreased significantly during ART. The comparator 
group of HIV uninfected persons had significantly lower proportions of IL-2 or 
TNF-α producing cells, and significantly higher proportions of IL-17A 
producing cells compared to HIV infected persons. Strickland et al. described 
that HIV uninfected persons had higher proportions of TNF-α producing cells 
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compared to HIV infected persons while the proportions of IL-2 producing 
cells could not be distinguished between the two cohorts [3].  
 
Lastly, we demonstrated that the proportion of CD4+ T cells with the ability to 
secrete three cytokines (IFN-γ+TNF-α+IL-2+) simultaneously significantly 
expanded in HIV infected persons during 6 months of ART. HIV uninfected 
persons had a significantly lower proportion of IFN-γ+TNF-α+IL-2+ 
polyfunctional CD4 T cells compared to HIV infected persons after 6 months 
of ART. The significant increase in the proportion of these cells in our cohort 
may be attributed to the overall increased proportion of CD4 T cells as a 
result of ART induced immune reconstitution, and thus these cells may have 
expanded as a result of clonal expansion. Our finding is in line with that of 
Bunjun et al. in which they found LTBI HIV infected persons to have a higher 
proportion of IFN-γ+TNF-α+IL-2+ polyfunctional T cells compared to HIV 
uninfected persons [4]. Bell and Westermann have proposed that in the 
absence of antigen contact antigen-primed T cells, such as polyfunctional T 
cells, return to a resting state [5]. Thus LTBI persons would be expected to 
have lower proportions of CD4 T cells secreting IFN-γ, TNF-α and IL-2 
compared to TB infected persons. Caccamo et al. and Sutherland et al. 
illustrated that persons with active TB disease had significantly higher levels 
of Mtb-specific CD4+ T cells secreting IFN-γ, TNF-α and IL-2 cytokines 
simultaneously compared to persons with LTBI [6, 7]. Thus the inclusion of a 
control group of TB infected individuals, in our study, would have been 
beneficial in order to compare the polyfunctional capacity of CD4 T cells to 
patients with active disease in our setting.  
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More importantly, we observed a significant increase in the proportion of 
CD4 T cells with the ability to produce 2 cytokines in HIV infected persons 
after therapy. After 6 months of ART, the quality of the immune response 
was dominated by bifunctional CD4 T cells (CD4+IFN-γ+TNF-α+, CD4+IL-
2+TNF-α+ and CD4+IL-17A+TNF-α+ cells). This finding is central to the fact 
that CD4 T cells are imperative for a protective response to TB. Furthermore, 
these findings were similar to that of Sutherland et al. [8] as they 
demonstrated a dominant polyfunctional CD4 T cell profile after ART 
whereby the cytokines TNF-α and IL-2 were produced by polyfunctional CD4 
T cells. Together these findings indicate that the increased polyfunctional 
profile associates with a reduced TB prevalence, and that CD4 polyfunctional 
T cells are therefore a key player in mediating protection to TB infection.  
 
Using multiplex assays we demonstrated a significant decline in 
concentrations of the pro-inflammatory cytokines, IFN-γ, IL-1α, IL-1β, IL-6, 
IL-17A and TNF-α, in HIV infected persons after 6 months of ART. 
Comparison with the HIV uninfected persons revealed no significant 
difference between the concentrations of cytokines between the two groups, 
indicating that the concentrations of analytes observed at 6 months of ART in 
the HIV infected persons, were similar to those observed in the control 
cohort, thus indicating effective ART. Pro-inflammatory cytokines play 
important roles in TB-HIV pathogenesis. IFN-γ contributes to the recruitment 
of cells to the sites of inflammation, and to phagocyte and DC activation 
leading to bacterial control. IL-1α and IL-1β have been shown to play roles in 
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autophagy and bacterial control [9] while TNF-α is responsible for granuloma 
formation, maintenance and bacterial control. Thus the decrease in 
concentrations of these cytokines during ART, indicate a decrease in 
immune activation, in parallel with ART induced reduction in HIV viral load.   
 
Lastly, using RT-PCR, we demonstrated a significant increase in the 
expression of central memory-specific genes, compared to effector memory-
specific genes, in HIV infected persons during 6 months of ART. More 
importantly, this increased expression was observed regardless of the 
housekeeping gene used for normalisation during data analysis thus 
illustrating a robust increase in expression of 8 central memory-specific 
genes.  
 
The products of these genes have been shown to play a role in processes 
such as cytoskeletal rearrangements, gene transcription, homing and 
migration, activation and proliferation. The AXIN2 and LEF1 gene products 
play an important role in the canonical Wnt signalling pathway, in which Wnt 
signalling has a role in conferring a more undifferentiated state [10]. This is in 
keeping with our data as central memory T cells are early differentiated cells, 
that have the ability to further differentiate into effector memory T cells upon 
receipt of appropriate signals and specific antigen presentation for which the 
cell has been primed. Okamura et al. demonstrated that LEF1-/- and TCF1-/- 
double knockout mice have a block in T cell differentiation indicating the 
importance of this gene in the interaction with the Wnt mediator, β-catenin 
[11]. This further demonstrates the crucial role that the Wnt signalling 
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pathway plays in delivering proliferative signals to immature T cells [12]. 
However the involvement of the Wnt signalling pathway in the T cell 
differentiation pathway can also be regulated at many different levels; and 
the assessment of protein markers, specifically the proteins translated from 
the aforementioned genes, is needed in order to fully determine the role of 
these genes in the context of ART induced immune reconstitution in HIV 
infected persons sensitised by Mtb. 
 
Therefore we observed indications of a decrease in immune activation in our 
cohort of HIV infected persons, using two technologies. Firstly the significant 
decrease in pro-inflammatory cytokines was observed during the 
assessment of soluble markers via Luminex, and secondly we also observed 
a significant decrease in the proportions of cells producing the same single 
cytokines in the same cohort of persons using flow cytometry. Furthermore 
activation, measured by the expression of the marker HLA-DR, was 
determined using flow cytometry and our results indicate a significant 
decrease in the proportion of activated CD4 T cells in HIV infected persons 
during ART. Adekambi et al. demonstrated that the activation markers CD38 
and HLA-DR expressed on Mtb-specific CD4 T cells, were able to distinguish 
between LTBI and active TB disease [13] with LTBI persons having a 
significantly lower proportion of HLA-DR+IFN-γ+ and CD38+ IFN-γ+ cells than 
persons with active TB disease. Additionally Adekambi and colleagues 
illustrated that the proportions of HLA-DR+IFN-γ+ and CD38+ IFN-γ+ Mtb-
specific T cells in LTBI persons were comparable to persons who had 
resolved TB successfully after TB treatment. This further supports our finding 
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of a decrease in immune activation during ART-mediated immune 
reconstitution in HIV infected persons.  Lastly our RT-PCR results describe a 
significantly increased expression of central memory-specific genes, when 
normalised to at least 2 housekeeping genes, in our patient cohort.  
 
A number of limitations of the study include: i) the reliance on antigenic 
stimulation in order to measure a Mtb-specific response. Persons that were 
unable to mount a detectable IFN-γ response were not included in the study; 
ii) additionally samples with missing timepoints resulted in a further 
decreased number of samples available for analysis; iii) this study would 
have also benefitted from the inclusion of an additional control group 
consisting of TB-HIV co-infected persons, sampled once, as a comparison to 
determine the loss of immune control. This would be of particular interest as 
a previous study in our group, Wilkinson et al. observed a significantly higher 
proportion of CD4+IFN-γ+HLA-DR+ CD4 T cells in TB-HIV co-infected 
persons compared to HIV infected persons [14] with the proportion of 
CD4+IFN-γ+HLA-DR+ CD4 T cells in HIV infected persons also being 
significantly higher than that of HIV uninfected persons.  
 
Two ways in which the findings of this PhD ought to be validated in furture 
studies include: 
1) Confirming that the finding of CD4+ T cell activation (HLA-DR+ and/or 
secreted as well as intracellular IL-2, IFN-γ and TNF-α) as being a 
marker of bacterial load and that may potentially identify persons with 
latent TB infection who would benefit from isoniazid preventive 
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treatment. In doing so, IPT would provide protection to TB by 
preventing the progression of latent TB to active TB disease in this 
group of persons at risk.   
2) More importantly the findings ought to be validated through the use of 
mouse models. Knocking out the gene(s), responsible for the 
production of potential markers of protection to Mtb (as identified in 
this PhD), in mice will allow us to determine whether it is actually 
these markers that are responsible for the protection provided. 
Furthermore, over-expressing these genes will also substantiate the 
abov. In order to achieve this, a conditional knockout mouse model 
ought to be used, as tissue-specific and inducible knockouts will be 
possible and will allow us to have control over the location and timing 
of the expression of these genes. Since these are vital genes, we 
need to control the timing of the deletion of the gene(s) in order to 
prevent a lethal phenotype.  
 
In conclusion we have shown that early differentiated CD4 T cells exhibiting 
a less activated phenotype, with the ability to secrete at least two cytokines, 
have the potential to serve as a correlate of decreased susceptibility to TB 
disease in HIV infected persons. This might aid in vaccine efficacy testing, 
vaccine design and host directed therapies. Moreover the correlate of 
protection could be used to identify potential vaccine candidates, optimise 
vaccine dose, the number of doses required and to provide preliminary 
evidence of immunogenicity amongst other functions. The use of blood-
based markers also has the ability to rapidly identify persons that have a 
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delayed or no response to vaccines and/or TB therapy, in the case where the 
markers will be used to measure treatment response. Finally this subset of 
CD4 T cells as a correlate of protection has the potential to be a marker 
indicative of bacterial load, thereby providing the ability to identify persons 
that will benefit from Isoniazid Preventative Therapy (IPT) in order to prevent 
disease progression from latent to active TB disease (Figure 7.1). Thus the 
validation of early differentiated CD4 T cells exhibiting a less activated 
phenotype, with the ability to secrete at least two cytokines as a potential 
correlate of protection is required in future clinical studies. 




Figure 7. 1: Mtb Infection: A Spectrum of Immune Responses. The 
spectrum describes persons with an effective immune response, thus 
enabling the clearing of infection, persons with subclinical active disease in 
which persons harbour replicating bacteria but do not exhibit clinical 
symptoms of disease and, persons with active TB disease presenting with 
clinical symptoms. We demonstrated that Mtb senstised, HIV infected 
persons display a decreased activation due to ART Induced immune 
reconstitution. A higher bacterial load increases CD4 T cell activation. 
Therefore the use of HLA-DR as a marker of activation may be useful in 
identifying a key population of persons that will benefit from IPT and in doing 
so, prevent disease progression to active TB disease (image from A/Prof. 
Katalin A. Wilkinson, based on Young et al., Barry et al., Lawn et al. and 
Esmail et al. [14-18].)    
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